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Abstract
SCOTTY MCGLOTHLIN BUFF. Reducing lung disease in cystic fibrosis: Model systems
and anti-inflammatory treatment. (Under the direction of ISABEL VlRELLA-LOWELL,
M.D.)

Cystic fibrosis (CF), the most common lethal autosomal receSSIve disease in
Caucasians resulting in a median life span of approximately 35 years, is caused by mutations
in the cystic fibrosis transmembrane conductance regulator (CFTR). The primary cause of
morbidity and mortality is respiratory failure caused by progressive obstructive lung disease.
CF airway disease is characterized by the abundance of proinflammatory cells, chemokines
and cytokines with a deficiency of regulatory/anti-inflammatory cytokine interleukin 10 (lL10). We hypothesized that CF airway obstruction originates from excessive inflammation and
gene transfer of IL-I0 would decrease inflammation in the airways of mice infected with
Pseudomonas aeruginosa, a common pathogen in CF.

IL-I0 gene transfer was accomplished using an adeno-associated viral vector (AAV)
selected for the inherent benefits of long-term gene expression, a proven safety profile, and
the ability to elicit a minimal inflammatory response in comparison to other gene transfer
agents. Using intratracheal injection, we administered

AAV5.C~-mILI0

to IL-I0 deficient

mice, chronically infected the mice with P. aeruginosa, and observed high levels of IL-l 0,
decreased lung pathology, and

IL-l~

and IL-8 (MIP-la and KC in mice), cytokines

frequently seen at increased levels in patients with CF.
To characterize IL-IO gene transfer in CFTR knockout mice, we modified a noninvasive procedure, aspiration challenge, to include surfactant phospholipids as a vehicle for
transfer of P. aeruginosa and AAV -based vectors. This was important because CFTR
knockout mice are sensitive to manipulations such as intratracheal injection, resulting in

XIX

mortality from the surgical procedure. We demonstrated aspiration challenge with surfactant
phospholipids was similar to intratracheal injection for P. aeruginosa and AAV delivery, as
measured by percentage weight loss, proinflammatory cytokine production, inflammationassociated histopathology, and bacterial burden for P. aeruginosa and vector distribution and
transgene expression for AAV.
Then, we characterized AAV5.C~-mILIO in CFTR knockout mIce chronically
infected with P. aeruginosa, observing decreased percentage weight loss, lung pathology,
pro-inflammatory cytokines

(IL-l~,

IL-6, TNF-a, KC, MIP-la), histopathology, and

neutrophil migration with no change in bacterial burden.
These studies support that inflammation is excessive to bacterial infection in CF and
demonstrate AAV-based IL-IO gene transfer is a promising anti-inflammatory therapeutic for
CF lung disease.
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Chapter 1.
Significance and Introduction

1.1.

Significance of Research Project
Like most human genetic diseases, cystic fibrosis (CF) requires life-long therapeutic

interventions. CF is a complex disease that manifests itself pathologically in several organs

with a range of symptoms that vary between individuals, due to the type of CF gene
mutation, a host of polymorphisms, and environmental influences [1] and the pleiotropic role
of the resulting defective CF protein. Current therapeutic approaches to CF are symptomatic
and can be timely and invasive with patients succumbing to early mortality, currently
approximately 36 years. Gene transfer has become a promising alternative, as it has the
potential for stable maintenance of therapeutic genes inside defective cells, ideally providing
long-term treatment within the diseased tissue without serious side effects. The first type of
gene transfer investigated for CF used the wild-type gene mutated in CF (the cystic fibrosis
transmembrane conductance regulator [CFTR]) because of the success of this approach in
correcting the CFTR channel defect in CF lung cells [2].
To date, there have been gene therapy clinical trials for CFTR correction with
liposomes, Adenovirus, and AAV. Early studies indicated that lipid-DNA complex delivery
to the nasal epithelial showed no treatment-related local or systemic adverse reactions [3],
but later studies showed non-specific inflammation is a major obstacle to both intravascular
and intratracheal delivery [4, 5]. Additionally, overall gene delivery by liposomes has been of
low efficiency, not producing consistent evidence of gene transfer to the nasal epithelium by
physiologic or molecular measures [6, 7].
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Adenoviral-based vectors can efficiently infect airway epithelia and are capable of
producing robust levels of gene expression [8-11]. However, adenovirus vectors also activate
the innate immune system and expression of numerous chemokines and cytokines, inducing
an acute inflammatory response which severely reduces adenovirus gene transfer efficiency
[11-15].
To date, the most promising gene transfer agent in CF is an AAV vector expressing
CFTR (tg-AAV.CF). Phase IJII clinical trials have been conducted in greater than 100 CF
patients without evidence of significant toxicity. The safety profile of this vector allows
patients as young as 12 years old to participate in clinical trials [16]. Tg-AAV.CF has been
instilled into the nose, maxillary sinus, and single lung lobe, and delivered through aerosol by
oral inhalation to the entire lung. In phase I maxillary sinus studies, dose dependent gene
transfer and changes in sinus transepithelial potential difference (TEPD) were observed,
consistent with production of wild-type CFTR [17]; however, the lack of sinus TEPD
measurements in patients without CF makes interpretation of these data difficult (I. VirellaLowell, personal communication). These studies demonstrate that tg-AAV.CF is safe with
minimal viral shedding in the sputum and no change in baseline inflammation in nasal
epithelium as measured by the lack of increase in proinflammatory cytokines in serial
bronchial wash fluids [16,

18]. Interestingly, follow-up studies with tg-AAV.CF

demonstrated a decrease in sinus concentrations of proinflammatory cytokine, IL-8, at day 14
post-treatment from the vector-treated side as compared to the placebo-treated side, which
correlated with absolute sinus neutrophil count [19].
A phase II double-blinded, placebo-controlled study of multiple doses oftg-AAV.CF
delivered by oral aerosol inhalation suggested that the aerosolized product, administered via
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nebulizer to the lung, was safe and well-tolerated by patients [20]. At day 14, levels of IL-8
were lower in patients receiving tg-AAV.CF, and at day 30, lung function improved
(p=O.04), both measurements compared to placebo. While a local and systemic AAV
neutralizing antibody response was observed, excellent gene transfer, as measured by DNA

PCR on cells removed by bronchoscopy, was found in all patients tested. This is the first time
in any trial for gene transfer of cystic fibrosis that clinical outcomes measured in the
treatment group were significantly improved over placebo.
While tg-AA V.CF has repeatedly been demonstrated to be safe and result in a stable
maintenance (weeks to months) of CFTR expression, it does not result in high enough levels
of gene expression to significantly change the clinical course of the disease. In addition, it
has been difficult to assess the relationship between its molecular action and the observed
clinical improvements, because AA V-specific mRNA has not been detected [21]. To address
this problem, Flotte et al studied primary nasal cells obtained from patients receiving tg-

AAV.CF [22]. The cells were collected at different time points after gene transfer and
expanded in vitro with the purpose of detecting CFTR mRNA expression to correlate AAV-

CFTR transfer and cystic fibrosis airway epithelial cell correction. Vector-specific mRNA
was detected in three out of five subjects and, of these three subjects, two displayed an
increase in chloride transport, suggesting a correlation between the presence of AAV-CFTR
vector genomes, CFTR mRNA expression, and cAMP-activated chloride channel function
detectable only after ex vivo expansion.
CFTR gene transfer relies on targeting relevant cells for CFTR function (believed to
be the submucosal glands) and generating high levels of CFTR expression, shown to be more
efficient in correct ion transport abnormalities in CF cells [23]. The limited success of AAV -
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mediated CFTR gene transfer and the realization that targeting the CFTR may not be
beneficial for the majority of patients with CF due to their extensive lung destruction, has led
researchers to evaluate therapeutics targeting the inflammatory cascade and slowing disease
progression. CFTR defects are related to immune regulation and the predisposition of
affected individuals to the persistent chronic endobronchial infections. In the CF airway
inflammation is excessive relative to the amount of infection in the CF airway, and patients
have increased stimulation of Nuclear Factor (NF)KB and heightened production of the proinflammatory cytokines Tumor Necrosis Factor (TNF)-a, Interleukin (IL )-1~, IL-6, and IL-8
[24-29]. They also have reduced amounts of IL-l 0, a regulator of inflammation, and IKBa, a
regulator ofNFKB [26, 28-37]. Aberrant regulation of inflammation results in recruitment of
large amounts of neutrophils to the airway where they release high levels of substances that
directly and indirectly damage the airways. The imbalance of pro- to anti-inflammatory
mediators is well established early in the life of a patient with CF, resulting in many years of
lung destruction and progressive airway obstruction.
Therapies for inflammation in CF have been mildly effective and limited in usage by
their side-effect profiles. Use of gene transfer to target inflammation could prevent further
lung destruction and alleviate obstruction in adolescents and adults with CF. If given in very
young patients, lung destruction due to inflammation could potentially be prevented. Pairing
the anti-inflammatory gene IL-I0, expressed at reduced levels in the CF lung, with AAV
delivery is an attractive approach because it has great potential to not only decrease
inflammation, but to increase patient adherence through long-term persistence of gene
expression. Use oflL-lO is supported by a previous study in our laboratory, Virella-Lowell et
al used microarrays to investigate the gene expression profile in a CF bronchial epithelial cell
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line (IB3-1) as it was altered by the addition of the wild-type CFTR gene, IL-IO, and/or
infection with Pseudomonas aeruginosa and demonstrated that IL-lO is able to reverse some

0/ the phenotypic changes in CF cells that are not observed in non-CF cells [38].
This dissertation investigates the therapeutic potential of modifying the abnormal
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immune response in CF by (1) using AAV -IL-I delivery and (2) optimizing a non-invasive
administration technique to measure attenuation, in vivo, of CF lung disease. We
hypothesized that AA V-ILl 0 gene transfer would significantly reduce inflammation in P.
aeruginosa-infected mice, while not causing systemic immunosuppression. In developing a

non-invasive method for in vivo analysis, we hypothesized that aspiration challenge of P.

aeruginosa-laden beads and AAV-ILlO vector with surfactant phospholipids would result
in a similar infection and gene transfer, respectively, to intratracheal injection while being
non-invasive and less difficult to perform. To characterize IL-IO gene transfer and optimize

the in vivo method of infection and therapeutic delivery, the following aims were designed.
Aim 1: To characterize AAV-ILIO as an anti-inflammatory therapeutic in a P. aeruginosa
chronic infection model in IL-l 0 deficient mice.
Aim 2: To develop an aspiration challenge with surfactant phospholipids method for
administration of P. aeruginosa-laden beads.
Aim 3: To develop an aspiration challenge with surfactant phospholipids method for
administration of AAV-based vectors.
Aim 4: To use aspiration challenge with surfactant phospholipids for P. aeruginosa-Iaden
bead and AAV -IL 10 vector administration, and characterize AAV -IL 10 as an antiinflammatory therapeutic in a P. aeruginosa chronic infection model in gut-corrected
CFTR knockout mice.
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1.2.

Cystic Fibrosis
Cystic fibrosis, a complex autosomal recessive disease that is primarily diagnosed in

children and young adults, is the most common autosomal recessive disease in the Caucasian
population. Heterozygotes, who obtain one mutant CF allele and one normal allele in this
region, are denoted carriers and are entirely asymptomatic; whereas the child of two carriers
has a one in four chance of inheriting the CF mutation on both alleles and being affected with
the disease. The prevalence of CF varies by ethnic origin, with the highest predominance in
the Caucasian population (1/3000, with 1120 carriers for the disease), followed by the
Hispanic (118000), Black (1117000), and Asian (1/90000) populations [1].
The first comprehensive description of CF was published by Anderson in 1938,
where the phrase "cystic fibrosis of the pancreas" was used to describe the extreme pathology
that resulted from the lack of pancreatic exocrine function [39]. Although the association
between salty skin and early death has been recognized since medieval times [40], DiSant'
Agnese was the first to demonstrate that children with CF exhibit excessive salt loss in their
sweat [41], a discovery that led to the development of a diagnostic tool whereby the
measurement of chloride and sodium in the induced sweat of children could be used identify
children with CF [42]. This test remains the gold standard for CF diagnosis today.
Early laboratory studies further defined the molecular characteristics of CF through
analysis of patient samples. Paul Quinton demonstrated poor re-absorption of N aCI in
isolated sweat ducts from CF patients and hypothesized this was the result of abnormally low
chloride permeability, the reason for the high concentration of NaCI in the sweat of CF
patients [43]. A similar abnormality was also demonstrated in the respiratory epithelia [44,
45]. Sato et al found that cells derived from patients with CF do not exhibit normal chloride
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emux by activation of a cyclic adenosine 3', 5'-monophosphate (cAMP) -dependent protein
tinase (PKA) in response to elevated cAMP levels [46]. In CF cells, activation of PKA was

; found to be intact, but did not result in chloride efflux [47]. Even though these early studies
provided increased knowledge into the underlying defect in CF, the results were inadequate
because they could not identify the specific gene which caused the chloride efflux deficiency.
In 1989, the CF gene was identified through positional cloning [48] and named the
cystic fibrosis transmembrane conductance regulator or the CFTR gene, reflecting the initial
findings of the protein's function. The direct association of the gene and CF was supported
by finding mutations in a gene located on the long (q) arm of chromosome at 7 position 31.2

in patients with CF, but not in the normal population.

a. Cystic Fibrosis Transmembrane conductance Regulator (CFTR)
The CFTR gene encodes a transmembrane protein of 1480 amino acids, with a
structure that has been compared to members of the ATPase or A TP binding cassette (ABC)
transporter family. This family and the CFTR share a homologous structure of two
membrane-spanning domains (MSD 1 and MSD2) and two Nuclear Binding Domains (NBD 1

and NBD2) [49] (Figure 1.1A).
MSD 1 and MSD2 each contain 6 transmembrane (TM) domains which contribute to
the formation of the chloride-selective pore [50], presumed to be about 3 Angstroms wide

(Figure LIB).
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Figure 1.1
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Figure 1.1 The CFTR is a symmetrical protein that forms a transmembrane channel in
epithelial cells. (A) The CFTR is a membrane spanning channel protein composed of two
membrane spanning domains (MSD 1 and MSD2), each of which contains six transmembrane
domains (TM), two nucleotide binding domains (NBDI and NBD2), and a regulatory (R)
domain. (B) The CFTR protein forms a pore lined with six positively charged amino acids
and regulates chloride ion translocation. NBD 1 and NBD2 hydrolyze ATP to regulate
channel gating. The R-domain contains phosphorylation sites which regulates interaction of
ATP with the NBDs and may control ATP hydrolysis and channel gating. Adapted from [49].
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The CFTR protein is predominantly expressed in epithelial cells, where it is
transcribed at relatively low levels [51]. Studies of CFTR in the human lungs have localized
the expression to the respiratory epithelium, which expresses very low levels, and the
submucosal gland (Figure 1.2), which show considerably higher levels [52, 53], suggesting
the submucosal glands might be an important site for CFTR function. In addition to being
expressed in the apical membrane, the CFTR has been localized to subcellular regions where
it may be involved in vesicle trafficking, including participation in endocytosis, exocytosis,
and endosome fusion, and intracellular chloride activity by importing chloride as a counterion to permit the organelle's acidification and regulate vacuolar pH while maintaining the
internal electrical neutrality [1, 54]
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Figure 1.2 Schematic of proximal airway shows sites of salt and water transport and
mucin secretion that lead to formation of airway surface liquid (ASL). Shading indicates
relative level of CFTR expression [53].
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The primary role of the CFTR protein is as a cAMP-activated chloride channel that
plays a key role in fluid and electrolyte secretion by contributing to the rate of transepithelial
salt and fluid transport. The CFTR provides a pathway for chloride movement across
epithelia as well as regulating the rate of flow. Its functions are pleiotropic, depending upon
on the tissue in which it is expressed. In the intestine, pancreas, and sweat gland secretory
coil, the CFTR regulates fluid and electrolyte secretion, while in the sweat gland duct and
airway epithelia, it participates in fluid and electrolyte absorption.
The CFTR may also regulate other ion channels, including outwardly rectifying
chloride channels (ORCC) and amiloride-sensitive epithelial sodium channels (ENaC). It
appears to have a stimulatory influence on the former and, conversely, an inhibitory role on
the latter. The ORCC acts as a floodgate with a resulting chloride conductance much higher
than that of the CFTR and its dysfunction may have a role in creating the CF phenotype,
secondary only to the CFTR [1, 55]. ENaC, which has heightened sodium absorption in the
absence of regulation by the CFTR and, with the development of an ENaC overexpressing
mouse model that seems to have spontaneous lung disease, is also being considered a prime
contributor to CF pathology [56].
Absence, mutations, or low abundance of the CFTR protein results in an ionic
imbalance and the dehydration of secretions along epithelial membranes. While a deletion of
phenylalanine in position 508

(~F508)

of the CFTR protein accounts for approximately 70%

of the mutant alleles in CF [57], over 1,300 mutations have been identified that cause CF and
are grouped in five different classes according to their affect on CFTR transcription,
trafficking, or abundance of expression (Figure 1.3) [1]. Class 1 mutations cause premature
termination signals and result in little or no protein production. Class 2 mutations, which
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include AF508, result in abnormal folding of the protein product and do not lead to normal
trafficking to the apical cell membrane. Class 3 contains mutations in the nucleotide binding
domains (NBDs) and result in normal protein production and trafficking, but defective
regulation of the protein. Class 4 have mutations in the amino acids lining the channel pore,
resulting in a chloride channel with normal regulation, but reduced single channel current.
Class 5 mutations target splicing of CFTR transcripts and lead to significantly decreased
production of normal CFTR. Some mutations may disrupt CFTR function in more than one
way and are categorized in multiple classes [58].
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b. Clinical Symptoms and Treatment

Current therapy for CF is palliative, with the combination of current therapeutics
extending the life expectancy of patients to 32-35 years (from <1 year in 1940). Although CF
is believed to be monogenetic, the symptoms vary between individuals. This difference is
somewhat explained by mutation type, but genotype and disease outcome do not completely
correlate. As a result, patients can experience multi-organ or unilateral clinical symptoms
from the build-up of thick dehydrated mucus along the epithelial lining of the pancreas,
reproductive organs, and the lungs.
Eighty percent of patients with CF experience pancreatic deficiency due to blockage
of pancreatic enzymes in their transport through the pancreatic ducts to the intestine, which
are clogged by the thick mucus build-up [1] and lead to malabsorption and malnutrition.
Currently, multivitamin and enzyme supplements are used in the treatment of the
nutrition/gastrointestinal complications; however, some patients still require the insertion of a
gastric feeding tube implanted to the stomach. Even with these treatments, patients with CF
generally have a low body mass index (BMI) when compared to children of comparable age.
Also, destruction of pancreatic cells results in diabetes in 30-50% of the patients.
In the reproductive organs, azoospermia, with consequent sterility, occurs In
approximately 99% of male patients with CF because of clogging of the vas deferens, which
stops the sperm in the testes [1]. There is currently no effective therapy available to combat
male infertility.
Chronic lung infection occurs in about 80% of patients with CF [59]. The
accumulation of mucus in the airway causes difficulty breathing and fosters an environment
prone to bacterial infection. Dehydration of mucus causes airway secretions to become more
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viscous and results in trapping microorganisms making infections with Pseudomonas
aeruginosa and Staphylococcus aureus inevitable, promoting inflammation and lung damage.

Airway clearance techniques are conducted with either traditional chest physiotherapy ("hand
clapping") or with the aid of oscillatory devices (the vest, intrapulmonary percussive
ventilation [IPV], and flutter devices) which create vibrations along the airway to dislodge
the mucus, move it toward the central airway, and help to thin secretions so they can be
removed by coughing or spitting. In coordination with airway clearance, patients take
aerosolized medications to open the airway and liquefy the mucus; these include
bronchodilators, anti-inflammatory therapeutics, and mucolytic agents such as dornase alpha
(Pulmozyme®, Genentech) which contains DNase. Even with the most rigorous airway
clearance regiment, persistent bacterial infections result, and most patients with CF remain
on a continuous dosage of antibiotics orally or through aerosol delivery [colistin, Tobramycin
(TOBI®, Chiron)].
However, the antibiotics only suppress an exacerbation of bacterial infection.
Embedded in the mucus, the microorganisms are protected from the body's airway defenses

as well as pharmaceutical agents, neither of which easily penetrates the biofilm the bacteria
form. Obstructive airway disease as a consequence of airway infection and inflammation is
the most frequent cause of morbidity in CF, with mortality caused by respiratory failure.

c. Molecular Mechanisms of CF Lung Disease
A number of additional functions for the CFTR are not well understood, including the

mechanism by which CFTR defects are related to immune regulation and predispose affected
individuals to chronic endobronchial infections. A model has been developed (Figure 1.4),

19

where the CFTR mutation leads independently to three sets of aberrations: (1) abnonnally
viscous, salty and/or under-hydrated airway secretions, (2) exaggerated release of
inflammatory mediators, such as interleukin (IL)-8, in the presence or absence of infection,

and (3) increased Pseudomonas aeruginosa retention in the lower respiratory tract. The
combination of an inherent pro-inflammatory environment in the lungs (all pathways) and an
excessive response (pathways 2 and 3) lead to inflammation, infection, and persistence of both.
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i.

Defective CFTR and Initiation of Disease

Two different hypotheses have been formulated to explain the role of the CFTR in CF
lung pathogenesis, both of which focus on the role of salt absorption [60] (Figure 1.5). The
classical hypothesis is the "low volume hypothesis" in which the lack of CFTR function
causes a defect in chloride secretion, resulting in sodium and water hyperabsorption (through
ENaC) and severe pathology in the pancreas, intestine, and airways. According to this model,
CF and normal individuals both have comparable levels of salt, but patients with CF have
decreased surface liquid (ASL) volume [61]. The airway epithelia regulate ASL salt
concentration, specifically, in the lungs, leading to a decrease in the ASL covering the
epithelia and impaired mucociliary clearance due to increased thickening of airway
secretions, promoting infections in the lung. Studies found no evidence that the liquids lining
airway surfaces were hypotonic or that salt concentrations differed between CF and normal
cultures; however, CF airway epithelia had high rates of ASL absorption and abolished
mucus clearance [61]. According to this model, therapeutics should target increasing ASL
volume with salt and water, not modulating the ionic composition. The role of ENaC as a
primary defect for pathogenesis is supported by animal studies and the clinical effects of
hypertonic saline [62].
The alternative hypothesis, the "high salt hypothesis," proposes the increase in
sodium and chloride in the ASL is due to poor absorption of salt, not sodium
hyperabsorption, leading to an excessively salty ASL because CFTR dysfunction causes
reduced transepithelial chloride conductimce. The high salt environment of the ASL
interferes with the bacterial killing of natural antibiotics such as defenses and lysozyme.
Studies were conducted in normal and CF airway epithelia, and CF epithelia had reduced
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ability to kill Pseudomonas aeruginosa and Staphylococcus aureus which was corrected by
reducing the NaCI concentration on CF epithelia [63]. In this model, ENaC plays only a
minor role to CFTR activity.
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Figure 1.5 The multiple roles of CFTR in salt and fluid absorption. (A) In the low
volume model, the primary defect is overactive ENaC activity due to lack of inhibition by
CFTR. Normal and CF cells have the same ASL salt concentration. Inhibition of ENaC
occurs in normal cells while CF cells have de-inhibition of ENaC, leading to elevated fluid
absorption, depleting the volume of ASL, and reducing mucociliary clearance due to viscous
build-up. (D) In the high salt model, the primary defect caused by CFTR dysfunction is lack
of chloride conductance. Normal and CF cells differ in the ASL salt concentration. Normal
cells absorb salt in excess of water. CF cells poorly absorb salt, leading to salty ASL and
inactivation of antimicrobial peptides. Adapted from [60].
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ii. Inflammation

The persistent inflammation in the CF lung is the major cause of progressive lung injury
and damage leading to decreased pulmonary function and death. Studies have shown that
patients with CF have an inherent pro-inflammatory environment in the lungs [27, 64-68] and
an excessive response to bacterial infection [69].
Shortly after birth, excessive endobronchial inflammation can be detected in the
bronchoalveolar lavage (BAL) of patients in the absence or presence of bacterial infection also
measured in the BAL. Specifically, BAL samples contain elevated levels of neutrophils, IL-8,
and neutrophil elastase (NE) when compared to subject controls [64-67]. Constitutive
activation of NFKB with a subsequent increase in IL-8 expression can result from endogenous
stimulation as a consequence of cell stress due to the accumulation of mutant CFTR in the
endoplasmic reticulum (ER) [70, 71] and may explain the presence of large quantities of
inflammatory cells and cytokines in the airways of infants and small children with CF prior to
any known infection or colonization [27, 64, 68]. Once, NFKB is activated, a massive release
of proinflammatory cytokines and chemokines such as

IL-1~,

IL-6, IL-8, and TNF -u occurs

[24, 25, 27-30, 72, 73]. Bronchoalveolar macro phages (BALMs) from uninfected patients
with CF produce elevated levels of proinflammatory cytokines compared to healthy controls
[26,29].
The CF chronic inflammatory response, pathologically, is marked by the massive
influx of polymorphonuclear neutrophilic leukocytes (PMNs) into the airways. While the role
of neutrophils in host defense is very important, their function is also potentially harmful if
turned against the host tissue where neutrophils accumulate and are linked to the long-term
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course and exacerbations of several acute and chronic lung disorders, including cystic
fibrosis.
Neutrophils are recruited by chemokines and release considerable quantities of NE,
which is thought to be the most important protease that damages the CF lung. NE degrades
elastin, a key structural lung component that prevents small airways from collapsing, and
leads to emphysema-like conditions in the lungs and possibly remodeling of airway tissue.
Interestingly, NE is present in increased concentration in uninfected CF patients when
compared to uninfected controls and these levels have been found to inversely correlate to
lung function [64]. NE can adversely affect the airways by enhancing mucus secretions [74-77],
amplifying the signal from inflammatory mediators [77, 78], directly injuring airway tissue [79],
and disrupting opsonization and elimination of bacterial pathogens [79-81].
In lungs of patients with CF, the normal levels of anti-protease defenses such as a-I
antitrypsin (AAT) are outmatched, exacerbating the already exaggerated inflammatory
response. Additionally, there is significant evidence that the key regulatory factors such as

IL-tO [26, 28-31] and lKEa [32-37], an inhibitor ofNFKE activation, are down-regulated or
rapidly degraded in CF; endogenous lung anti-proteases are repressed as well. The reSUlting
imbalance of pro- to anti-inflammatory mediators is well-established early in life, allowing for
many years of lung destruction and progressive airway obstruction.

iii. Bacterial Infection

A direct correlation exists between bacteria colony forming units (cfu) and intensity
of airway response in the BAL of patients with CF, including significant increase in
inflammatory cells and increased IL-8 concentration [82]. In addition, upon infection with P.
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aeruginosa CF respiratory epithelial cells produce IL-8 at four times the level observed in

normal cells [69].
While initiation of chronic bacterial infection can be explained by the change in ASL
volwne or salt composition and/or by the early onset of an innate pro inflammatory airway
environment, these models do not explain why patients with CF are consistently colonized by
specific pathogens. Early infections in the CF lung are mainly caused by Staphylococcus
aureus and Haemophilus influenza, but chronic infection with Pseudomonas aeruginosa is

more significantly correlated with clinical outcomes in CF [83, 84]. Infection with P.
aeruginosa occurs at a very young age (~ 3 yrs) and is detected by a positive antibody

response and culture growth from samples taken by bronchoscopy [85] or throat swabs from
young, non-sputum producing children [86]. Prevalence of P. aeruginosa infection increases
with age in patients with CF and is accompanied by a corresponding decrease in prevalence
ofS. aureus and H influenza.
P. aeruginosa is an opportunistic pathogen naturally resistant to many antibiotics and

significantly causes nosocomial infections. Because patients with CF are specifically susceptible
to chronic infections with P. aeruginosa, a number of theories have been proposed for the
predisposed risk in this population. Most theories describe factors such as alterations in the

ASL, decreasing antimicrobial peptide activity, or increased viscosity of secretions, impeding
mucociliary clearance, but would not explain the overwhelming presence of P. aeruginosa in
respiratory tract infections. For this reason, the CFTR protein has been implicated in recognition
and elimination of P. aeruginosa, potentially acting directly as a receptor for P. aeruginosa
and/or indirectly by influencing bacterial adherence, endocytosis, and clearance of bacteria from
the airway (Figure 1.6).
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Figure 1.6 Schematic outlines potential factors causing increased susceptibility to P.
aeruginosa infection in patients with CF. (A) CFTR and P. aeruginosa interaction result in
internalization of the bacteria by epithelial cells. (B) CFTR mutations cause defective chloride
transport across epithelial cell surfaces, altering the viscosity of ASL and decreasing bacterial
killing. (C) Inactivation of innate antimicrobial features allows bacteria to survive in the airway.
(D) In the CF epithelia, asialo-GMI receptors are increased and bind P. aeruginosa stimulating
IL-8 production and recruitment of PMNs to the airway. (E) Dysregulated inflammatory
response leads to PMN degranulation and release of toxic factors promoting tissue injury [87].
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Observations have been made by several groups that P. aeruginosa adheres to CF
epithelial airway cells more efficiently than non-CF cells [88, 89]. Polarized CF bronchial cells
bind P. aeruginosa in a reversible and dose-dependent manner, significantly greater than
compared matched pairs rescued with the CFTR [88]. Adherence of P. aeruginosa to nasal
epithelial cells from patients with CF was significantly greater than to cells from normal
subjects [89]. Despite increased adherence, CF cells do not appear to internalize the bacteria.
Compared to cells expressing wild-type CFTR, cells expressing the

~F508

CFTR were

defective in uptake of P. aeruginosa [90]. Murine cells expressing wild-type CFTR ingested P.
aeruginosa at rates from 30-100 higher than cells lacked CFTR or expressing the ~F508 CFTR

[91]. Adherence and internalization have been directly linked in one laboratory;
demonstrating human airway epithelial cells efficiently ingest P. aeruginosa, an effect which

was reversed by addition of purified CFTR [91]. In addition, this laboratory showed P.
aeruginosa specifically binds the first extracellular domain of CFTR [91]. This strongly

suggests the CFTR may contribute to a host-defense mechanism that is important for
elimination of P. aeruginosa and its absence in patients with CF results in persistence of the
organism in the respiratory tract.
In addition or despite the fact that CFTR may be a receptor for P. aeruginosa, there is
also evidence that links the jnability of CF cells to ingest P. aeruginosa to the tetrasaccharide of
an asialoganglioside 1 (aGM1) moiety (asialyated glycolipids), located in abundance in the
apical membrane of CF epithelia [88, 92], but not normal epithelia. In CF polarized bronchial
cells, there was undersialylation of apical proteins and a higher concentration of
asialoganglioside 1 (aGM1) in apical membranes of CF compared with rescued epithelia
[88]. This was supported by studies in CF regenerating respiratory epithelial cells obtained
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from nasal polyps showing increased aGMl correlated to the increased P. aeruginosa affinity
for CF cells [92]. In addition, there were increased numbers of asialoGMl residues available
on the surface of the epithelial cells with altered CFTR function which also correlated with
higher P. aeruginosa adherence in CF epithelia the [93].
Specific P. aeruginosa adhesions (pilin, flagellin) are necessary for initial infection and
stimulate IL-8 production from respiratory epithelial cells [69]. The inflammatory response is
perpetuated by a P. aeruginosa autoinducer (PAl), an exoproduct secreted during chronic
infection that stimulates IL-8 production in a dose-dependent manner [69].
Mucoid P. aeruginosa is associated with the worst clinical outcome in CF [83, 84].
Transition of P. aeruginosa from non-mucoid to mucoid strain generally is the result of
initial colonization not being efficiently treated and is the result of an overproduction of
exopolysaccharide alginate. Chronic infections of alginate-coated mucoid strains of P.

aeruginosa are almost impossible to eradicate, probably due to biofilm formation and the poor
penetration of antibiotics even with intensive regimens [94, 95].
I

1.3.

Anti-inflammatory Therapies in CF

A growing body of evidence emphasizing the role of inflammatory mediators in CF
pathogenesis has led to a recent surge in the development and assessment of anti-inflammatory
therapy for CF lung disease. Importantly, treatment of patients with CF using anti-inflammatory
therapeutics slows the progression of lung disease, but has not been found to exacerbate
infection [96-100].
Corti~osteroids

are potent anti-inflammatory medications. They inhibit neutrophil

chemotaxis, adhesion, and tissue infiltration by reducing expression of cell adhesion
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molecules (CAMs) on the vessel wall, and suppress proinflammatory cytokine release, but
their specific mechanism of action in CF is still unclear [101, 102]. Although glucocorticoids,
such as prednisone, have been found to decrease moderately the rate of decline in pulmonary
function in patients with CF, after two years of use they have been associated with significant
side effects, including cataracts, lower bone mineral density, and diabetes; therefore,
glucocorticoids are usually only used in acute or end-stage lung disease [101, 102]. Inhaled
corticosteroids (lCS) have minimal side effects, but have not been found to decrease
inflammation significantly, most likely due to difficulties in getting such medications to
penetrate through the mucus and reach lower airways [103-108].
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, mediate their antiinflammatory effects through inhibiting cellular cyclooxygenase activity and prostaglandin
synthesis; however, they do not mediate any suppression of cytokine release, although highdose ibuprofen (>50 Jlg/ml) may reduce neutrophil migration to the lung [109]. High-dose
ibuprofen was found to slow the progression of lung disease in patients with CF [110], but its
use has been limited by the need to obtain individual pharmacokinetics and concern about
side effects, such as the risk of gastric and pulmonary bleeds and renal failure, a specific
concern in patients with CF because they are almost continuously on aminoglycoside
antibiotics, which like ibuprofen, are cleared by the kidneys. When ibuprofen is used in
combination with aminoglycosides (e.g., tobramycin) the blood levels of the aminoglycoside
may increase, presumably because the elimination of aminoglycosides from the body is
reduced.
Azithromycin is a macrolide antibiotic which inhibits protein synthesis of the bacterial
ribosome by blocking the exit of the growing peptide chain in sensitive microorganisms
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[111]. It has recently been found to have additional anti-inflammatory characteristics that
may involve inhibition of pro inflammatory cytokine expression (IL-8 and TNF-a) through
interaction with NFKB [111-113]. Azithromycin use three times a week has demonstrated a
modest improvement or temporary halt in the decline in forced expiratory volume (FEV)-1 (a
measure of pulmonary function), reduction in hospitalizations (470/0), increase in weight gain

(0.8 g), decreased need for antibiotics, decreased or no change in bacterial infection [97-99], and
a generally improved quality of life [97-99] with far fewer side effects making it a more
commonly used anti-inflammatory agent in CF.
A significant amount of inflammation persists in the CF aIrway despite current
therapeutics, indicating more potent anti-inflammatory agents are needed, some of which are in
clinical trials. A recent clinical trial with inhalation of 25 mg of al-anti-trypsin (AAT) for 4
weeks decreased elastase activity, neutrophil migration, pro-inflammatory cytokine production,

and colonization with P. aeruginosa, but had no effect on lung function [114]. Higher doses,

250 mg and 500 mg, of AAT for 4 weeks resulted in a trend toward reduction in NE and
myloperoxidase (MPO) activity, markers of neutrophil activity and migration, respectively

[115].
Another major inhibitor of NE, secretory leukocyte protease inhibitor (SLPI), may also
increase levels of anti-oxidants, such as glutathione (aSH), which are decreased in the airways
of patients with CF [116]. Reduction of aSH in vitro has been associated with enhanced
susceptibility to oxidative stress, an increased inflammatory cytokine release, and impairment
of T cell responses [117, 118]. In patients with CF, recombinant human SLPI given by aerosol
at 100 mg for 7 days decreased NE levels by 67% [119]. Additionally, aSH prodrug oral N-

35

acetylcysteine found to decrease sputum elastase levels, neutrophil migration to the lung, and
IL-8 in the sputum of patients with CF [120].
A preliminary study in 8 patients with CF showed that administration of colchicine over

6 months resulted in better respiratory function tests in 5 and clinical status improved in all
[121]. Colchicine has anti-inflammatory properties which include inhibition of neutrophil
migration, chemotaxis, and phagocytosis [122].
In addition to clinical trials, researchers are investigating a number of anti-inflammatory
agents. IL-IO and interferon (INF)-'Y are counter-regulatory cytokines that inhibit TNF-a, IL-l~,
and IL-8, key proinfiammatory cytokines responsible for the damaging inflammation present

in the CF airway. Anti-microbial peptides against P. aeruginosa have been shown to decrease
bacterial burden and proinflammatory cytokines in rats [123]. Mercaptoethylguanidine (MEG),
a selective inhibitor of inducible nitric oxide synthase (iNOS) and a scavenger of the potent
oxidant peroxynitrite, has been found reduce weight loss, lung injury, proinflammatory
cytokine production

(IL-l~,

TNF-a, and macrophage inflammatory protein [MIP]-2), and

MPO activity, while not increasing bacterial load in the lungs of rats chronically infected
with P. aeruginosa [124]. Proteosome inhibitors, such as MB-132, inhibit proteasomemediated IKB degradation and TNF-a induced IL-8 production in A549 cells (lung carcinoma
cell line) by limiting NFKB-mediated gene transcription [125].

1.4.

Interleukin 10
Patients with CF have low levels of IL-l 0 intracellularly (in alveolar macrophages

obtained by bronchoscopy) and in airway secretions (sputum and BAL) when compared to
their levels of proinflammatory cytokines (INF-a, IL-6, IL-8) [28-30]. This elevation has
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been observed after an infection has been resolved as well as in the absence of infection
(measured in uninfected infants), suggesting that inflammation in CF is not dependent on
infection [27]. Microarrays have been used to investigate the gene expression profile in a CF
bronchial epithelial cell line (IB3-1) as it was altered by the addition of the wild-type CFTR
gene, IL-I0, and/or infection with Pseudomonas aeruginosa and demonstrated that IL-I0 is
able to reverse some of the phenotypic changes in CF cells that are not observed in non-CF
cells [38]. These studies suggest lack of1L-10 may contribute to the initiation/progression of
CF lung disease and that IL-l 0 may have therapeutic potential in CF.

a. Molecular Biology of IL-l 0
The basic parameters of IL-IO signaling have been under investigation for a while
(around 14 years), indicating the complexities of the pathway; however, it is clear IL-IO
signaling is a non-redundant pathway that serves to limit inflammatory responses [126].
The receptor for IL-IO is a complex composed of four transmembrane polypeptides;
the two chains of IL-l ORa (or IL 1ORl) bind the ligand and the two chains of IL-l OR~ (or
ILI0R2) initiate signal transduction [127]. Janus kinase (JAK)-l is constitutively bound to
IL-I0Ra while tyrosine kinase (TYK)-2 constitutively associates with IL-l OR~. Binding of
IL-IO to the ILIO receptor activates JAK-l and TYK-2 (presumably through crossphosphorylation), initiating phosphorylation of the IL-I0Ra chain and recruiting signal
transducers and activators of transcription (STAT)-3 to the IL-IO receptor complex.
Subsequently, phosphorylation of STAT-3, STAT-2, and STAT-5 by JAK-l and TYK-l
occur, producing homodimers and heterodimers of the STAT proteins that translocate to the
nucleus to inhibit STAT responsive genes, initiating the anti-inflammatory cascade (Figure
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1.7). Many receptors use the STAT3 pathway, but do not mediate anti-inflammatory
responses due to the activities of the suppressor of cytokine signaling (SOCS) [128].
Specifically, SaCS3 regulates STAT3 signaling from receptors such as IL-6, preventing
activation of these receptors from mediating an anti-inflammatory response. While SaCS3
expression is strongly induced in macrophages upon IL-10 stimulation, IL-10R is not
inhibited by any member of the sacs family and maintains a strong anti-inflammatory
signal [126].
IL-10 regulates a subset of genes induced by TLR stimulation, not as general block
on TLR-induced gene transcription [129, 130]. Although the target of STAT3 that executes
the anti-inflammatory response has not been found, specific mechanisms are believed to
include augmenting IKBa mRNA expression [131] to inhibit NFKB translocation to the
nucleus and gene transcription and decreasing gene-specific mRNA, as has been shown for a
number of cytokines including IL-6 and IL-8 [132].
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Figure 1.7
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Figure 1.7 The overall mechanism for IL-I0 signal transduction. IL-IO signals through
JAKI then STAT3, activating STAT3 responsive genes and inhibiting proinflammatory
cytokine production. JAKI is the only JAK family member required for IL-IO signaling and
STAT3 is the only STAT protein required for the anti-inflammatory effects of IL-IO [126].
This example shows proinflammatory cytokine production through TLR activation with
subsequent signaling through mitogen-activated protein kinase and NFKB pathways. The
target of STAT3 and mechanistic link between the pathways has not been elucidated. IKK,
IKB kinase; MKK, mitogen activated protein kinase kinase. Adapted from [126].

40

The mechanism of IL-l 0 preventing cytokine production was originally believed to
be an inhibition of the antigen presentation by macrophages and dendritic cells, but there is
also direct inhibition of cytokine synthesis for several genes in addition to preventing the
inflammatory effects of these cytokines on their target cells [127]. To limit ongoing immune
responses and inflammation, IL-10 plays important roles in blocking cytokine production, the
expression of co-stimulatory molecules, and chemokine secretion as well as controlling the
differentiation and proliferation of many immune cells, such as T, B, and antigen-presenting
cells (APC) [133, 134]. In addition, IL-IO modifies chemokine receptor expression, increases
cell adhesion molecule expression such as intercellular adhesion molecule (ICAM)-l, and
reduces the production of inflammatory mediators such as nitric oxide and free radicals
[127]. IL-IO inhibits major histocompatability complex (MHC)-II expression and
presentation, macrophage activation, and may decrease myeloid cells and prevent cell to cell
communication between macrophages and T cells, further resulting in decreased production
of proinflammatory cytokines and cytotoxic factors

[135].

IL-10 also regulates

inflammation/immune responses by inhibiting neutrophil-derived cytokine, chemokine, and
mediator production in response to different stimuli, particularly LPS [136].
The primary producers of IL-10 are T cell subsets; either TH-1 or TH-2 polarized
subsets can produce IL-IO, regulating inflammation in TH-I and TH-2-driven immune
responses [126]. An in vivo model of T-cell specific inactivation of IL-1 0 has demonstrated
that IL-l 0 production from T cells is critical for regulation of chronic inflammation while IL10 production from TLR-activated macrophages and dendritic cells is important for
regulation of acute inflammation [126, 137]. In chronic infections with bacteria such as P.

aeruginosa, IL-10 may control the intensity of inflammation through controlling T-cell
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tolerance to the pathogens [138]; however, because IL-I0 is produced from several different
sources (antigen specific T and B cells as well as myloid-derived cells) in a chronic infection,
the mechanistic basis of IL-I0 production in T cells verses myeloid-derived cells
(macrophages and dendritic cells) and in chronic versus acute inflammation is still not welldeveloped [126].
Lack of IL-l 0, as shown by studies in IL-l O-deficient transgenic (IL-I0T) mice, leads
to greater neutrophil recruitment, more severe weight loss, higher pro-inflammatory cytokine
production (IL-6, KC) in the BAL, and increased areas of lung inflammation than seen in
wild-type mice when chronically infected with endobronchial P. aeruginosa [139], but does
not have an effect on bacterial load. In addition, a functional IL-I0 deficiency in the lungs of
CFTR knockout and IL-I0T mice was found to enhance T-cell co-stimulatory molecule, B7

and co-stimulatory activation of alveolar macrophages, suggesting reductions in pulmonary
IL-I0 in CF may enhance B7 expression and local immune responses [140].

h. Use as a Therapeutic in Inflammation
Many of the pathologies noted with P. aeruginosa infection were reversed by
administration of IL-I0 in wild-type mice [139, 141] and CFTR knockout mouse models [37,
140]. In a model of chronic P. aeruginosa infection of CD-l mice, intraperitoneal
administration of recombinant IL-I0 (rIL-I0) resulted in increased survival, fewer
neutrophils in the BAL, and decreased areas of lung inflammation when compared to
placebo-treated mice with no decrease in bacterial burden [139]. Recombinant IL-IO was
intraperitoneally administered I hr before, 8 hrs after, or before and after acute P. aeruginosa
infection in Balb/c mice [141]. The most successful dosing was the pre/post administration,
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demonstrating decreased lung injury and mortality, and a decreased inflammatory response
(increase in IFN-y and slight decrease in TNF-a).
In CFTR knockout and IL-10-deficient transgenic mice, intraperitoneal injection of
rIL-10 resulted in decreased expression of T-cell co-stimulatory molecule, B 7, and reduced
co-stimulatory activity ofbronchoalveolar macrophages (BALMs) [140]. An acute model of
intratracheal lipopolysaccharide (LPS) challenge in CFTR knockout mice resulted in a
significant decrease of PMNs and TNF-u, which correlated with decreased NFKB activity
and increased IKBu, upon subcutaneous administration of rIL-1 0 [37].

1.5.

Adeno-associated Virus (AAV)
To date, the therapies available for inflammation in CF have had modest success and

are limited in usage by their side-effect profiles. Gene transfer has become a promising
alternative, as it has the potential for stable maintenance of therapeutic genes inside defective
cells, ideally providing long-term treatment within the diseased tissue without serious side
effects. Adeno-associated virus (AA V)-based vector gene transfer has much promise as a
therapeutic for CF and has proven safe in mUltiple clinical trials.

a. Background
Adeno-associated virus (AAV) was first discovered as a contaminate of Adenovirus
(Ad) stocks (Figure 1.8), hence the name "Adeno-Associated," but was later characterized as
a distinct virus with no known cytopathic effect in mammalian cell lines or animal models
[142].
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Figure 1.8
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Figure 1.9 Transcriptional map of AAV2. AAV has three promoters, defined by their map
positions: p5, p19, and p40. AAV2 contains two ORFs, rep and cap, and two inverted
terminal repeats (ITR), represented by boxes. Below each genome are the major mRNA
synthesized by AAV2. The number to the left is the size of the transcript and the name to the
right are the viral proteins translated from each mRNA. * indicates transcription from an
alternate start codon. Adapted from [145].
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If there is no helper virus present, AAVenters the lysogenic or latent phase of its life
cycle (Figure 1.10). During this phase, only a small amount of Rep78 is produced, and it
binds the pS Rep binding element (RBE) site, located within pS, to inhibit further
transcription. RepS2 and Rep40 also inhibit pS promoter activity, but they do not contain

RBE domains and their mechanism for inhibition is not clear, although it may include
interaction with host transcription factors. RepS2 additionally inhibits p 19 transcription.
Repression of the p40 promoter has not been demonstrated, but in the absence of helper
infection, there is little accumulation of p40 transcripts or Cap proteins [14S]. Rep78
interacts with the AAV ITRs and the host genome at the AAVSI site (19q) to mediate sitespecific integration of the AAV genome [149]. Alternately, Rep68 may bring chromosome
19 and the AAV genome together through Rep-Rep contacts usually resulting in integration
of multiple copies in head-to-tail tandem within the host genome, although AAV can also
persist in episomal forms [ISO].
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Figure 1.10 Latent life cycle of AAV. AAV2 binds its primary cell receptor, heparin sulfate
proteoglycans, and is (1) adsorbed and (2) uncoated followed by (3) entry of DNA into the
nucleus, the processes of which are poorly understood for all Parvoviridae. In the absence of
helper virus, AAV integrates into the host cell DNA, establishing a latent infection. (4)
Minor replication of the single-stranded genome is required to (5) produce double stranded
DNA for transcription from the p5 promoter. (6) Translation of this transcription product
produces the Rep proteins (Rep78/68), (7) required for integration as well as inhibition of
transcription from the other promoters. (8) Site-specific integration occurs through Rep
proteins binding a specific sequence in chromosome 19 and the viral genome, bringing them
together via Rep-Rep contacts [151].
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In the presence of Ad, HSV, or other helper co-infection, AAV goes through its lytic
phase (Figure 1.11), beginning with rapid induction of AAV gene transcription. In the case
of Ad superinfection, Ad early (E)IA transactivator (TA) protein induces transcription from
the pS promoter to generate high levels of Rep78 and Rep68. Rep78 and Rep68 induce pS
promoter expression by interacting with the TATA binding protein (TBP) or repress pS by
binding pSRBE, also self-inhibiting. The mechanism is unclear, but may be through
interaction with YYl, a cellular protein, which can function as a transactivator (TA) or
repressor [14S, IS2] and may displace Rep78 and Rep68 from the pSRBE, thereby 'derepressing' the pS promoter. Rep78 and Rep68 also induce transcription from the p19
promoter. RepS2 and Rep 40 also inhibit pS in the absence of Ad or de-repress pS when Ad
is present. Additionally, the overexpression of Rep78 and Rep68 inhibits Cap protein at the
post-transcriptional level [145].
The net effect is tight regulation of these elements for a constant ratio of the Rep and
Cap proteins, which is important because overexpression of rep increases the replicative pool
of DNA at the expense of packaging and overexpression of cap promotes premature deletion
of the pool of replicative AAV intermediates required to sustain a productive infection [lSI].
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Figure 1.11 Lytic life cycle of AAV. In the presence of (9) co-infection with a helper virus,
or rescue by superinfection, AAVenters a productive infection. In the case of adenovirus,
(10) expression of the early genes EIA, EIB, E4, and E2A is required for entry of the host
cell into S phase and expression of host cellular proteins needed for (11) viral DNA
replication. Expression of the adenoviral E 1A and other early proteins (12) induces
transcription from the p5 promoter, (13) producing large amounts of Rep78/68 mRNA and
proteins. While in latency these proteins were powerful repressors, in the lytic life cycle they
become potent transcriptional activators, (14) inducing transcription from p5 and pI9
promoters. Viral DNA replication is initiated by recognition of the tenninal resolution site
(trs) by the Rep78/68 proteins, (15) producing a large number of replicating fonns (106 ds
genomes/cells) (16) which can be in dimeric head-to-head and tail-to-tail orientations. The
(17) capsid proteins are produced in the cytoplasm, (18) self-associate in the nucleus during
viral assembly, and (19) progeny virions are released usually upon destruction of the cell
[151 ].
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b. AAV -based Vectors

AA V-based vectors have been studied extensively and predominate as one of the
most promising vectors for gene transfer in CF (Table 1.1). Vectors derived from AAV can
transduce dividing and non-dividing target cells [153] and provide prolonged gene expression
in the host through episomal persistence or integration [154-157] in such models as the lungs
of rhesus macaques and New Zealand white rabbits following a single dose administration [143,
158]. In addition, AAV vectors deliver therapeutic genes without co-transfer of any viral
genes and, therefore, induce minor inflammatory responses. Indeed, experiments of AAV mediated gene transfer into skeletal muscle cells have shown persistent transgene expression
(up to 1.5 years) with no inflammatory responses in animal models [159-162]. AAV-based
vectors have also been found safe in a number of animal models and human clinical trials [143,
155].
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Table 1.1 Properties of AAV supporting its potential role in gene therapy.

Non-pathogenic
Capable of persistent infection
Present in over 100 variants with diverse cell tropisms
Generally elicits mild innate cytokine response
Genome readily modified in proviral plasmids
Recombinant production and purification methods in place
Adapted from [163].
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i.

Design and Production

Due to the small packaging capacity of AAV, which has been found to be 4.0 to 4.8
kb, AAV-based vectors traditionally do not contain either ORF from the wild-type genome as
genomes <4.1 kb are packaged in duplicate and genomes >4.9 kb are inefficiently packaged
[164]. Instead, this region is replaced with the transcription cassette of interest and only the
ITRs of the wild-type virus are retained [165]. The ITRs are needed for integration of the
vector and are also recognized by Rep for replication and Cap for packaging. Therefore, to
produce AAV -based vectors, Rep and Cap must be supplemented in trans, along with the
helper virus genes needed, to promote replication and packaging of the vector.
Currently, there are several methods of AAV vector production: multiple transfection,
wild-type or recombinant helper super-infection, and AAV packaging cell lines. The multiple
transfection method consists of the transfection of two or three plasmids: the AAV vector
(containing the expression cassette of interest), a plasmid carrying the helper genes (from Ad
or HSV), and a plasmid carrying the AAV rep and cap genes; a double transfection can be
performed if the helper genes and AAV rep and cap genes are supplied from one plasmid.
The plasmids are re-transfected with each expansion of the culture to produce high titer of
the vector [166]. Although laborious, this method is currently the technique of choice when
generating good-manufacturing-practice (GMP)-grade vector for clinical trials because there
is no helper contamination, which can cause an adverse immune response [167].
The second technique for AAV vector production uses AAV packaging cell lines
which contain the AAV rep and cap genes stably integrated into their genome [168] and are
transfected with the AAV vector and then infectedltransfected with helper virus components,
which would promote rep and cap expression. The predominant limitation of these cell lines
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is that they only contain one copy of Rep per cell, when it has been determined that the ratio
of Rep to AAV vector is optimal when 5: 1 [164]. Additionally, He La (human cervical cancer
cell line) and A549 (human lung carcinoma cell line) are the current packaging cell lines
[169-171] which cannot be used for production of GMP-grade vector
Another method of AAV vector production is wild-type helper super-infection
(typically with Ad), which occurs after co-transfection of the AAV vector and the rep/cap
construct. This technique is the most successful at generating high titer AAV vector due to
the multiple copies of helper genes expressed in each cell and the reduction of the number of
plasmids for transfection. The limitation of this technique is the high amount of helper virus
contamination, which requires additional steps to obtain a pure stock of AAV vector. The
most common technique for Ad and AAV separation is Cesium chloride (CsCI) gradient
purification, based on AAV being denser than Ad. Separation can also be done by
chromatography-based systems using the coxackie associated receptor (CAR) for Ad and
heparin sulfate proteoglycan (HSP) for AAV-2 [167, 172-175] or by heat treatment (55°CIl
hr) which inactivates Ad, but not AAV; however, this is less commonly used because the
components of the helper virus are still present to elicit an immune response.
Additionally, recombinant adenoviruses have been constructed to carry the AAV rep
and cap genes for the purpose of higher multiplicity of infection (MOl) and multiple copies
of Rep and Cap (RIC) per cell [176]. These strategies require a single transfection of the
AAV vector followed by recombinant (r) Ad.RlC super-infection. Unfortunately, it is

difficult to generate these recombinant helper vectors due to the extreme cytotoxicity and
inhibition of helper virus replication mediated by the Rep proteins, predominantly Rep78 and
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Rep 68 [176]. This method currently lacks an efficient mechanism to ensure recombinant
helper virus production is highly reduced or eliminated to prevent contamination.

ii. Immune Response
AAV-based vectors do not contain any viral open reading frames and, therefore, do
not produce viral proteins, making these vectors particularly useful due to their lack of host
cell mediated immunity or acute inflammation. There are few studies examining the innate
immune response to AAV vectors [177]. The lack of inflammatory responses documented in
numerous in vivo gene transfer models employing AAV vectors suggest that these agents do
not interact significantly with the innate immune system [143]. In contrast to Adenovirus
vectors, AAV vectors do not induce chemokine/cytokine expression in epithelium-derived
cells [15]. Additionally, intravenous administration of AAV -LacZ resulted in rapid induction
ofTNF-a mRNA in the liver, but returned to normal after 6 hours compared to the prolonged
induction (> 24 hours) ofTNF-a mRNA levels and TNF-a expression exhibited by Ad-LacZ
[15]. The increased cytokine expression was accompanied by neutrophil migration to the
liver, transient with AAV -LacZ and greater in magnitude and prolonged with Ad-LacZ. AAV
vectors may interact significantly with macrophages as the absence of liver macrophages
(Kupffer cells) eliminated the innate immune response elicited by the vector [15]. These
studies suggest that the reduced inflammatory properties of AAV vectors are due to the
vector not efficiently activating the innate immune system; however, transient activation
might contribute to the adaptive response generating neutralizing antibodies to the AAV
capsid.
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Thirty-five to eighty percent (depending upon age and geographical location) of the
population have neutralizing activity to AAV2 [177]; therefore, making the humeral immune
response to AAV capsid proteins an important barrier against re-infection for clinical gene
transfer. Capsid neutralizing antibody production elicited by AAV is both T-cell-independent
and -dependent, possibly varying by route of vector administration. Intramuscular
administration of AAV vector in mice and rhesus monkeys demonstrated T-cell-dependent
antibody production [178] as did tail vein administration, completely inhibiting antibody
production with depleting CD4-antibody [179]. Inhibiting T-cell responses when AAV
vector was administered into the portal circulation had no effect on antibody production,
although the T-cell independent B cell response was short-lived compared to the T-celldependent response [179].
Route and time between administrations also contribute to overall antibody
production as demonstrated by lung-specific gene transfer. Intranasal administration of an

AAV2/5 vector to the mouse lung was found to be successful 5 months after the original
administration [180]. Aerosol delivery of an AAV2 vector by three serial doses (three
administrations) was found to be successful despite increasing titers of neutralizing
antibodies in the lungs of rhesus macaques [181]. Aerosol and maxillary sinus deliver of tg-

AAV.CF resulted in serum neutralizing antibodies in treated patients with CF [19, 20, 182],
but gene transfer was detected by bronchoscopy. Importantly, repeat administration is safe
and well-tolerated in clinical studies.
Current strategies to overcome humoral immunity to the AAV capsid include AAV
capsid modifications which may have altered immune function and overcome pre-existing
immunity [177]. Additionally, alternative serotypes of AAV have decreased presence of
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neutralizing antibodies and may be used to pseudotype the AAV2 vector genome into capsids
of other AAV serotypes. A study comparing neutralizing antibodies in the normal adult and

CF population found adults in both populations were seropositive for AAV2

('""-J 30%),

but at a

lower rate for AAV6 (20-30%) and AAV5 (10-20%) [183]. Children with CF «18 yrs) were
seropositive to AAV2, AAV5, or AAV6, but at much lower rates (4-15%). This study
indicates pre-existing immunity will not limit AAV -based gene transfer for the majority of
individuals with CF and vectors made with AAV 5 and AAV6 capsids will enhance evasion
of the adaptive immune response.

iii. Targets for Optimization of Gene Transfer and Expression
Although DNA transfer efficiency and safety have been consistently favorable, thus
far gene expression from AAV -based vectors has been variable and insufficient for a
successful therapeutic effect. There are several modifications to optimize AAV vectors for
gene transfer being developed which include capsid mutagenesis, the use of alternate AAV
serotypes, and the development of stronger, more compact promoters.
The efficiency of AAV -2 entry of the airway epithelial cells through the apical
surface is less efficient than that from the basolateral side of the epithelia., presumably due to
the low density of heparin sulfate proteoglycan (HSP) receptors. Altering the targeting of

AAV by modifying or inserting binding ligands into the structural proteins of the AAV
capsid has led to promising results with respect to enhancing and/or directing vector
infectivity to preferred cell types the virus would not normally infect [184, 185].
The tropism of AAV is very important for efficient transduction of airway cells,
especially considering all the barriers to CF gene therapy in the lung. Recent experiments
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comparing the differential transduction efficiency of AAV serotypes have determined AAV 1 [186, 187], AAV-5 [187, 188], and AAV-6 [189, 190] demonstrate higher levels of
transduction in the airway epithelia when compared to the traditionally used AAV-2. AAV-5

has markedly different capsid proteins from AAV-2, which alter its tropism [191, 192] and
allow it to bind the apical surface of airway epithelial cells more efficiently via receptors
other than HSP and result in a 50-fold increase in gene transfer to the airway [188].
Studies in the translocation and processing of AAV upon viral infection demonstrated

a delay in viral entry to the nucleus, leading to the accumulation of vector particles persisting
up to 48 hrs in a paranuclear location [193]. Engelhardt and colleagues have determined that
AAV-2 and AAV-5-based vectors are susceptible to ubiquitinlproteosome interactions that

interfere with the ability of the virions to complete their life cycles and enter the nucleus; the
use of proteasome inhibitors significantly enhances transduction of both serotypes from the
apical membrane [193, 194].
The limited packaging capacity of AAV has made it difficult to use this vector for the
transfer of large genes (such as the CFTR) with efficient promoters. Early studies showed the
optimal size range for AAV packaging to be between 4.0 and 4.8 kb [164]. Although AAV
can package a vector up to 5.0 kb, the packaging efficiency decreases sharply with increasing
vector size. As the complementary (c )DNA of the CFTR gene is 4.6 kb and the AAV vector
itself is 300 base pairs (bp), including only the two ITR regions, it is difficult to incorporate a
strong promoter to express the CFTR cDNA using the AAV -based system. This size
limitation is the reason the current AAV -based vector in clinical trials (tg-AAV.CF) relies on
the promoter activity of the already-needed ITRs to transcribe the CFTR [147].
Circumventing the packaging capacity of AAV relies on an inherent feature of the virus
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where independent genomes can form large circular concatemers through intermolecular
recombination [195-197]. Manipulation of this feature has been successful in expanding the
AAV vector packaging capacity through a trans-splicing event mediated by AAV
heteroconcatemerization [198-201]. This approach divides either the transcription regulation
components or the transgene itself between two distinct AAV viruses. Co-expression of the
two viruses leads to reconstruction of the intact expression cassette of the trans gene with its
regulatory components through ITR-mediated intermolecular concatemerization. The
efficiency level of trans gene expression ranges from very low to reportedly as high as a
single vector system carrying the complete gene [199, 200, 202, 203] although it was
recently reported that AAV5 pseudotyped vectors are more efficient than AAV2, suggesting
that efficiency may be serotype specific [201]. This natural mechanism of AAV can allow
full-length or enhanced trans gene expression through heterodimerization.
Several promoters have been optimized for AAV gene expression. One which is
compact (500 bp) and produces high levels of gene expression in the lungs was developed by
combining essential features (immediate-early, ie) of the commonly-used and robust
cytomegalovirus (CMV) promoter to produce the CMVie/chicken beta-actin hybrid

(C~)

promoter and resulted in significantly increased gene expression of human AAT both in vitro
and in vivo as measured in the serum and lung [204]. Human AAT expression peaked at 8
weeks, achieving therapeutic levels which persisted for 1 year at which time the mice were
sacrificed. Another promoter, CC10, was derived from 350 bp of the Clara cell promoter and
is epithelial cell-specific [205], exhibiting comparable protein levels to CMV in the murine
lung and also achieving therapeutic levels of trans gene expression, persisting to 5 months
after vector delivery [180]. A third, the Fox./J promoter (900 bp), was analyzed with the
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development of transgenic mice and found the promoter to be lung-specific, required for
ciliated cell differentiation, and activated in the presence of cilia, in the tracheal, bronchial,
and nasal epithelium [206].
While an AAV vector essentially "gutted" of all wild-type proteins is viewed
beneficial from a host immune response standpoint, it also results in the deletion of features
need for Rep-dependent site-specific integration. There are three RBEs in AAV, two
identical ones in the ITR regions (RBE[itrD and one in p5 (RBE[p5]) [207, 208]. A 16 bp
section of RBE(itr) was found to be sufficient for mediating Rep-dependent site-specific
integration, which was more effective and specific than the RBE(p5) in Rep-dependent
integration at the AAVS 1 site [207].

1.6.

Animal Models of CF Lung Disease
Analysis of potential therapeutics in vivo for CF has been hampered by the lack of a

representative animal model. While the current animal models of CFTR gene targeting do not
spontaneously develop chronic obstructive airway disease and die of respiratory failure, the
most common cause of death in CF, great progress has been made in developing an in vivo
model of CF lung disease, characterized by neutrophil migration, rise in inflammatory
cytokines, and histopathological changes similar to that seen in patients with CF.

a. CFTR Knockout Mice
Several CF transgenic mice have been made through deletions, insertions and
mutations of the CFTR gene, but none of them have the lung complications that are the most
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common symptom in humans [209]. This may be due to an alternate chloride channel in the
mouse lung [1, 55], the physiology of the mouse airway [209], or the lack of sodium
hyperabsorption in the mouse airway epithelia [210]. The majority of CF mice have a lethal
intestinal phenotype from bowel obstruction which results in a limited lifespan and difficulty
of breeding; therefore, a transgenic CFTR knockout (homozygous for the S489X mutation of
the CFTR gene) mouse [211] was gut-corrected by having the CFTR reintroduced into the
mouse under the control of a Fatty acid-binding promoter (FABP) [212]. Gut-corrected
CFTR knockout mice do not have gut complications, but are still smaller in size and body
weight than their wild-type littermates [212]. CFTR targeting of other animals such as ferrets
[213] and pigs [214] are being conducted to find an in vivo model with spontaneous lung
disease.

b. Murine Models of Chronic P. aeruginosa Lung Infection
Because CFTR knockout mice do not have lung disease, it must be induced to create
animal models of CF lung disease. In CF mice, infection with Pseudomonas aeruginosa
produces an in vivo model with histology and cytokine elevation representative of chronic CF
lung disease. In vivo chronic infection with P. aeruginosa has been accomplished by
colonizing the mouse lung through feeding mice drinking water containing P. aeruginosa
[215] and repeatedly challenging mice in an enclosed chamber with aerosolized P.

aeruginosa [216].
Intratracheally injecting beads that have heen embedded with P. aeruginosa [217] is a
short-term infection (3-5 days); however, this model is the most appropriate in vivo
representation of CF lung disease, producing histologic and inflammatory changes
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characteristic of a chronic infection, and is often used as a "chronic infection" model. In fact,
the P. aeruginosa-Iaden bead approach is the most widely-used and least variable model for
chronic infection, originally developed in rats [218], mice [219], and optimized for
reproducible results [217] (Figure 1.12). In non-CF mice, infection with P. aeruginosa-Iaden
beads can persist for up to 28 days [220-222], while CFTR knockout mice appear to have
more severe mortality and inflammation, characterized by high levels of pro-inflammatory
mediators (TNFu, KC, and MIP-2) 3 days after exposure to the beads, despite having the
same bacterial load as their non-CF counterparts [220,223].
Three days post-inoculation with the beads, P. aeruginosa-infected mIce have
leukocyte infiltration involving the airways, bronchus-associated lymphoid tissue (BALT),
and adjacent parenchyma with early fibrosis occurring in the more severely affected regions
of the lung [220]. These histopathology features closely mimic those of individuals with CF.
Impaired bacteria killing occurs between days 3 and 7 after infection of CF mice with 80% of
death on day 7, compared to wild-type mice with 50% mortality rate [220, 224]. A sacrifice
date of 3-4 days is documented to be optimal for analysis of cytokines and lung pathology
[217].
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Figure 1.12
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Figure 1.12 Schematic for making P. aeruginosa-embedded agarose beads. An aliquot of
late-log phase bacteria is added to warm (50-55°C) 20/0 low melting agarose in PBS, then an
aliquot of bacteria-agar mixture is added to warm (50-55°C) heavy mineral oil containing a
stir bar. The mixture is stirred rapidly at room temperature, followed by cooling with slow
additions of ice. The volume of agarose beads and mineral oil are transferred to a separatory
funnel; the mineral oil removed and agarose beads washed with sodium deoxycholate (SDC)
and PBS. The settled P. aeruginosa-Iaden bead slurry is collected, titered, and instilled in the
animal airway to create a model of chronic infection [21 7].

68

c. IL-IO Deficient Mice
IL-IO-deficient transgenic (IL-IOT) mice have been genetically altered to be deficient
in IL-IO production, resulting in more severe infection as measured by greater neutrophil
recruitment, more severe weight loss, and increased areas of lung inflammation than seen in
wild-type mice when chronically infected with endobronchial P. aeruginosa [37, 139, 225].
These findings are similar to those of P. aeruginosa-infected CF mice [37, 215, 220, 226].
IL-IOT mice repeatedly exposed to mucoid P. aeruginosa have higher mortality rates and
more severe lung pathology when compared to C57BL/6 controls that were similarly infected
[216] and have a prolonged inflammatory response to acute P. aeruginosa challenge [35].
These characteristics of IL-IOT mice further suggest lack of IL-IO may contribute to the
initiation/progression of CF lung disease.
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Chapter 2.
IL-IO delivery by adeno-associated vector attenuates inflammation in mice
with Pseudomonas pneumonia.

2.1 Introduction

Cystic fibrosis (CF) is the most common monogenic disorder in Caucasians. In CF,
the dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) results in
a complex phenotype. Individuals with CFTR mutations have abnormalities in chloride and
sodium ion transport across epithelial membranes, contributing to the development of
progressive obstructive airway disease, malabsorption, sinusitis, liver dysfunction, and CFrelated diabetes. As the disease progresses, the airways of patients with CF become infected
and colonized with a variety of opportunistic pathogens, predominantly Pseudomonas
aeruginosa [227]. Presently, the foremost cause of morbidity and mortality in CF is

respiratory failure due to persistent pulmonary infections with P. aeruginosa, intense
neutrophil-dominated airway inflammation, and progressive bronchiectasis and lung damage.
A number of studies support the premise that CF lungs have an abnormal, upregulated
proinflammatory cytokine profile [26-30, 64, 65, 68, 228, 229]. Whether the mechanism of
the altered immune response in CF is directly or indirectly due to CFTR mutations and/or
other polymorphisms present in patients with CF is not known. However, there is a body of
evidence supporting the presence ofa relative IL-10 deficiency in patients with CF [29,230].
IL-10 inhibits cytokine production by T lymphocytes and potently suppresses macrophage
production of activating and/or chemotactic cytokines, including the PMN chemoattractant
IL-8 and otherNF-KB-dependent cytokines, including TNF-a,

IL-l~,

and IL-6 [231-234]. IL-

10 may also facilitate resolution of lung inflammation by promoting apoptosis of PMNs
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[235]. Deficiency of IL-I 0 production, as shown by studies in IL-I O-deficient transgenic (ILlOT) mice [236], leads to greater neutrophil recruitment, more severe weight loss, and
increased areas of lung inflammation compared to wild-type mice with analogous chronic
endobronchial P. aeruginosa infection [37, 139, 225]. These findings are similar to those of
P. aeruginosa-infected CF mice [37, 215, 220, 226]. IL-I0T mice repeatedly exposed to

mucoid P. aeruginosa have higher mortality rates and more severe lung pathology when
compared to C57BL/6 controls similarly infected [216]; additionally, IL-I0T mice have a
prolonged inflammatory response to acute P. aeruginosa challenge [237]. Treatment with IL10 has been documented to reduce leukocyte recruitment, proinflammatory cytokine
production, weight loss, neutrophil recruitment, and tissue injury in the airways of sensitized
animals following antigen exposure or P. aeruginosa challenge [37, 139-141, 238, 239],
supporting the use of IL-l 0 in ameliorating inflammation.
Gene transfer of IL-l 0 would convey the advantage of long-term gene expression, an
inherent feature of adeno-associated virus (AAV)-based vectors [143, 155, 158]. These
vectors have a proven safety profile and the ability to elicit a minimal inflammatory response
in comparison to other gene transfer agents [17, 19, 182, 240]. To increase lung specific
delivery and promote high levels of gene expression, we used an AAV5 pseudotyped vector for
efficient airway transduction [188, 241, 242] and the CMV/chicken-beta-actin hybrid

(C~)

promoter, a promoter with robust activity in the murine lung [204]. Using these elements, we
hypothesized that AAV-based gene transfer of IL-l 0 would result in high levels of lung-specific
IL-I0 expression, ameliorating the excessive response in the lung without systemic
immunosuppression. In this study, we characterize AAV5.C~-mILI0 in an IL-I0T mouse
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model of chronic P. aeruginosa lung infection to determine whether IL-10 gene delivery and
expression specifically reduce the proinflammatory response in the lung.

2.2 Materials and Methods

Eight-week old IL-10-deficient transgenic (IL-10T) mIce (C57BL/6 background)
were purchased from the Jackson Laboratory (Bar Harbor, ME), shipped in protective,
filtered containers, transported in climate-controlled trucks, and allowed to acclimate for at
least 3 days prior to use. Mice were fed autoclaved or irradiated Harlan Teklad Sterilizable
Rodent Blox 8656 (Harland Teklad, Indianapolis, IN) and bedded on autoclaved 1/8" com
cob bedding and com husk nesting material (Harland Teklad, Indianapolis, IN). Mice were
housed, 2-4, in Micro-Isolator Top Flow Ventilated cages (Tecniplast, Exton, PA) in
ventilated racks. All caging supplies were cleaned with an automated cage wash and
autoclaved prior to use in animal rooms. Muse is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care, International (AAALAC,
International), and the mice were maintained in specific pathogen-free (SPF) conditions.
Each rodent rack in the facility was assigned 1-4 cages of sentinels which are housed in
microisolator cages without filter tops. Sentinel animals are exposed to dirty bedding from
different shelves of animals at each cage change, but serology was negative for Sendai virus
(SEND), Pneumonia virus of mice (PVM), Mouse hepatitis virus (MHV), Mouse polio virus
(TMEV), Reovirus (REO), Mycoplasma pulmonis (MPUL), Mouse arvovirus (MPV), and
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Mouse rotavirus (EDIM). Mouse feces were negative for Helicobacter. The procedures were
approved by the Institutional Animal Use and Care Committee (lACUC) at MUSC.

Recombinant AAV -interleukin-l 0 vector

Murine cDNA for the cytokine IL-I0 were cloned into the pAAV2.C~ plasmid
containing AAV -2 inverted tenninal repeats (lTRs), a CMVIchicken-beta-actin hybrid (CP)
promoter including an intron, and the SV40 polyadenylation region [243]. To facilitate
pseudotyping, pAAV.Cp-mILI0 was co-transfected with pXYZS, an adenoviral helper
plasmid with AAV2 rep/AAVS cap [167]. Anion-exchange chromatography was used to
purify the AAVS pseudotyped vector and the dot-blot assay was used to detennine the titer of
rAAV virions harboring vector genomes. The pseudotyped packaged vector was then
designated as AAVS.Cp-mILI0 (Figure 2.1).
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Figure 2.1 Schematic of the AAVS.Cp-mILI0 vector. AAV5.C~-mILI0 contains the
CMVIchicken-beta-actin hybrid promoter including an intron, the murine IL-IO coding
sequence, and the SV40 polyadenylation region. Adapted from [243].
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Pseudomonas aeruginosa-laden bead preparation

The mucoid Pseudomonas aeruginosa isolate, PA 15719, was obtained from the
sputum of a patient with CF using a protocol approved by the Institutional Review Board
(IRB) at MUSC. Bacteria were maintained as glycerol stocks and stored at -80°C. Bacteriaimpregnated agar beads were prepared as described by van Heeckeren et al [217, 220] with
minor modifications. Briefly, an inoculation loop was used to collect a sample of frozen
mucoid P. aeruginosa stock, streaked for isolation on a tryptic soy agar (TSA) plate, and
incubated at 37°C overnight. One colony was picked from the plate and used to inoculate 50
ml tryptic soy broth (TSB) in a 125 Erlenmeyer flask, which was placed, shaking, overnight
at 37°C. A 0.1 ml aliquot of the culture was used to inoculate a second flask of 50 ml TSB in
a 125 Erlenmeyer flask. Bacteria were grown to late log phase, shaking, in a 37°C incubator.
The bacterial culture was concentrated by centrifugation, resuspended in 10 ml TSB, and 5
ml added to warm (50°C) 2% low melting agarose (Type 1 low EEO; Sigma) in PBS. The
bacteria-agar mixture was added to warm (50°C) heavy mineral oil (0122-4, Fisher)
containing a stir bar, and stirred rapidly at room temperature for 6 min, followed by cooling
with slow additions of ice over a 10-min period. The agar beads were transferred to a
separatory funnel; the mineral oil removed, and washed one time with 0.5% sodium
deoxycholate (SDC), one time with 0.25% SDC, and four times with PBS. The P.
aeruginosa-Iaden agarose beads were collected and allowed to settle. Additional liquid was

removed to obtain a final volume of 75% beads and homogenized using a Kinematica
Polytron PTI0/35 homogenizer for 4 min at high speed to obtain beads predominantly 100120 f.lm in diameter. The size of the beads was measured microscopically before and after
homogenization. Using serial dilutions, quantitative bacteriology was performed on an
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aliquot of the homogenized bead slurry to determine bacterial concentration in colony
forming units (cfu) per milliliter. Sterile agar beads were prepared by the same method,
without the addition of P. aeruginosa culture, and were verified for sterility by serial
dilutions plated on TSA plates. The homogenized bead slurries for both preps were prepared
the day before inoculation of the mice, stored at 4°C, and concentration of bacteria calculated
on the day of inoculation.

Assessment of weight loss

Body weight was measured in all mIce before PBS or AAV5.C~-mILI0
administration, before infection with sterile beads or P. aeruginosa-Iaden beads (6 weeks
later), and at time of sacrifice (3 days after infection). A record was made of any hunching,
poor grooming, fatigue, or increased respiratory effort following inoculation with agarose
beads.

Intratracheal injection

In preparation for intratracheal injection, mice were sedated through inhalation of
isoflurane. A transverse cervical incision was made, and the trachea was exposed and
intubated with a sterile, flexible 2I-gauge SURFLO winged infusion set (Terumo
Corporation, Tokyo, Japan) attached to a I.O-ml syringe. Thirty microliters containing IxIO I2
vg AAV5.C~-mILI0 or PBS was injected into the trachea. All incisions were closed by
suture. Six weeks after treatment with AAV5.C~-mILIO or PBS, the mice underwent
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intratracheal injection with sterile agarose beads or P. aeruginosa-Iaden beads. Anesthesia
6

and intratracheal injection were performed as before, with 50 f.LI of sterile beads or 5x 10 cfu
P. aeruginosa-Iaden beads being injected.

Collection and processing of samples

At 3 days following P. aeruginosa-Iaden bead infection, the mice were anesthetized
with isoflurane and sacrificed by exsanguination. Blood and bronchoalveolar lavage fluid
(BALF) were collected. For the BAL collection, the trachea was isolated by blunt dissection.
An incision was made in the upper portion of the trachea, which was cannulated with a 21gauge shielded LV. catheter (BD Bioscience, San Hose, CA) attached to a 5 ml syringe. The
alveoli were washed 3 times, each with 1 ml PBS. The volume of bronchoalveolar lavage
fluid (BALF) recovered was approximately 1-2 ml. Lungs were collected and weighed for
histology and cytokine analysis of lung homogenate. For histology, the lungs were inflated
and fixed with 4% paraformaldehyde, while for lung homogenization, the lungs were
immediately submerged in liquid Nitrogen and stored at -80°C.

To obtain homogenate cytokine values, the lungs were thawed and washed in 0.5 ml
cell wash buffer (Bio-Rad, Hercules, CA). One milliliter of cell lysis buffer (Bio-Rad) was
added to each lung, which was then homogenized for 60 seconds at high speed using
Kinematica Polytron PTI0/35 homogenizer (Brinkmann Instruments Co., Westbury, NY).
The homogenized lung samples were frozen at -80°C, thawed on ice, and then sonicated in
ice-cold water. They were centrifuged at 1500xg at 4°C for 10 min; the supernatant was
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aspirated and the homogenate stored at -80 D C. Cytokine analysis was performed within 24
hrs of homogenization.

Measurement of cytokine levels

Cytokine levels in the serum, BAL, and lung homogenate were measured using a
customized Bio-Plex cytokine kit (Bio-Rad) containing detection for

IL-I~,

TNF-a, IFN-y,

IL-IO, KC, and MIP-1a. Analysis was conducted using the Bio-Plex multiplex suspension
array system (Bio-Rad) per the company's protocol. Each sample was performed in
duplicate. Epithelial lining fluid (ELF) values were obtained through correction of the BAL
dilution using a ratio of urea nitrogen concentrations in the airway. fluid and in the serum by
the Enzymatic Urea Nitrogen (blood urea nitrogen [BUN]) procedure (Stanbio, Boerne, TX).
Homogenate levels were standardized by lung weight for a final value of picogram (pg) per
gram of lung.

Histological analysis

After the lungs were fixed in 4% paraformaldehyde for 48 hrs, they were embedded
in paraffin and cut in 150-200 Jlm step-sections. The step-sections were left unstained (for
immunohistochemistry) or stained with hematoxylin and eosin (H&E) using standard
techniques.
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Immunohistological staining protocol

Five Jlm lung paraffin sections were soaked in Hemo-de for 10 min followed by
rehydration in graded alcohol (100%, 80%, 40%, 20%) and water, each for 5 min. The
sections were blocked with universal blocking solution (KPL, Gaithersburg, MD) for 30 min
at 25°C and rinsed with water and Tris buffer. Then, the sections were blocked with goat
serum at 25°C for 15 min and incubated with rat anti-mouse IL-I0 monoclonal antibody
(1: 1000 dilution; BD PharMingen, San Diego, CA) overnight at 4°C in a humidity chamber.
The next day, the sections were washed in Tris buffer and incubated with biotinylated goat
anti-rat IgG-horseradish peroxidase (HRP) (1: 100 dilution; BD PharMingen) at 25°C for 1 hr.
The sections were further incubated with HRP-streptavidin (KPL) for 30 min at 25°C and
then incubated with true blue substrate solution (KPL) for 10 min at 25°C. After being
washed in water and counter-stained in orcein (KPL) for 3 min, the sections were dehydrated
in graded alcohol and soaked in Hemo-de for 10 min.

Statistical analysis

Data are presented as average

± SD. Change in body weight is expressed as the

percentage of weight lost from the original weight three days before inoculation. Statistical
analysis of percentage weight loss, and cytokine levels were determined by unpaired, twotailed Student's t test using the Graph Pad InStat statistics software program (GraphPad
Software, San Diego, CA). Welch correction was applied when standard deviations were
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significantly different. For all data sets, p values less than 0.05 were determined to be
statistically significant.

2.3 Results
AAV5.Cp-mILIO and PBS-treatment result in similar percentage weight loss in IL-IOT
mice infected with P. aeruginosa-Iaden beads.
IL-I0T mice were inoculated, intratracheally, with lxI012 vector genomes (vg) of
AAV5.C~-mILI0 or PBS. Six weeks later, the mice that received AAV5.C~-mILI0 were
infected with 5xl06 cfu of P. aeruginosa-Iaden beads (n=5). Mice that received PBS were
either given sterile beads (n=4) or infected with 5x 106 cfu of P. aeruginosa-Iaden beads
(n=6). Mice were sacrifice after 3 days.
To ensure that AAV5.C~-mILl 0 did not impact mouse weight, the mIce were
weighed before administration with AAV5.C~-mILI0 or PBS and 6 wks later before P.
aeruginosa-laden bead infection. There was no significant difference in the percentage

weight gain between the groups (p>O.05).
The mice were weighed a second time before administration with P. aeruginosaladen beads and 3 days later before sacrifice. The average pre-infection weight of the mice
receiving

AAV5.C~-mILI0

(n=5) was 23.3 g with mice losing an average body weight of

16.4% ± 9.9 over the 3 days after P. aeruginosa infection and before sacrifice. This profile
was similar to the mice in the PBS group infected with P. aeruginosa (n=6): initial weight
was 22.2 g with mice losing an average body weight of 22.4% ± 1.3. Mice that were not
infected and, instead, received sterile beads as a control for surgery (n=4) had an average

82

initial weight of 22.6 g, losing an average body weight of 5.3% ± 1.6. There was no
significant difference in the percentage weight loss between AAV5.C~-mILIO and PBS mice
infected with P. aeruginosa-laden beads (p>0.05); statistical difference could not be obtained
from mice receiving sterile beads due to the small sample size.

Intratracheal administration of AAV5.CIJ-mILIO produces significant levels of IL-IO
protein in the lung.

IL-IO expression following AAV5.C~-mILI0 administration in the lungs of IL-IOT
mice infected with P. aeruginosa was measured to verify gene transfer and expression
efficiency. In the AAV5.CJ3-mILIO-treatment group, mice were infected with lxI05 cfu P.
aeruginosa-Iaden agarose beads by intratracheal injection. Mice receiving PBS were either

given sterile beads or infected with P. aeruginosa-Iaden agarose beads. Three days later, the
mice were sacrificed and BALF, lung tissue, and blood were collected from each animal.
The administration of AAV5.C~-mILl 0 successfully resulted in the production of IL10 as measured in the ELF (average, 25,000 pg/ml) and lung homogenate (average, 12,000
pg/gram-lung) (Figure 2.2). IL-IO production was also measured in the serum to determine
whether production was systemic. IL-IO was undetectable in the serum of mice in all
treatment groups (data not shown), thus confirming localized secretion of IL-I0 from the
AAV5.C~-mILIO vector.
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Figure 2.2
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Figure 2.2 Successful intratracheal administration of AAVS.Cp-mILIO to the murine
lung. Anesthetized mice were intratracheally injected with PBS or Ixl012 vg of AAV5.C~
mILIO. After 6 weeks, AAV5.C~-mILI0-treated mice were intratracheally infected with
5xl06 cfu P. aeruginosa-Iaden beads while PBS-treated mice were infected with P.
aeruginosa-Iaden beads or sterile beads. Untreated mice did not receive the vector, PBS, or
agarose beads. Mice were sacrificed 3 days later. IL-IO protein levels were measured in the
ELF (~) and lung homogenate ~). **p<O.005 compares PBS and AAV5.C~-mILIO
treatments in IL-IO levels in the ELF and lung homogenate, respectively. Data shown are
average ± standard deviation for 3 or more animals in each group from 2 experiments.
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AAVS.Cp-mILIO mediates IL-IO protein expression in the alveoli.

In addition to determining gene expression levels, we sought to identify the specific
cells responsible for protein expression. An immunostaining protocol for IL-IO was
developed using paraffin-embedded lung sections. Positive IL-IO staining was evident in
lung sections from P. aeruginosa-infected IL-IOT mice that received AAVS.Cp-mILIO
(Figure 2.3A) with no IL-IO staining in the lung tissue harvested from IL-IOT mice that
received PBS (Figure 2.3B). These data confirm that resident alveolar cells have been
successfully infected with the IL-I 0 vector and are responsible for protein production.
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Figure 2.3
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Figure 2.3 Lung sections from IL-IOT mice receiving AAV5.CIi-mILIO stain positive for
IL-IO expression in the alveoli. Anesthetized mice were intratracheally injected with PBS
or IxIOl vg of AAV5.C~-mILI0. After 6 weeks, anesthetized mice were intratracheally
infected with 5xI06 cfu P. aeruginosa-laden beads. Mice were sacrificed 3 days later. Lungs
were collected and fixed in paraformaldehyde, then sectioned and immunostained for IL-IO
protein expression. Arrows point to blue staining to indicate IL-IO protein expression. (A)
AAV5.C~-mILI0 (B) PBS. Magnification 40x. Observations represent the findings from 4 or
more animals from 2 experiments.
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AAVS.Cp-mILIO produces a significant decrease in proinflammatory cytokine levels in
the lung.
The lung homogenates from IL-IOT mice receiving AAV5.C~-mILIO or PBS and
infected with P. aeruginosa were analyzed for cytokine levels. AAV 5. C~-mIL 10 reduced
chemokines levels: a 9-fold reduction in KC and a 4-fold reduction in MIP-Ia compared to
PBS treatment (Figure 2.4A). There was also a decrease in pro inflammatory cytokine levels
5-fold reduction in

IL-l~

(Figure 2.4A) and a 0.5 fold reduction in TNF-a (Figure 2.4B)

with an increase (IO-fold) of IFN-y. Chemokine and cytokine levels in the ELF showed a
trend towards decreasing

IL-I~,

KC, and MIP-Ia levels, and an increase IFN-y (data not

shown). To determine if the dramatic reduction in lung pro inflammatory cytokines had a
systemic effect, we measured circulating proinflammatory cytokine concentrations in the_
serum and did not observe a decrease (data not shown).
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Figure 2.4
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Figure 2.4 AAV5.CI}-mILIO decreases proinflammatory cytokine levels in the lungs of
IL-IOT mice. Anesthetized mice were intratracheally injected with PBS or lxl012 vg of
AAV5.C~-mILIO. After 6 weeks, anesthetized mice were intratracheally infected with 5xl06
cfu P. aeruginosa-Iaden beads. Mice were sacrificed 3 days later. Lungs were collected,
homogenized, and cytokine levels measured. (A) IL-l~, KC, and MIP-l a were measured
with PBS (0) or AAV5.C~-mILI0 treatment (II). (B) IL-IO, IFN-,,(, and TNF-a. were
measured with PBS (0) or AAV5.C~-mILl 0 treatment (II). *p < 0.05, **p < 0.005 Data
shown are average ± standard deviation for 5 or more animals in each group from 2
experiments.
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IL-IO expression from AAV5.CIJ-mILIO decreases inflammation-associated lung
pathology.

Despite fairly high IL-IO levels in the lung, there was no indication of systemic
infection or immunosuppression modulated by IL-IO. This was confirmed by histological
examination of lung sections obtained from mice receiving AAV5.C~-mILIO and infected
with P. aeruginosa, which contained fewer neutrophils and lymphocytes, primarily found in
discrete nodules (Figure 2.5A, B). The lung sections of PBS-treated mice infected with P.
aeruginosa had extensive inflammatory cell infiltration and lung consolidation (Figure 2.SC,

D) while PBS-treated mice given sterile beads did not exhibit any inflammation-associated
histopathology (Figure 2.SE, F). This pathology corroborates our cytokine findings and
supports our hypothesis that AAV5.C~-mILIO can effectively reduce inflammation in P.
aeruginosa- infected lungs.
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Figure 2.5
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Figure 2.5 Inflammation-associated pathology is reduced in AAV5.Cp-mILIO-treated
mice. Anesthetized mice were intratracheally injected with PBS or IxI012 vg of AAV5.C~
mILIO. After 6 weeks, AAV5.C~-mILIO-treated mice were intratracheally infected with
5xI06 cfu P. aeruginosa-Iaden beads while PBS-treated mice were infected with P.
aeruginosa-Iaden beads or sterile beads. Mice were sacrificed 3 days later. Lungs were
collected and fixed in paraformaldehyde, then sectioned and H&E stained. (A, B) AAV5.C~
mILIO with P. aeruginosa-Iaden beads, (C, D) PBS with P. aeruginosa-laden beads, and (E,
F) PBS with sterile beads. Magnifications are 4x (A, C, E) and lOx (B, D, F). Observations
represent the findings from 3 or more animals from 2 experiments.
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2.4 Discussion
IL-I0 is necessary to balance the pro inflammatory response and serves to limit and
terminate the cascade of inflammatory cytokines triggered by NFKB activation. By regulating
cytokine secretion and the differentiation and proliferation of many immune cells, such as T,

B, natural killer (NK), antigen-presenting cells (APC), mast cells, and granulocytes, IL-I0
helps maintain immune homeostasis. Stimulation of the IL-I0 receptor regulates signaling
pathways, including JAKISTAT3, PI 3-kinase, MAPK, and suppressor of cytokine signaling
(SOCS) [128] by selective inhibition of transcription through STAT3, not as a general block
on NFKB activation [130]. IL-IO may also decrease myeloid cells and prevent cell to cell
communication between macrophages and T cells, resulting in decreased production of
pro inflammatory cytokines and cytotoxic factors. Via these mechanisms, IL-IO reduces the
production and release ofTH-l cytokines (including IL-2, IL-6, IL-8, and TNF-a).
Decreased IL-I0 production has been documented in CF and is thought to contribute to
the excessive inflammation present in the airway during active and chronic infection [26, 30].
Supporting this theory are studies of chronic P. aeruginosa infection in IL-IOT and CFTR
knockout mice, demonstrating dramatic weight loss, greater PMN infiltration, and higher
concentrations of proinflammatory cytokines following infection compared to wild-type mice
[37,139,215,220,225,226]
In this study, we performed intratracheal injection of AAV5.C~-mILIO 6 weeks prior
to chronic P. aeruginosa infection in IL-I0T mice. IL-IO was expressed in the alveoli and
produced at significantly higher levels in the ELF and lung homogenate in vector-treated
mice compared to mice that received PBS. IL-IO production correlated with a significant
decrease in proinflammatory cytokines

IL-l~,

KC, and MIP-la, as well as a decrease in
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TNF-a, and inflammation-associated lung pathology (neutrophil influx and lung
consolidation). This corroborated the results found by others when IL-I0 was administered as
recombinant protein [37, 139, 141]. In a chronic P. aeruginosa infection in CD-l mice,
intraperitoneal administration of recombinant IL-I0 (rIL-I0) resulted in increased survival,
fewer neutrophils in the BAL, and decreased area of lung inflammation when compared to
placebo-treated mice with no decrease in bacterial burden [139]. A study was also done with
intraperitoneal injection of rIL-l 0 to CFTR knockout mice resulting in decreased T-cell costimulatory molecule, B7, and poor co-stimulatory activity of bronchoalveolar macrophages
(BALMs) [140]. Because BALMs from patients with CF have been shown to actively
produce the proinflammatory cytokines which are elevated in CF BAL [26, 29], treatment
with IL-I0 may suppress synthesis of these proinflammatory cytokines and alter T-cell
responses. Sawa et al administered recombinant IL-I0 (rIL-I0) intraperitoneally before or
after acute P. aeruginosa infection in Balb/c mice [141], demonstrating decreased lung injury
and mortality, and a decreased inflammatory response (increase in IFN-y and slight decrease
in TNF-a) as shown in our studies with AAV5.C~-mILI0. Recombinant IL-I0 was also
administered, subcutaneously, in an acute model using intratracheal LPS challenge in CF
mice and resulted in a significant decrease of PMNs and TNF -a, which correlated with
decreased NFKB activity and increased IKBa [37].
Importantly, blood levels of proinflammatory cytokines and IL-I0 from mice receiving
AAV5.C~-mILI0

were not significantly different from those measured in PBS-treated mice.

This rmding supports a localized IL-I0 effect, an important safety feature because IL-l 0 leakage
into the circulation could mediate systemic immunosuppression or even become
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immunostimulatory at high systemic doses [244]; rIL-IO administered systemically was
previously found to attenuate both local and systemic effects [139].
There were several limitations in this study. Instead of using CFTR knockout mice, we
used the IL-IOT mouse model because of its strong similarities to CFTR knockout mice in
response to both chronic and acute P. aeruginosa lung infections. Greater neutrophil
recruitment, more severe weight loss, and increased areas of lung inflammation result
compared to wild-type mice [35, 37, 139, 215, 220, 225, 226] suggesting an important role for
IL-IO in regulating the inflammatory response to P. aeruginosa. IL-IOT mice still produce
background levels of IL-l 0, demonstrated in our PBS-treated mice infected with P. aeruginosa
(Figure 2.2); however this level was significantly less than the levels of IL-IO produced by

AAV5.C~-mILIO (p<O.005).
We did not use a sham AAV vector to ensure the AAV did not impact P. aeruginosa
infection or IL-l 0 production. While AA V-mediated gene transfer leads to the development of
antibodies against the vector capsid, possibly preventing vector re-administration, the lack of
inflammatory responses documented in numerous in vivo gene transfer models employing
AAV vectors suggest that these agents do not interact significantly with the innate immune
system [143]. Studies in non-human primates with AAV-CFTR showed the vector did not
result in an increase in pro inflammatory cytokines and neutrophil influx as measured in the
BALF [143]. Additionally, studies in murine models have shown that AAV-GFP has the
same response as PBS when measuring percentage weight loss and neutrophil migration (Dr.
Tom Ferkol, unpublished studies), supporting our use of PBS as a negative control.
In the current study, we did not measure bacterial burden. We observed that mice
receiving IL-IO prior to P. aeruginosa infection appeared to be healthier (more active, less
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respiratory distress, better groomed) than mice given PBS. That high levels of IL-I0 do not
promote bacteremia is supported by studies showing chronic P. aeruginosa infection in IL-IOT
and CF mice models have no difference in bacterial burden when compared to wild-type mice
[220]. Additionally, the bacterial burden following systemic IL-IO administration is unchanged
in IL-I0T and CF mice [139]. Furthermore, treatment of CF patients with anti-inflammatory
therapeutics slows the progression of lung disease, but does not exacerbate infection [96, 99,
100]. At present, we are testing AAV5.CJ3-mIL10 in a chronic P. aeruginosa infection model in
CFTR knockout mice to substantiate these fmdings and will examine bacterial load in all
infected mice to verify that a decrease in the inflammatory response does not promote the spread
of infection in the lung or systemically.
The model of chronic infection using P. aeruginosa-Iaden agarose beads was over a
short period of time (3 days) and seems counterintuitive as a chronic model; however, this most
commonly-used approach of chronic lung infection and most appropriate in vivo
representation in experimental models of CF. In non-CF mice, infection with P. aeruginosaladen beads can persist for up to 28 days [220-222], while CFTR knockout mice appear to
have more severe mortality and inflammation, characterized by high levels of proinflammatory mediators (TNF-a, KC, and MIP-2) 3 days after exposure to the beads.
Impaired bacteria killing occurs between days 3 and 7 after infection of CF mice with 80% of
death on day 7, compared to wild-type mice with 500/0 mortality rate [220, 224]. A sacrifice
date of 3-4 days is documented to be optimal for analysis of cytokines and lung pathology
[217].
Historically, AAV gene transfer has not led to sufficient gene expression in the CF
lung due to a number of factors including the deficiency of the AAV2 receptor (heparin sulfate)
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on the apical surface of epithelial cells, the lack of a strong promoter in AAV -based vector
cassettes, and the presence of significant physical barriers to viral entry in epithelial cells. We
addressed two of these barriers in our vector construct by employing an AAV5 pseudotyped
vector, which binds to apically-expressed receptors [2,3-linked sialic acid and the plateletderived growth factor (PDGF)] [188, 241, 242] and a potent promoter

(C~),

previously

demonstrated to be highly effective in the murine lungs [204]. Furthermore, because our
therapeutic gene, IL-I0, is produced by a variety of cells and is a secreted protein, it has more
available targets and may demonstrate its anti-inflammatory effects in sites removed from the
successfully transduced cells.
In recent decades, many advances have been made in the treatment of cystic fibrosis,
contributing to a longer life span and less morbidity for patients with CF. However, airway
inflammation and infection continue to be problematic for the majority of patients, leading to
progressive airway obstruction, lung damage, and, eventually death. The role of inflammation in
the pathogenesis of CF has been controversial, but the majority of current evidence supports the
hypothesis that airway inflammation in CF is exaggerated and pathologic [26-30, 64, 65, 68,
228, 229]. Although anti-inflammatory treatments for CF airway disease have been associated
with modest improvements in lung health, none have achieved a high rate of success, and
several carry the risk of significant side effects. Therefore, the development of safer and more
effective anti-inflammatory therapies continues to be essential. In this study, we prove our
hypothesis that in a chronic P. aeruginosa infection model, AAV5.C~-mILI0 mediates high
levels of lung-specific IL-I0 expression and reduction in proinflammatory cytokines with no
systemic leakage. The anti-inflammatory activity of AAV5.C~-mILI0 is an important step
towards finding new, effective therapies for inflammation in CF and validating the use of
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AAV gene transfer to alter the local proinflammatory immune response in the lung. Future
studies should analyze the duration of AAV-mediated gene expression, shown for some
transgenes to persist for 1.5 years in animal models [159-162], a feature that is clinically
relevant for a population of patients with CF that receive multiple therapies a day [245].
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Chapter 3.
Non-invasive delivery of P. aeruginosa-Iaden beads produces a murine
model of chronic lung disease.

3.1 Introduction

The leading cause of morbidity and mortality in patients with CF is chronic
endobronchial infections with mucoid Pseudomonas aeruginosa [83, 84]. CF is caused by
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR); however,
similar mutations of the CFTR gene to create an animal model of CF have not resulted in a
spontaneous in vivo model of CF lung disease [209]. CFTR knockout mice are generally
difficult to breed, yielding small litters, and having early mortality, succumbing to a lethal
intestinal phenotype, rather than the obstructive airway disease commonly seen in patients
with CF. The high mortality of CFTR knockout mice led to the creation of gut-corrected
CFTR knockout mice, CFTR knockout mice that have overexpression of human CFTR from
the fatty acid-binding promoter (FABP) to improve the intestinal phenotype and increase
viability [212]. While the mortality rates were dramatically reduced, gut-corrected CFTR
knockout mice are still smaller in size and body weight than their respective litter-mates,
making them more sensitive to manipulation [217, 246].
Because CFTR knockout mice do not have lung disease, it must be induced in animal
models of CF lung disease. The most commonly-used model of chronic lung infection in vivo
uses intratracheal injection of P. aeruginosa-Iaden agarose beads, a technique developed by
Cash et al in rats [218], modified by Stark et al for mice [219], and further optimized for
reproducible results by van Heeckeren et al [217]. In non-CF mice, the infection can persist
for up to 28 days [220. .222], while CFTR knockout mice appear to have more severe
mortality and inflammation, characterized by high levels of pro-inflammatory mediators
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(TNF-a, KC, and MIP-2) 3 days after exposure to the beads. Impaired bacteria killing occurs
between days 3 and 7 after infection of CF mice with 80% of death on day 7, compared to
wild-type mice with 500/0 mortality rate [220, 224]. This finding demonstrates that mice
lacking CFTR function are relevant in vivo models for studying CF lung disease because they
are predisposed to bacterial lung infection, but the mechanism of increased susceptibility is
unclear, although it is suspected that the underlying CF -specific host factors in animal
models are the same as in humans.
Although intratracheal injection of P. aeruginosa-Iaden beads produces chronic lung
infection characteristic of CF, the complexity of reproducing P. aeruginosa lung infection in
vivo coupled with the difficulties of using CFTR knockout mice has led researchers to seek

alternative, non-invasive methods of administration. Guilbalt et al recently published a
method of non-invasive P. aeruginosa-Iaden bead administration using microscopic guidance
for delivery to the trachea [246] and the model resulted in increased weight loss, higher
bacterial burden, and more elevated polymorphonuclear alveolar cell recruitment into the
lungs in CFTR knockout mice compared to wild-type mice. Aspiration challenge has also
been used successfully for P. aeruginosa-Iaden bead delivery [247], but neither approach has
been directly compared in successful lung delivery to the widely-used intratracheal injection
method. While the microscopic guidance method was better characterized for reproducibility
of P. aeruginosa infection, the technical difficulty of performing this procedure led us to
focus on aspiration challenge for P. aeruginosa-Iaden bead delivery.
Aspiration challenge was originally described by Wills-Karp et al [248] who later
made minor modifications to improve lung delivery and reproducibility between animals
[249]. This non-invasive method results in even distribution to the lung with reportedly no
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delivery to the esophagus or stomach [248, 250] and is seldom used, but could be a beneficial
procedure as it is less technically difficult and could result in less mortality associated with
surgical instillation of the bacteria.
The purpose of these experiments is to refine the method of aspiration challenge
using surfactant phospholipids as a carrier for delivery of P. aeruginosa-Iaden beads as a
viable alternative to intratracheal injection. Surfactant, a mixture composed of phospholipids
and surfactant associated (SA) proteins, lowers surface tension and, when used as a vehicle,
aids in uniform distribution to the peripheral and distal regions of the lungs [251,252]. We
hypothesize that aspiration challenge with surfactant phospholipids results in similar or
enhanced lung delivery of P. aeruginosa-Iaden beads when compared to intratracheal
injection. If the non-invasive technique produces the same characteristics of chronic lung
infection (weight loss, cytokine release, histopathology, and bacterial burden) with
reproducibility and less mortality, then it can serve as a model of CF lung disease.

104

3.2 Materials and Methods

Eight-week-old CD-1 mice were purchased from the Charles River Laboratories, Inc
(Wilmington, MA), shipped in protective, filtered containers, transported in climatecontrolled trucks, and allowed to acclimate for at least 3 days prior to use. Mice were fed
autoclaved or irradiated Harlan Teklad Sterilizable Rodent Blox 8656 (Harland Teklad,
Indianapolis, IN) and bedded on autoclaved 1/8" com cob bedding and com husk nesting
material (Harland Teklad, Indianapolis, IN). Mice were housed, 2-4, in Micro-Isolator Top
Flow Ventilated cages (Tecniplast, Exton, PA) in ventilated racks. All caging supplies were
cleaned with an automated cage wash and autoclaved prior to use in animal rooms. MUSC is
fully accredited by the Association for the Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC, International), and the mice were maintained in
specific pathogen-free (SPF) conditions. Each rodent rack in the facility was assigned 1-4
cages of sentinels which are housed in microisolator cages without filter tops. Sentinel
animals are exposed to dirty bedding from different shelves of animals at each cage change,
but serology was negative for Sendai virus (SEND), Pneumonia virus of mice (PVM), Mouse
hepatitis virus (MHV), Mouse polio virus (TMEV), Reovirus (REO), Mycoplasma pulmonis
(MPUL), Mouse arvovirus (MPV), and Mouse rotavirus (EDIM). Mouse feces were negative
for Helicobacter. The procedures were approved by the Institutional Animal Use and Care.
Committee (lACUC) at MUSC.
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Amido black dye
Anesthetized mice received 0.04% amido black dye (Bio-Rad, Hercules, CA) in
phosphate buffered saline (PBS) through aspiration challenge with surfactant phospholipids
or intratracheal injection. After 1 hr, anesthetized mice were sacrificed by cervical
dislocation and lungs, stomach, and spleen collected.

Pseudomonas aeruginosa-laden bead preparation

The mucoid Pseudomonas aeruginosa isolate, PA 15719, was obtained from the
sputum of a patient with CF using a protocol approved by the Institutional Review Board
(IRB) at MUSC. Bacteria were maintained as glycerol stocks and stored at -80°C. Bacteriaimpregnated agar beads were prepared as described by van Heeckeren et al [217, 220] with
minor modifications. Briefly, an inoculation loop was used to collect a sample of frozen
mucoid P. aeruginosa stock, streaked for isolation on a tryptic soy agar (TSA) plate, and
incubated at 37°C overnight. One colony was picked from the plate and used to inoculate 50
ml tryptic soy broth (TSB) in a 125 Erlenmeyer flask, which was placed, shaking, overnight
at 37°C. A 0.1 ml aliquot of the culture was used to inoculate a second flask of 50 ml TSB in
a 125 Erlenmeyer flask. Bacteria were grown to late log phase, shaking, in a 37°C incubator.
The bacterial culture was concentrated by centrifugation, resuspended in 10 ml TSB, and 5
ml added to warm (50°C) 2% low melting agarose (Type 1 low EEO; Sigma) in PBS. The
bacteria-agar mixture was added to warm (50°C) heavy, mineral oil (0122-4, Fisher)
containing a stir bar, and stirred rapidly at room temperature for 6 min, followed by cooling
with slow additions of ice over a 10-min period. The agar beads were transferred to a
separatory funnel; the mineral oil removed, and washed one time with 0.5% sodium
106

deoxycholate (SDC), one time with 0.25% SDC, and four times with PBS. The P.
aeruginosa-Iaden agarose beads were collected and allowed to settle. Additional liquid was

removed to obtain a final volume of 75% beads and homogenized using a Kinematica
Polytron PTI0/35 homogenizer for 4 min at high speed to obtain beads predominantly 100120 !lm in diameter. The size of the beads was measured microscopically before and after
homogenization. Using serial dilutions, quantitative bacteriology was performed on an
aliquot of the homogenized bead slurry to determine bacterial concentration in colony
forming units (cfu) per milliliter. Sterile agar beads were prepared by the same method,
without the addition of P. aeruginosa culture, and were verified for sterility by serial
dilutions plated on TSA plates. The homogenized bead slurries for both preps were prepared
the day before inoculation of the mice, stored at 4°C, and concentration of bacteria calculated
on the day of inoculation.

Surfactant phospholipid Iiposomes preparation

DPPC

and

pOPC

(I-Palmitoyl-2-0Ieoyl-sn-Glycero-3-Phosphocholine)

phospholipids were purchased (Avanti Polar Lipids, Alabaster, AL) with stock
concentrations of20 mg/ml (DPPC in chloroform) and 10 mg/ml (POPC in chloroform). For
every ml of finalliposome suspension, 17.5 mg DPPC (0.875 ml stock) and 7.5 mg

pope

(0.75 ml POPC stock) were added in a clean, sterile 13xl00 mm glass tube. The tube was
capped and mixed well via vortex. The solvent was removed via nitrogen stream, with the
tube submerged in 40°C water bath, and mixed during the drying process. After the samples
were dry, the tubes were transferred to a lyophylization flask and vacuum-dried overnight
without additional heating. PBS (1.0 ml) was added to each tube, and then the tubes were
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heated at 45°C for 15 min, vortexed for 30 sec, and sonicated for 10 sec. This step was
repeated 3 times to ensure the liposome preparation had consistent viscosity and did not
contain large liposome aggregates. The liposomes were transferred to sterile screw-cap
plastic cryovials using sterile pipette tips and stored at 4°C. The stock phospholipid liposome
concentration was 7:3 (mol/mol) DPPCIPOPC at 25 mg/ml total phospholipid. For
administration, a concentration of 4 mg/ml phospholipid liposomes was used.

Intratracheal injection
Mice were anesthetized through inhalation of a mixture of oxygen and isoflurane in a
closed chamber, then transferred and immobilized in a supine position on a surgical table
(Figure 3.1A). During the procedure, mice were under continuous anesthesia with isoflurane
through a conical nosepiece. A small transverse incision was made (about 0.5 mm) just
cranial to the thoracic inlet followed by blunt dissection of the salivary glands and
musculature to expose the trachea. A sterile, flexible 21-gauge SURFLO winged infusion set
(Terumo Corporation, Tokyo, Japan) was inserted into the trachea between the tracheal
rings for delivery to both lobes of the lung. A one milliliter syringe pre-loaded with 0.050
ml containing sterile beads or 4mg/ml surfactant phospholipid liposomes with 5x 106 cfu P.
aeruginosa-Iaden beads was attached to the winged infusion set and the plunger depressed

for injection into the trachea (the same procedure was followed for the amido dye injection).
The attached set was removed and incision closed by suture. Mice were monitored for
recovery which occurred within 10 min of procedure completion.
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Aspiration challenge with surfactant phospholipids

Aspiration challenge was conducted using previously published methods [248, 249]
with minor modifications. Mice were anesthetized through inhalation of a mixture of oxygen
and isoflurane for 5 min in a closed chamber. Mice were removed from anesthetization
chamber and suspended by their front incisors in a supine position on an acrylic platfonn at a
60° angle (Figure 3.1B). Coated forceps were used to extend the tongue from blocking the
trachea (Figure 3.te). Using a p200 pipette, 0.040 ml containing sterile beads or 4mg/ml
surfactant phospholipids with 5x 106 cfu P. aeruginosa-Iaden beads was instilled at the back
of the oral cavity above the tracheal opening (the same procedure was followed for the amido
dye injection). Immediately after, the mice aspirated the liquid, evidenced by the mouse
gulping. Mice were monitored for recovery which occurred within 5 min of the
administration.
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Figure 3.1
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Figure 3.1 Apparatus set-up for intratracheal injection and aspiration challenge with
surfactant phospholipids. A. Intratracheal injection. Mice were anesthetized through
inhalation of a mixture of oxygen and isoflurane in a closed chamber, then transferred and
immobilized in a supine position on a surgical table. During the procedure, mice were under
continuous anesthesia with isoflurane through a conical nosepiece. A small transverse
incision was made (about 0.5 mm) just cranial to the thoracic inlet followed by blunt
dissection of the salivary glands and musculature to expose the trachea. A sterile, flexible
2I-gauge SURFLO winged infusion set (Temmo Corporation, Tokyo, Japan) was inserted
into the trachea between the tracheal rings for delivery to both lobes of the lung. A one
milliliter syringe was attached to the winged infusion set and the plunger depressed for
sample (dye or beads) injection into the trachea. The attached set was removed and incision
closed by suture. Mice were monitored for recovery which occurred within 10 min of
procedure completion. B, C. Aspiration challenge with surfactant phospholipids. Mice were
anesthetized through inhalation of a mixture of oxygen and isoflurane for 4 min in a closed
chamber. Mice were removed from anesthetization chamber and mice suspended by their
front incisors in a supine position on an acrylic platform at a 600 angle (B). Coated forceps
were used to extend the tongue from blocking the trachea (C). Using a p200 pipette, the
sample (dye or beads) was instilled at the back of the oral cavity above the tracheal opening.
Immediately after, the mice aspirated the liquid, evidenced by the mouse gulping. Mice were
monitored for recovery which occurred within 5 min of administration.
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Assessment of weight loss
Body weight was measured In all mIce before P. aeruginosa or sterile bead
inoculation and at time of sacrifice (3 days later). A record was made of any hunching, poor
grooming, fatigue, or increased respiratory effort following inoculation with agarose beads.
At 3 days following P. aeruginosa-Iaden bead or sterile bead inoculation, mice were
anesthetized with isoflurane and sacrificed by cervical dislocation. Blood was obtained from
all mice.

Bronchoalveolar lavage collection
Following sacrifice, bronchoalveolar lavage fluid (BALF) was collected. The trachea
was iso.lated by blunt dissection and an incision made in the upper portion of the trachea,
which was cannulated with a 21-gauge shielded LV. catheter (BD Bioscience, San Hose, CA)
attached to a 5 ml syringe. The alveoli were washed 3 times, each with I ml sterile PBS.
Approximately 1-2ml of bronchoalveolar lavage fluid (BALF) was recovered. Cytokine
levels were measured using a customized Bio-Plex cytokine kit (Bio-Rad) for detection of
IL-I~,

IL-6, TNF -u, KC, and MIP-I u. Analysis was conducted using the Bio-Plex multiplex

suspension array system (Bio-Rad) following the company's protocol. Each sample was
performed in duplicate. Cytokine concentrations were normalized for urea dilution using a
ratio of urea nitrogen concentrations in the airway fluid and in the serum by the Enzymatic
Urea Nitrogen -(BUN) procedure (Stanbio, Boerne, TX). Final values were expressed as
pg/ml epithelial lining fluid (ELF).
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Lung histopathology

Lungs were inflated and fixed with 4% paraformaldehyde. After 48 hr, the lungs were
embedded in paraffin, cut in 150-200 J.UIl step-sections, and stained with hematoxylin and
eosin (H&E) using standard techniques. Histopathologic scoring parameters were based on
published criteria [217] with the following designations: O=within normal limits; 1=darker
red than normal; 2=0-2 lymphocytic infiltrated nodules present; 3=3-6 lymphocytic
infiltrated nodules and <Jf4 lung consolidated; 4=Jf4 to

~

lung consolidated; and

5=~

to %

lung consolidated.

Lung homogenate collection and quantitative bacteriology

Lungs were collected and placed on ice. The same day of sacrifice, the lungs were
weighed (OHAUS Adventurer balance, 1.000 g sensitivity) and washed in 0.5 ml cell wash
buffer (Bio-Rad, Hercules, CA). Using surgical scissors, lungs were cut into small pieces, 2
ml of PBS was added, and the lungs were homogenized for 60 seconds at high speed using
Kinematica Polytron PT10/35 homogenizer (Brinkmann Instruments Co., Westbury, NY).
For quantitative bacteriology, the lung homogenate was diluted with PBS in ten-fold
serial dilutions, spread on TSA plates, and incubated at 37°C overnight.
For cytokine analysis, the homogenized lungs were further processed by freezing at 80°C, thawing on ice, and sonicating in ice-cold water for 45 sec. The processed lung
homogenates were centrifuged at 1500xg at 4°C for 10 min, supernatants collected, and
stored at -80°C. Cytokine levels were measured using a customized Bio-Plex cytokine kit
(Bio-Rad) for detection of IL-l~, IL-6, TNF-a, KC, and MIP-la. Analysis was conducted
using the Bio-Plex multiplex suspension array system (Bio-Rad) following the company's
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protocol. Each sample was performed in duplicate. Cytokine concentrations were
standardized for lung weight by multiplying the cytokine value by the volume of sample
(2ml) and dividing by the lung weight to obtain final values in picogram (pg) per gram of
lung tissue.

Statistical analysis

Percentage body weight, cytokine levels and quantitative bacteriology are presented
as average ± SD. Change in body weight is expressed as the percentage of weight lost from
the original weight three days before inoculation. Statistical analysis of cytokine levels and
quantitative bacteriology was determined by unpaired, two-tailed Student's t test with Welch
correction using the Graph Pad InStat statistics software program (GraphPad Software, San
Diego, CA). Histological scoring is presented as individual grades per lung section;
significance was determined by Mann-Whitney statistical analysis. For all data sets, p values
less than 0.05 were determined to be statistically significant.
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3.3 Results
Administration by aspiration challenge with surfactant phospholipids and intratracheal
injection results in similar dye distribution.

To compare the location of inoculation between the two procedures, preliminary
experiments were performed using amido black dye to ascertain the administration route.
Anesthetized-mi.Q~ved

amido black dye through aspiration challenge with surfactant

phospholipids or intratracheal injection. After 1 hr, mice were sacrificed and the lungs,
stomach, and spleen collected. Both methods resulted in distribution throughout the lungs
with some delivery to the stomach, but no delivery to the spleen (Figure 3.2). The
experiment was repeated and the data shown representative of 4 or more animals.
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Figure 3.2
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Figure 3.2 Amido black dye is distributed throughout the lungs after administration by
aspiration challenge with surfactant phospbolipids and intratracheal injection.
Anesthetized mice received amido black dye through aspiration challenge with surfactant
phospholipids or intratracheal injection. After 1 hr~ mice were sacrificed by cervical
dislocation and the lungs, stomach, and spleen collected. Administration by aspiration
challenge with surfactant phospholipids (left column) or intratracheal injection (right
column) resulted in delivery predominantly to the frontal (A, B) and dorsal (C, D) lung, with
some expression in the sto'jaCh (E, F), and no expression in the spleen (G, H). Arrows
indicate areas of amido blac dye distribution. Observations represent the findings from 4 or
more animals in each group om 2 experiments.
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Delivery of P. aeruginosa-Iaden beads by aspiration challenge with surfactant
phospholipids results in the same weight loss as intratracheal delivery.
Weight loss following P. aeruginosa infection by aspiration challenge with surfactant
phospholipids or intratracheal injection to CD-I mice was measured to determine the severity
of infection. The mice were weighed before administration with 5x 106 cfu P. aeruginosaladen beads or sterile beads and 3 days later before sacrifice. The average pre-infection
weight of the mice in the aspiration challenge with surfactant phospholipids group (n=29)
was 28.8 g;

'ce lost an average body weight of 17.4% ± 5.1 after administration of the P.

aeruginosa-Iaden

e

s. The average pre-infection weight of the mice (n=22) in the

intratracheal administration group was 27.2 g with mice losing an average body weight of
18.9%

± 5.4

following infection. There was no mortality in the mice from the infection;

however, 3 mice in the intratracheal injection group died as a result of complications in the
injection operation (i.e. excessive bleeding). While there was no significant difference
between the groups in percent weight loss following infection (p>0.05), the aspiration
challenge with surfactant phospholipids and intratracheal injection of P. aeruginosa-Iaden
beads had significantly greater percentage weight loss when compared to intratracheal
injection of sterile beads (p<0.05 for both groups).

P. aeruginosa infection results in lung homogenate inflammatory cytokine levels that
are not significantly different by the method of delivery.
Pro-inflammatory cytokine expression following administration with P. aeruginosa
was analyzed to compare the immune response to infection between the administration
groups. CD-I mice were inoculated with 5xl06 cfu P. aeruginosa-laden beads by aspiration
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challenge with surfactant phospholipids, intratracheal injection, or with sterile beads by
intratracheal injection. Three days later, the mice were sacrificed, lungs collected, and
cytokines levels measured in the lung homogenate. Cytokine levels in the aspiration
challenge with surfactant phospholipids group:

IL-l~

(63

±7

ng/gram-Iung), IL-6 (9

±4

ng/gram-Iung), TNF-u (13 ± 4 ng/gram-Iung), KC (56 ± 11 ng/gram-Iung), and MIP-lu (40 ±
12 ng/gram-Iung) were not significantly different from those in the intratracheal injection
group:

IL-l~

(47 ± 16 ng/gram-Iung), IL-6 (17 ± 7 ng/gram-Iung), TNF-u (10 ± 5 ng/gram-

lung), KC (40

± 12 ng/gram-Iung), and MIP-lu (37 ± 11

ng/gram-Iung) (Figure 3.3A, B).

Both groups had significantly higher cytokine levels than mice intratracheally injected with
sterile beads (Figure 3.3A, B).
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Figure 3.3

A.

80000
70000

!

NSD

NSD

**

60000

=

;:; 50000
C)

c

-=

40000

~

30000

~

20000
10000

o

+-~UL~~

__-L~_ _~~~~_ _~,-~~~~~~~

IL-1b

KC

MIP-1a

B.
30000
G)

25000

!= 20000

NSD

**

NSD

**

Q

C

.2 15000
E

~

10000

Q
Q.

5000

IL-6

TNF-a

120

Figure 3.3 P. aeruginosa infection causes rise in lung homogenate inflammatory
cytokine levels that are not significantly different in the method of administration.
Anesthetized mice received 5x106 cfu P. aeruginosa-Iaden beads by aspiration challenge
with surfactant phospholipids or intratracheal injection or sterile beads by intratracheal
injection. Mice were sacrificed 3 days later. Lungs were collected and homogenized.
Cytokines (A) IL-l~, KC, and MIP-1a and B) IL-6 and TNF-a. were measured in the groups
of aspiration challenge with surfactant phospholipids (0) or intratracheal injection for
delivery of P. aeruginosa-laden beads (D) or administration of sterile beads by intratracheal
injection. NSD is not significantly different (p>O.05) and **p<O.005, comparing the P.
aeruginosa infection methods to delivery of sterile beads. Data shown are the average ±
standard deviation for 5 mice in each group from 2 experiments.
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Inflammatory cytokine levels in the epithelial lining fluid are not significantly different
by the method of P. aeruginosa-Iaden bead delivery.
The bronchoalveolar lavage fluid (BALF) was collected and analyzed for
inflammatory cytokine levels. Cytokine concentrations were normalized for urea dilution
using a ratio of urea nitrogen concentrations in the airway fluid and in the serum. Levels of
cytokines in the BALF were not significantly different upon infection of mice with P.

aeruginosa-Iaden beads by aspiration challenge with surfactant phospholipids compared to
intratracheal injection (Figure 3.4). The serum was also analyzed to determine whether
proinflammatory cytokine production was systemic. There was no significant difference
(p>O.05) in any of these cytokine levels in the serum when comparing the two P. aeruginosaladen bead administration groups, aspiration challenge with surfactant phospholipids (n= 15)
and intratracheal injection (n=12) (data not shown), thus confirming a lung-specific infection.
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Figure 3.4
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Figure 3.4 Inflammatory cytokine levels in the epithelial lining fluid are not
significantly different in the administration method used for P. aeruginosa delivery.
Anesthetized mice received 5xl06 cfu P. aeruginosa-Iaden beads by aspiration challenge
with surfactant phospholipids or intratracheal injection. Mice were sacrificed 3 days later.
BALF was collected, cytokine levels analyzed, and the measurements corrected for urea
nitrogen dilution to obtain ELF values. Levels of IL-1P, IL-6, TNF-a, KC, and MIP-la were
measured with administration by aspiration challenge with surfactant phospholipids ~) or
intratracheal injection for delivery of P. aeruginosa-Iaden beads (D). NSD is not
significantly different (p>O.05). Data shown are the average ± standard deviation for 12 mice
in the aspiration challenge group and 8 mice in the intratracheal injection group from 2
experiments.
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Administration methods produce similar levels of inflammation-associated lung
pathology.

To determine if increased inflammatory cytokines correlated with histopathology,
lung sections were obtained from mice receiving P. aeruginosa-Iaden beads by aspiration
challenge with surfactant phospholipids or intratracheal injection. Histological examination
revealed similar levels of inflammatory cell infiltration and lung consolidation (Figure 3.SA,
B). Histological scoring was used to show that the inflammatory changes were not
significantly different when comparing the two administration groups (p>O.05, Table 1).
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Figure 3.5
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Table 3.1 Histopathologic scores of lung sections from CD-l mice infected with 5xl0
cfu P. aeruginosa-Iaden beads by aspiration challenge with surfactant phospholipids or
intratracheal injection.
P. aeruginosa
administration method
Aspiration challenge
with surfactant
phospholipids

Number o/mice

Score

Average+ SD

9

4
4

4.0 ± 0.5

5
4
4
4
4
4

3
Intratracheal inj ection

9

4

3.8 ± 0.4

3
4
4

3
4
4
4

4

p value

p>O.05

Anesthetized mice were infected with 5xl06 cfu P. aeruginosa-Iaden beads by aspiration
challenge with surfactant phospholipids or intratracheal injection. Mice were sacrificed 3
days later. Lungs were collected and fixed in parafonnaldehyde, then sectioned and H&E
stained. Sections were graded by a blinded pathologist.
Histopathologic scoring parameters were based on previously published criteria [217].
O=within nonnallimits
1=darker red than nonna!
2=0-2 lymphocytic infiltrated nodules present
3=3-6 lymphocytic infiltrated nodules, <Y4lung consolidated
4=Y4 to Y2lung consolidated
5=Y2 to 314 lung consolidated
6~>3h lung consolidated
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Aspiration challenge with surfactant phospholipids and intratracheal injection of P.

aeruginosa-Iaden beads results in comparable levels of bacterial burden in the lung.
In addition to determining the cytokine response and pathology, we wanted a direct
measurement of bacteria delivered to the lung. Homogenized lungs obtained from mice in
both administration groups were spread in lO-fold serial dilutions, in duplicate, on TSA
plates. Colonies were counted on each plate and bacterial load was not significantly different
between the administration groups (Figure 3.6). These data confirm that aspiration challenge
with surfactant phospholipids for delivery of P. aeruginosa-Iaden beads produces the same
infection in the lung as intratracheal injection. These data corroborate our cytokine and
histopathologic findings, supporting our hypothesis that delivery of P. aeruginosa-Iaden
beads by aspiration challenge with surfactant phospholipids produces the same chronic lung
infection as intratracheal injection.
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Figure 3.6
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Figure 3.6 Similar level of bacterial burden results from P. aeruginosa administration
by aspiration challenge with surfactant phospholipids and intratracheal administration.
Anesthetized mice received 5x106 cfu P. aeruginosa-Iaden beads by aspiration challenge
with surfactant phospholipids or intratracheal injection or sterile beads by intratracheal
injection. Mice were sacrificed 3 days later. Mice were sacrificed 3 days later. Lungs were
collected, homogenized, and spread in serial dilutions on TSA plates. After 24 hr colonies
were counted and bacterial titer calculated. Data is shown for administration ofP.
aeruginosa-Iaden beads by aspiration challenge with phospholipids (0) or intratracheal
injection (0) and sterile beads administered by intratracheal injection (~). NSD is not
significantly different (p>O.05). Data points are bacterial burdens for 5 mice in each group
from 2 experiments; the black line is the average of each group. IT is intratracheal injection.
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3.4 Discussion

A representative in vivo model of CF lung disease is essential for characterizing
potential therapeutics. Because CFTR knockout mice do not have spontaneous lung disease,
it must be induced, commonly through infection with Pseudomonas aeruginosa, the
pathogen that most highly correlates with clinical outcome in patients with CF [83, 84].
Chronic lung infection has been achieved by colonization of the lungs of mice through P.
aeruginosa in drinking water [215] and repeated P. aeruginosa aerosol aspiration challenge

[216]. The most commonly-used model of chronic lung infection in vivo uses intratracheal
injection of P. aeruginosa-Iaden beads. Administration of P. aeruginosa trapped in agar
beads slows the growth of the bacteria, resulting in a chronic infection that most accurately
resembles that seen in patients with CF [220]. The beads localize the bacteria in the distal
airways and mimic the morphology of bacterial infection observed in the CF lung [220, 224,
253]. Unfortunately, intratracheal instillation is particularly challenging to perform in CFTR
knockout mice because they are smaller in size and more sensitive to manipulation than wildtype mice [217, 246].
Because of the extensive use of intratracheal injection of P. aeruginosa-Iaden beads,
we were interested in making a direct comparison to characterize fully the resulting infection
and inflammation in this method when compared to a non-invasive method of infection.
Additionally, due to the surface tension properties of surfactant, we used the phospholipid
fraction of surfactant to enhance lung-targeted delivery. Surfactant forms a thin layer over the
alveolar surface and is comprised of lipids and proteins [254]. The lipid fraction (900/0)
includes Dipalmitoylphosphatidylcholine (DPPC) and Phosphatidylglycerol (PO); the protein
fraction (5-10%) includes hydrophilic surfactant-associated proteins (SP-A and SP-B) and
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hydrophobic proteins (SP-B and SP-C). Surfactant lowers surface tension, aids in rapid
adsorption and spreading and contributes to stability of the airway film [254]. It is nonimmunogenic and plays an important role in host defense of the lung, specifically surfactantassociated proteins (SP-A and SP-D) bind bacteria and have antimicrobial properties in vitro
[255]. To eliminate any antimicrobial activity against P. aeruginosa, as shown against other
bacteria, we removed the surfactant-associated protein fraction and used the phospholipid
portion as a carrier to aid in spreading and delivery of P. aeruginosa-laden beads to the murine
rurway.
A preliminary experiment with administration of dye showed that 1 hr postadministration by aspiration challenge with surfactant phospholipids and intratracheal
injection both resulted in delivery primarily to the lung. Our main goal was to compare
methods for delivery of P. aeruginosa-laden beads. Mice received 5xl06 cfu P. aeruginosaladen beads by aspiration challenge with surfactant phospholipids or intratracheal injection
and were sacrificed 3 days later. No significant difference in percentage weight loss was
found when the groups were compared nor was there a difference in inflammatory cytokine
levels

(IL-l~,

IL-6, TNF-a, KC, and MIP-la) in the lung homogenate or BALF. Tissue

sections revealed that the groups were pathologically similar in inflammation, infiltration,
and lung consolidation, using a grading scale. Bacterial burden, as measured by serial
dilutions of the lung homogenate, was not significantly different between administering P.
aeruginosa-Iaden beads by aspiration challenge with surfactant phospholipids or intratracheal

injection, although bacterial load was higher in these groups than in mice receiving sterile
beads by intratracheal injection. None of the mice in the aspiration challenge with surfactant
phospholipids group died as a result of the chronic P. aeruginosa administration; however, 3
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mIce in the intratracheal injection group died from surgical complications. Importantly,
measurements of infection and inflammation from chronic P. aeruginosa administration by
aspiration challenge with surfactant phospholipids were as reproducible as intratracheal
injection when comparing the standard deviation between the groups.
There were several limitations to this study. We did not compare surfactant
phospholipids to total surfactant for enhanced lung delivery or measure specific antimicrobial
activity against P. aeruginosa due to the interaction of surfactant proteins and
lipopolysaccharide (LPS) [255]. In an earlier experiment, we found no difference in P.
aeruginosa growth in the presence or absence of surfactant phospholipids when plating in
serial dilutions on TSA plates. Because intratracheal injection and aspiration challenge with
surfactant phospholipids both resulted in delivery to the stomach, we did not quantify the
expression level. Delivery to the stomach with aspiration challenge was a surprise and
contradictory to other literature [248, 250]. A better marker to visualize lung distribution
such as a viral vector with a reporter gene would have allowed for quantification and more
clear definition of lung delivery. Our use of surfactant phospholipids did not result in
enhanced lung delivery over intratracheal injection and may be due to removing the
surfactant-associated proteins.
The non-invasive model of P. aeruginosa-Iaden bead administration described here
results in the same infection and inflammation characterized by intratracheal administration
of the bacteria, currently the most-employed method for creating CF lung disease in vivo.
The technique could be especially beneficial for investigators working with CFTR knockout
mice because they are generally more sensitive to surgical manipulations [246] strongly
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impacting experimental outcomes associated with adverse reaction to the surgical instillation
of P. aeruginosa-Iaden beads in the trachea.
Future directions include using this method of administration in CFTR knockout mice
to determine if mortality is reduced and to compare dosing of P. aeruginosa-Iaden beads. It
would also be interesting to administer free P. aeruginosa to determine if an acute model of
infection could be developed with this administration method. Delivery of other agents such
as drugs and gene transfer agents have been shown to be enhanced using surfactant as a
carrier [256, 257] and could be used in our aspiration challenge model for non-invasive
delivery and characterization of therapeutics for lung disease.
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Chapter 4.
Non-invasive method of AAV vector administration with surfactant
phospholipids results in successful vector distribution and transgene
production in the murine lung.

4.1 Introduction

Gene transfer with recombinant adeno-associated virus (AAV)-based vectors has
been studied extensively for diseases which impact the lung such as cystic fibrosis (CF) and
alpha-l antitrypsin (AAT) deficiency. Vectors derived from AAV can transduce dividing and
non-dividing target cells [153] and provide prolonged gene expression in the host through
episomal persistence or integration [154-157] following a single dose administration [143,
158]. In addition, AAV vectors deliver therapeutic genes without co-transfer of any viral
genes and, therefore, are not likely to induce inflammatory responses [159-162]. AAV-based
vectors have also been found safe in a number of animal models and human clinical trials [143,
155].
One of the current limitations for therapeutic gene delivery to the epithelia by AAV is
the low level of trans gene expression [22]. This can be influenced by a number of obstacles
that impede or limit access of vectors to receptors or binding sites on epithelial cells
following vector administration. Physical barriers such as mucins, surface fluid lining layers,
glycoproteins, as well as the availability of cell entry receptors are present in the airway of
normal lungs and often increased in diseased lungs [258].
The method of vector administration to the lungs can affect efficiency of delivery and
lung-specific trans gene expression. While therapeutic efficiency of AAV vectors in vivo has
been characterized by administration through intranasal [180, 190], aerosol [181],
intrapleural [259], and intratracheal [204, 260, 261] routes for delivery to the lungs, the
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optimal method of AAV vector delivery to the lungs has not been determined. The most
commonly-used approach is catheter or bronchioscopic-directed vector delivery, but this
method requires surgical instillation. However during surgical

instillatio~

the addition of

perfluorochemical (PFC) liquids, chemically inert fluorinate carbon chains with high
solubility for

02

and CO2, has been shown to enhance lung transgene expression in the distal

airway and alveolar epithelium of experimental animals when co-instilled with adenoviral
[252, 262-264] and AAV vectors [262, 265], requiring less vector for efficient transduction.
Properties of PFC liquids, such as high density and low surface tension, aid in widespread
distribution throughout the lungs following intratracheal administration [251]. Surfactant, a
mixture of phospholipids and surfactant-associated (SA) proteins, also has the capacity to
lower surface tension and has been shown to aid in a uniform distribution pattern in the lungs
when used as a carrier following intratracheal delivery in hamsters [251]. When compared,
PFC liquids and surfactant have been found to aid in similar distribution of intratracheally
injected adenoviral vectors throughout the rat lung [252].
We were interested in developing a murine model of non-invasive lung delivery for
AAV vectors. While intratracheal delivery has been superior to nebulized delivery of
surfactant [266], administration by aspiration challenge has not been evaluated for surfactant.
In our laboratory we observed that delivery of P. aeruginosa-laden beads with surfactant
phospholipids through aspiration challenge results in the same chronic lung disease as
administration of P. aeruginosa-Iaden beads by intratracheal injection.
The present study provides a strategy for non-invasive AAV delivery to the murine
lung using surfactant phospholipids as a vehicle. We hypothesized that aspiration challenge
with surfactant phospholipids will result in AAV distribution and gene expression in the
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lungs similar or enhanced to intratracheal injection. We used an AAV5 pseudotyped vector
because this serotype results in higher levels of transduction and gene expression when
compared to other serotypes due to the prevalence in its primary receptor, N-linked sialic
acid (N-SA), in apical airway epithelia [188, 204]. We compared aspiration challenge with
surfactant phospholipids in lung delivery and protein expression to intratracheal injection to
determine the effectiveness of this administration method for in vivo characterization of
AAV-based therapeutics.
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4.2 Materials and Methods

Eight-week old C57BL/6 mice were purchased from the Charles River Laboratories,
Inc (Wilmington, MA). Mice were housed in a specific pathogen-free facility at the Medical
University of South Carolina (MUSC). The experimental protocols were approved by the
Institutional Animal Use and Care Committee (IACUC) at MUSC.

Recombinant AAV-al anti-trypsin vector

A recombinant AAV vector carrying alpha-l anti-trypsin (AAT) was used for these
studies. AAV.C~-AAT (see Figure 4.1) contains AAV2 inverted terminal repeats (ITRs), a
CMV/chicken-beta-actin hybrid

(C~)

promoter including an intron, a full length human

alpha-l anti-trypsin (AAT) sequence, and the SV40 polyadenylation region. AAV.C~-AAT
was cloned, pseudotyped with the AAV 5 capsid, and titered using previously published
methods [167, 243]. The pseudotyped packaged vector was then designated as AAV5.C~
AAT.
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Figure 4.1
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Figure 4.1 Schematic of the AAV5.Cp..AAT vector. AAV5.C~-AAT contains the
CMVIchicken-heta-actin hybrid promoter including an intron, the human AAT coding
sequence, and the SV40 polyadenylation region. Adapted from [204].
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Surfactant phospholipid lioosomes preparation

DPPC

and

POPC

(1-Palmitoyl-2-0Ieoyl-sn-Glycero-3-Phosphocholine)

phospholipids were purchased (Avanti Polar Lipids, Alabaster, AL) with stock
concentrations of 20 mg/rol (DPPC in chlorofonn) and 10 mg/ml (POpe in chloroform). For
every ml of final liposome suspension, 17.5 mg DPPC (0.875 ml stock) and 7.5 mg

pope

(0.75 ml POPC stock) were added in a clean, sterile 13xlOO mm glass tube. The tube was
capped and mixed well via vortex. The solvent was removed via nitrogen stream, with the
tube submerged in 40°C water bath, and mixed during the drying process. After the samples
were dry, the tubes were transferred to a lyophylization flask and vacuum-dried overnight
without additional heating. PBS (1.0 ml) was added to each tube, and then the tubes were
heated at 45°C for 15 min, vortexed for 30 sec, and sonicated for 10 sec. This step was
repeated 3 times to ensure the liposome preparation had consistent viscosity and did not
contain large liposome aggregates. The liposomes were transferred to sterile screw-cap
plastic cryovials using sterile pipette tips and stored at 4°C. The stock phospholipid liposome
concentration was 7:3 (mol/mol) DPPCIPOPC at 25 mg/ml total phospholipid. On the day

C57BU6 mice were infected, the phospholipid liposomes were diluted to 4 mg/ml with
AAV5.C~-AAT.

Labeling of AAV vector with tluorophore dye
AAV5.C~-AAT was incubated with reactive dye solution (IOmg/ml Alexa 610
succinimidyl ester fluorophore dissolved in DMSO, Invitrogen) with continuous stirring at
room temperature for 1 hr. A Sephadex G column was used to separate the

AAV5.C~-AAT
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labeled with Alexa610 from the unreacted labeling reagent. The labeled AAV vector denoted
AAV5.CI3-AAT* Alexa610 was stored at 4°C.

Intratracheal injection
Mice were anesthetized through inhalation of a mixture of oxygen and isoflurane in a
closed chamber, then transferred and immobilized in a supine position on a surgical table.
During the procedure, mice were under continuous anesthesia with isoflurane through a
conical nosepiece. A small transverse incision was made (about 0.5 mm) just cranial to the
thoracic inlet followed by blunt dissection of the salivary glands and musculature to expose
the trachea. A sterile, flexible 21-gauge SURFLO winged infusion set (Terumo Corporation,
Tokyo, Japan) was inserted just into the trachea between the tracheal rings for delivery to
both lobes of the lung. A I-ml syringe pre-loaded with 0.050 m1 containing PBS or 4mg/ml
surfactant phospholipid liposomes with Ixl0 12 or 2x1012 vector genomes (vg) of AAV vector
was attached to the winged infusion set, and the plunger depressed for injection into the
trachea. The attached set was removed and incision closed by suture. Mice were monitored
for recovery which occurred within 10 min of procedure completion. All incisions were
closed by suture.

Aspiration
challenge with surfactant phospholipids
,
.
'

Aspiration challenge was conducted using previously published methods [248, 249]
with minor modifications. Mice were anesthetized through inhalation of a mixture of oxygen
and isoflurane for 4 min in a closed chamber. Mice were removed from anesthetization
chamber and mice suspended by their front incisors in a supine position on an acrylic
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platform at a 60° angle. Using coated forceps, the tongue was extended and moved aside
from blocking the trachea. Using a p200 pipette, 0.040 ml containing lxlOI2 or 2xl012 vg of
AAV vector was instilled at the back of the oral cavity above the tracheal opening.
Immediately after, the mice aspirated the liquid, evidenced by the mouse gulping. Mice were
monitored for recovery which occurred within 5 min after the administration.

Analysis of AAV vector distribution
Two hr after lxl012 vg of AAV5.Cp-AAT* Alexa610 was administered; mice were
anesthetized with isoflurane and sacrificed by cervical dislocation. To detennine whole organ
distribution, the lungs,

h~

and spleen were removed and visualized under UV light. For

cellular distribution, the lungs were inflated and fixed with 4% parafonnaldehyde. After 48
hr, the lungs were embedded in paraffin, cut in 150-200 pm step-sections, and viewed

microscope with a Rhodamine filter.

Analysis of AAV-based protein expression
SacrifICe and sample coUection
Six weeks following 2xlOl2 vg of AAV5.Cp-AAT administration, mIce were
anesthetized with isoflurane and sacrificed by cervical dislocation. Blood was obtained from
all mice. Lungs were collected and placed on ice. The same day of collection, the lungs were
weighed (ORAUS Adventurer balance, 1.000 g sensitivity) and washed in 0.5 ml cell wash
buffer (Bio-Rad, Hercules, CA). Using surgical scissors, lungs were cut into small pieces, 2
ml of PBS was added, and the lungs were homogenized for 60 seconds at high speed using
Kinematica Polytron PTIO/35 homogenizer (Brinkmann Instruments Co., Westbury, NY).
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The homogenized lungs were further processed by freezing at -80°C, thawing on ice, and
sonicating in ice-cold water for 45 sec. The processed lung homogenates were centrifuged at
1500xg at 4°C for 10 min, supernatants collecte<L and stored at -80°C.

AATELISA
Human AAT expression in sera and lung homogenate was measured by enzymelinked immunosorbent assay (ELISA). The plate was coated with goat anti-bAAT (Sigma) in
Voller's buffer (2.76g Na2C03, 1.916g NaHC03, 0.2g NaN3 in 1 liter, pH 9.6). After washing
the plate in PBS-Tween (PBS- T) 3 times, the serial dilution of standard AAT and samples
(mice sera or lung homogenate) were added to the wells and incubated at 37°C for 60 min.
The plate was washed and blocked by Bovine Serum Albumin (3% BSA in PBS-T) solution
for 60 min at 37°C. After washing, the plate was incubated with 1: 1000 dilution of rabbit
anti-bAAT (Sigma) for 60 min at 37°C. Then, the plate was washed and incubated with
1:2500 dilution of goat anti-rabbit IgG conjugated HRP (Sigma) for 60 min at 37°C. The

plate was washed and incubated with 100 ,.d of TMB substrate (Research Diagnostics Inc.,
Flanders, NJ) for 5 min. Then, 100 JlI of O.5N HCI was added to stop the reaction. The plate
was read at 450 nm using a VERSAmax tunable microplate reader (Molecular Devices).

Statistical analysis

Data are presented as average ± SD. Statistical analysis of AAT levels in the lung
homogenate was determined by unpaired, two-tailed Student's t test, and statistical analysis
of AAT levels in the serum was determined by unpaired, two-tailed Student's t test with
Welch correction using the Graph Pad InStat statistics software program (GraphPad
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Software, San Diego, CA). For all data sets, p values less than 0.05 were determined to be
statistically significant.

4.3 Results
Administration by aspiration chaUenge with surfactant pbospholipids and intratracheal
injection results in similar vector distribution.
AAV5.Cf3-AAT was labeled with an Alexa 610 probe to compare the delivery
location between the two methods of administration. Anesthetized mice received lxlOl2 vg
of AAV5.CJ3-AAT* Alexa61 0 through aspiration challenge with surfactant phospholipids or
intratracheal injection. After 2 hr, mice were sacrificed and lungs, stomach, and spleen
collected. Aspiration challenge with surfactant phospholipids and intratracheal injection
resulted in similar distribution throughout the lungs with some delivery to the stomach and
no delivery to the spleen (Figure 4.2). AAV5.Cf3-AAT*Alexa610 was distributed to the
bronchial epithelial cells (Figure 4.3A) and alveoli (Figure 4.3B) as defmed by sectioning of
lung tissue. Similar distribution of the vector in both aspiration challenge with surfactant
phospholipids and the intratracheal injection occurred. The experiment was repeated and the
data shown representative of 4 or more animals.
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Figure 4.2
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Figure 4.2 AAVS.Cp-AAT* Alexa610 is distributed throughout the lungs after
administration by aspiration cbaUenge with surfactant pbospholipids and intratracheal
injection. Anesthetized mice received lxl012 vg of AAV5.Cp-AAT*Alexa610 through
aspiration challenge with surfactant phospholipids or intratracheal injection. After 2 hr, mice
were sacrificed and lungs, stomach, and spleen collected. Administration of AAV5.C~
AAT* Alexa61 0 by aspiration challenge with surfactant phospholipids (left column) or
intratracheal injection (right column) predominantly distributed to the frontal (A, B) and
dorsal (C, D) lung, with some expression in the stomach (E, F), and no expression in the
spleen (G, H) as viewed under ultraviolet light. All observations represent 4 or more animals
from 2 experiments.
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Figure 4.3A
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Figure 4.3B
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Figure 4.3 AAV5.CIJ-AAT* Alexa610 has similar localization in both administration
groups. Anesthetized mice received Ixl012 vg of AAV5.C~-AAT* Alexa610 by aspiration
challenge with surfactant phospholipids or intratracheal injection, or were not treated. Two hr
later, mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Lungs
were inflated and fixed with 4% paraformaldehyde. After 48 hr, the lungs were embedded in
paraffin, cut in 150-200 urn step-sections, and microscopically viewed under a Rhodamine
filter. Representative (A) low-power views (xIO) and (B) higher-power views (x40) of the
lungs after indicated treatment are shown. Untreated mice received no treatment.
Observations represent the findings from 3 or more animals from 2 experiments.
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Delivery of AAVS.Cp-AAT by aspiration challenge with surfactant phospholipids
results in the same protein expression levels as intratracheal delivery.
A second study was conducted to ascertain the similarity of AAV -mediated transgene
expression by measuring gene transfer and protein production of AAT. AAT, a secreted
protein, is easily detected in the serum and lung. Mice received 2xl012 vg of AAV5.C~-AAT
by aspiration challenge with surfactant phospholipids (n=7) or intratracheal injection (n=7),
and were sacrificed six weeks later. In the lung homogenate, AAT levels in the aspiration
challenge with surfactant phospholipids group (47

± 6 nglml) were not significantly different

from those in the intratracheal injection group (43

±4

nglml) (Figure 4.4). Similar

expression of AAT between the groups was also detected in the serum (Figure 4.4).
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Figure 4.4
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Figure 4.4 AAVS.Cp-AAT produces AAT levels that are not significantly different in
the lungs and serum in the administration groups. Anesthetized mice received 2x 10 12 vg
of AAV5.C~-AAT by aspiration challenge with surfactant phospholipids or intratracheal
injection. Mice were sacrificed 6 weeks later and blood collected. Lungs also were collected
and homogenized. AA T protein levels were measured by adniinistration of the vector
aspiration challenge with surfactant phospholipids (D) or intratracheal injection (fa) in the
serum and lung homogenate. NSD is not significantly different (p>O.05). Data shown are the
average ± standard deviation for 7 mice in each group.
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4.4 Discussion
Therapeutic gene transfer has been tested successfully in experimental models of
chronic lung disease. These studies suggest the promise of gene therapy for lung diseases
such as CF and AAT deficiency; however, gene transfer efficiency is limited by factors
including host defenses and distribution of cell entry receptors. Circumventing these barriers
and enhancing gene transfer will positively impact the use of these vectors as therapeutics.
The small diameters of the airways in the periphery of the lung inhibit the movement of
fluids with high surface tension, requiring high pressure for passage of these liquids in the
airway. Surfactant, a mixture of phospholipids and SA proteins, lowers the surface tension
resulting in rapid dispersion, beneficial for lung gene transfer. Use of surfactant as a vehicle
has been shown to improve dispersion of adenoviral and AAV vectors in the lungs of rats
[262, 265]. In these studies, minimal trans gene expression was observed in the trachea and
main bronchi, suggesting surfactant aids in distribution to the bronchial epithelium and
alveoli.
For the first time, the current study compared the effectiveness of a non-invasive
method (aspiration challenge) of AAV vector administration with surfactant phospholipids to
intratracheal injection of AAV vector, the most-employed method of lung delivery in
experimental models. We demonstrated that the use of surfactant phospholipids during
aspiration challenge of AAV vector results in similar lung distribution and total transgene
activity in the serum and lung homogenate when compared to intratracheal injection.
Delivery was predominantly to the lung specifically to the columnar epithelium of the
bronchioles and alveolar cells as was seen in a previous study [252]. Some expression was
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observed in the stomach, but no expression in the spleen. AAT protein expression revealed
high levels of transgene expression in the serum and lungs when delivered by both methods.
Our hypothesis that aspiration challenge with surfactant phospholipids would result in
similar lung delivery to intratracheal injection was proven, but we did not observe the
enhanced gene expression that was seen in a previous study [252]. This could be due to the
removal of surfactant-associated (SA) proteins from our vehicle, which may further aid in
peripheral spreading and clearance of the virus to the distal airway; however, we did not
compare aspiration challenge with surfactant phospholipids to intratracheal injection with
surfactant, the method of enhanced gene delivery used in this study.
There were several limitations to our experiments. There was no quantification of
percentage AAV vector delivery to the stomach, although the expression level was similar to
intratracheal injection. We did not employ a control of unlabeled AAV vector to determine
the background of AAV vector dissemination, but AAV vector auto-fluorescence has not
been reported. There was no comparison of total surfactant to surfactant phospholipids for
AAV delivery. Removal of the SA fraction may not be necessary for antimicrobial reasons as
it was not shown to impact adenoviral titer, but may aid in proximal lung delivery (a more
appropriate target for CF) as previous studies demonstrated delivery was exclusively to the
alveoli [252]. Vector delivery with surfactant phospholipids was localized to the peripheral
(bronchioles) and distal lung (alveoli), but we did not determine which cells were transduced.
This will be important to determine because surfactant is metabolized by type 2 alveolar
epithelial cells, which raises the possibility that co-transport of AAV and surfactant into these
cells may be a mechanism for uptake [252].

157

This study supports the use of surfactant as a carrier for non-invasive lung delivery of
gene transfer agents in animal models. This administration method will be especially useful
for researchers working with chronic infection models for CF lung disease. Current in vivo
assessment of gene transfer therapeutics for CF relies on multiple surgeries for instillation of
P. aeruginosa-Iaden beads and the therapeutic. Mortality in CFTR-targeted mice increases

with each surgery and having a non-invasive method for both administrations is beneficial
for mouse numbers as well as obtaining relevant inflammation data from the therapeutic
agent, not influenced by surgical manipulation. In addition, the use of surfactant allowed for
lower doses of adenovirus and AAV to be used in a previous study [252]. Obtaining high
titers of AAV vectors is difficult and conducting a dosing study with AAV is a logical future
study to increase the application of this vector as a gene transfer agent.
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Chapter 5.
Adeno-associated vector delivery of IL-l 0 to the lungs of cystic fibrosis
mice reduces inflammation in a model of chronic P. aeruginosa
infection.

5.1 Introduction

Cystic fibrosis is the most common lethal autosomal recessive disease in the
Caucasian population. In CF, dysfunction of the cystic fibrosis transmembrane
conductance regulator (CFTR) in airway epithelial cells and submucosal glands results in
chronic disease of the respiratory tract, characterized by airway obstruction and persistent
infections of the lung and sinuses, beginning early in life [85, 86]. The CF lung is
particularly susceptible to infection with Pseudomonas aeruginosa, which plays an
important role in development and progression of pulmonary disease in patients with CF
[83, 84]. Almost all patients succumb to progressive lung disease associated with chronic
infection of this organism due to an excessive, predominantly neutrophilic, inflammatory
response that is more destructive than protective and causes the majority of tissue injury.
Patients with CF have elevated pro inflammatory cytokines

(IL-l~,

IL-6, IL-8, and

TNF-a) and a negligible amount of anti-inflammatory cytokine, IL-I0, in their

bronchoalveolar lavage fluid (BALF) as compared to healthy subjects [26, 28]. In
addition, airway epithelia cells and T lymphocyte clones from patients with CF are
deficient in IL-I0 production when compared to healthy controls. IL-I0 inhibits
production of IL-l~, IL-6, IL-8, and TNF-a and its constitutive expression in the lungs of
healthy individuals may be responsible for maintaining a balance that inhibits
inflammation. Likewise, a pathologic imbalance of inflammation may result from
decreased or absent levels of IL-l O. Deficiency in IL-I0 production, as shown by studies
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to greater neutrophil recruitment, more severe weight loss, and increased areas of lung
inflammation inflammation than seen in wild-type mice when chronically infected with
endobronchial P. aeruginosa [37, 139, 225]. These findings are similar to those of P.
aeruginosa-infected CF mice [37,215,220,226]. When repeatedly exposed to mucoid P.
aeruginosa, IL-I0T mice exhibit a prolonged inflammatory response to acute P.
aeruginosa challenge [237] and have higher mortality rates and more severe lung

pathology when compared to C57BL/6 controls similarly infected [216]. In acute and
chronic infection models with P. aeruginosa, treatment with IL-I0 has been shown to
reduce weight loss and pro inflammatory cytokine production, leukocyte and neutrophil
recruitment, and tissue injury in the lungs [139, 141]. While the administration of
exogenous IL-l 0 has been shown to reduce inflammation, over-expression of IL-l 0 could
suppress

normal

host

defenses

and

be

detrimental,

mediating

systemic

immunosuppression or even becoming immunostimulatory at high systemic doses [244].
Our laboratory demonstrated that gene transfer with IL-I0 using an adeno-associated
vector (AAV5.C~-mILI0) reduced pro-inflammatory cytokine production and lung
pathology in IL-I0T mice chronically infected with P. aeruginosa, further suggesting the
importance of IL-I0 in preventing excessive activation of the inflammatory cascade.
While systemic administration of recombinant IL-I0 was found to attenuate both local and
systemic cytokine levels [139], our studies with AAV5.C~-mILI0 resulted in lung-specific
IL-I0 expression with no effect on systemic proinflammatory cytokines or IL-I0
production compared to placebo-treated mice.
Anti-inflammatory therapy using prednisone and ibuprofen in patients with CF
has been successful, providing evidence that the inflammatory response in the CF lung is
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excessive relative to the burden of bacterial infection [101, 103]. In CFTR knockout mice
that were infected with P. aeruginosa, increased local concentrations of proinflammatory
mediators, more severe weight loss, and increased mortality resulted compared to their
wild-type counterparts, but there was no increase in bacterial burden [220]. These results
further suggest that inflammation is dysregulated and excessive to bacterial infection in
the CF lung. The reduction in inflammation mediated by IL-I0 is similar to
corticosteroids and ibuprofen, suggesting that IL-IO may have similar benefit in patients
withCF.
Because decreased IL-IO levels may contribute to high levels of proinflammatory
cytokine production in CF, we hypothesized that administration of IL-I0 as a therapeutic
would ameliorate the excessive response. In a chronic infection model of P. aeruginosa in
IL-I0T mice, we previously characterized AAV5.C~-mILI0 based on the inherent
benefits of IL-I0 gene transfer from AAV: long-term gene expression, a proven safety
profile and the ability to elicit a minimal inflammatory response in comparison to other
gene transfer agents [17, 19, 143, 155, 158, 182, 240]. Additionally, we optimized lung
delivery of P. aeruginosa-Iaden beads by aspiration challenge with surfactant
phospholipids in CD-l mice to create a model of chronic infection using a non-invasive
technique. In CD-l mice, a dose of 5xl06 colony forming units (cfu) was used for P.
aeruginosa-Iaden bead

administration by aspiration challenge with surfactant

phospholipids. CFTR knockout mice are generally more susceptible to P. aeruginosa
infection, associated with higher mortality [220, 224]; in this report, we conduct dosing
studies of P. aeruginosa-Iaden beads to determine the optimal dosage for inflammation in
gut-corrected CFTR knockout mice. Then, we characterize AAV5.C~-mILl 0 in a gut-
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corrected CFTR knockout mouse model of chronic P. aeruginosa lung infection to
determine whether IL-I0 gene delivery and expression specifically reduces the
proinfiammatory response in the lung.

5.2 Materials and Methods
Mice

Breeding paIrs of stock CFTR S489X(-I-); FABP-hCFTR(+I+), denoted gutcorrected CFTR knockout mice, were received from the University of Florida, originally
obtained from The Jackson Laboratory (Bar Harbor, MN). These mice were bred at the
Medical University of South Carolina in a specific pathogen-free facility. All caging
supplies were cleaned with an automated cage wash and autoclaved prior to use in animal
rooms. Mice were fed autoclaved or irradiated Harlan Teklad Sterilizable Rodent Blox
8656 (Harland Teklad, Indianapolis, IN) and bedded on autoclaved 1/8 inch com cob
bedding and com husk nesting material (Harland Teklad, Indianapolis, IN). Mice were
housed, 2-4, in Micro-Isolator Top Flow Ventilated cages (Tecniplast, Exton, PA) in
ventilated racks. Mice were placed in fresh microisolator cages immediately after
instillation of AAV or P. aeruginosa-Iaden agarose beads. Gut-corrected CFTR knockout
mice used in these studies ranged from age 10 wks to 24 wks for P. aeruginosa dosing
experiments. At the onset of the AAV5.Cp-mILI0 experimental studies, the mice ranged
from age 8 wks to 15wks with an average age of 10.6

± 2.5 wks. The procedures were

approved by the Institutional Animal Use and Care Committee (IACUC) at MUSC.
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Surfactant phospholipid Iiposomes preparation
DPPC

and

(1-Palmitoyl-2-0 leoyl-sn-Glycero-3 -Phosphocholine)

POPC

phospholipids were purchased (Avanti Polar Lipids, Alabaster, AL) with stock
concentrations of20 mg/ml (DPPC in chloroform) and 10 mg/ml (POPC in chloroform).
For every ml of final liposome suspension, 17.5 mg DPPC (0.875 ml stock) and 7.5 mg
POPC (0.75 ml POPC stock) were added in a clean, sterile 13xl00 rom glass tube. The
tube was capped and mixed well via vortex. The solvent was removed via nitrogen
stream, with the tube submerged in 40°C water bath, and mixed during the drying
process. After the samples were dry, the tubes were transferred to a lyophylization flask
and vacuum-dried overnight without additional heating. PBS (1.0 ml) was added to each
tube, and then the tubes were heated at 45°C for 15 min, vortexed for 30 sec, and
sonicated for 10 sec. This step was repeated 3 times to ensure the liposome preparation
had consistent viscosity and did not contain large liposome aggregates. The liposomes
were transferred to sterile screw-cap plastic cryovials using sterile pipette tips and stored
at 4°C. The stock phospholipid liposome concentration was 7:3 (mol/mol) DPPC/POPC
at 25 mg/ml total phospholipid. For administration, a concentration of 4 mg/ml
phospholipid liposomes was used.

Administration of AAV vector

A recombinant AAV vector carrying IL-I0 was used for these studies. AAV .C~
mILI0 (see Figure 5.1) contains AAV-2 inverted terminal repeats (ITRs), a
CMVIchicken-beta-actin hybrid

(C~)

promoter including an intron, a full length murine

IL-IO sequence, and the SV40 polyadenylation region. AAV .C~-mIL 10 was cloned,
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pseudotyped with the AAV -5 capsid, and titered using previously published methods
[167,243]. The pseudotyped packaged vector was then designated as AAV5.Cp-mILI0.

Aspiration challenge was conducted using previously published methods [248,
249] with minor modifications, including the addition of surfactant phospholipids. Mice
were anesthetized through inhalation of a mixture of oxygen and isoflurane for 5 min in a
closed chamber. Mice were removed from anesthetization chamber and suspended by
their front incisors in a supine position on an acrylic platform at a 60° angle. Coated
forceps were used to extend the tongue from blocking the trachea. Using a p200 pipette,
0.040 ml containing PBS or 4mg/ml surfactant phospholipid liposomes with 8.21xl09 vg
of AAV5.Cp-mILIO was instilled at the back of the oral cavity above the tracheal
opening. Immediately after, the mice aspirated the liquid, evidenced by the mouse
gulping. Mice were monitored for recovery which occurred within 5 min of the
administration.
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Figure 5.1
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Figure 5.1 Schematic of the AAVS.Cp-mILI0 vector. AAV5.C~-mILl 0 contains the
CMVIchicken-beta-actin hybrid promoter including an intron, the murine IL-I0 coding
sequence, and the SV40 polyadenylation region. Adapted from [243].
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Pseudomonas aeruginosa-embedded bead preparation and infection

The mucoid Pseudomonas aeruginosa isolate, PA 15719, was obtained from the
sputum of a patient with CF using a protocol approved by the Institutional Review Board
(lRB) at MUSC. Bacteria were maintained as glycerol stocks and stored at -80°C.
Bacteria-impregnated agar beads were prepared as described by van Heeckeren et al
[217, 220] with minor modifications. An inoculation loop was used to collect a sample of
frozen mucoid P. aeruginosa stock, streaked for isolation on a tryptic soy agar (TSA)
plate, and incubated at 37°C overnight. One colony was picked from the plate and used to
inoculate 50 ml tryptic soy broth (TSB) in a 125 Erlenmeyer flask, which was placed,
shaking, overnight at 37°C. A 0.1 ml aliquot of the culture was used to inoculate a second
flask of 50 ml TSB in a 125 Erlenmeyer flask. Bacteria were grown to late log phase,
shaking, in a 37°C incubator. A 2 ml aliquot from was added to warm (50°C) 2% low
melting agarose (Type 1 low EEO; Sigma) in PBS. The bacteria-agar mixture was added
to warm (50°C) heavy mineral oil (0122-4, Fisher) containing a stir bar, and stirred
rapidly at room temperature for 6 min, followed by cooling with slow additions of ice
over a 10-min period. The agar beads were transferred to a separatory funnel; the mineral
oil removed, and washed one time with 0.5% sodium deoxycholate (SDC), one time with
0.25% SDC, and four times with PBS. The P. aeruginosa-Iaden agarose beads were
collected and allowed to settle. Additional liquid was removed to obtain a final volume of
75% beads and homogenized using a Kinematica Polytron PTI0/35 homogenizer for 4
min at high speed to obtain beads predominantly 100-120 Jlm in diameter. The size of
the beads was measured microscopically before and after homogenization. Using serial
dilutions, quantitative bacteriology was performed on an aliquot of the homogenized bead
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slurry to determine bacterial concentration in colony forming units (cfu) per milliliter.
The homogenized bead slurry was prepared the day before inoculation of the mice, stored
at 4°C, and concentration of bacteria calculated on the day of inoculation.
Mice were infected with 1x105 cfu P. aeruginosa-Iaden beads by aspiration
challenge with surfactant phospholipids and monitored for recovery which occurred
within 5 min of administration. Mice were sacrificed after 4 days.

Assessment of weight loss
Body weight was measured in all mIce before PBS or AAV5.Cp-mIL1 0
administration, before infection with P. aeruginosa (6 weeks later), and at time of
sacrifice (4 days after infection). A record was made of any hunching, poor grooming,
fatigue, or increased respiratory effort following inoculation with agarose beads. At 4
days following P. aeruginosa-Iaden bead inoculation, mice were anesthetized with
isoflurane and sacrificed by cardiac puncture. Blood was obtained from all mice.

Bronchoalveolar lavage collection
Following sacrifice, bronchoalveolar lavage fluid (BALF) was collected. The
trachea was isolated by blunt dissection and an incision made in the upper portion of the
trachea, which was cannulated with a 21-gauge shielded I.V. catheter (BD Bioscience,
San Hose, CA) attached to a 5 ml syringe. The alveoli were washed 3 times, each with 1
ml sterile PBS. Approximately 1.5-3ml of bronchoalveolar lavage fluid (BALF) was
recovered and pooled.
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BALF cell type count and percentages

The BALF samples were centrifuged at 2000 rpm for 10 min at 4°C, the
supernatant transferred to a new tube, and stored at -80°C. The BALF cell pellet was
resuspended in 1 ml PBS and a hemacytometer used to count the number of cells. A 500
JlI aliquot of the cell suspension was transferred to a microscope slide using a cytospin
(Shandon Cytospin® 4 Cytocentrifuge, Thermo Scientific, Waltham, MA) by
centrifuging at 1000 rpm on medium speed for 5 min. The fluid on the slide was allowed
to dry, then stained with hematoxylin and eosin (H&E) using standard techniques. A
manual count of approximately 300 cells was performed, identifying the cell type as
alveolar macrophages, neutrophils, or lymphocytes. The percentage of cells for each cell
type was calculated and multiplied by the absolute cell count to get the total cells of that
cell type in the BALF.

Lung histopathology

Lungs were inflated and fixed with 4% paraformaldehyde. After 48 hr, the lungs
were embedded in paraffin, cut in 150-200 Jlm step-sections, and stained with H&E using
standard techniques. Histopathologic scoring parameters were based on published criteria
[217] with the following designations: O=within normal limits; 1=darker red than normal;
2=0-2 lymphocytic infiltrated nodules present; 3=3-6 lymphocytic infiltrated nodules and
<V4 lung consolidated; 4=V4 to

~

lung consolidated; and 5=~ to % lung consolidated.
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Lung homogenate collection, quantitative bacteriology, and cytokine analysis
Lungs were collected and placed on ice. The same day of sacrifice, the lungs were
weighed (OHAUS Adventurer balance, 1.000 g sensitivity) and washed in 0.5 ml cell
wash buffer (Bio-Rad, Hercules, CA). Using surgical scissors, lungs were cut into small
pieces, 2 ml of PBS was added, and the lungs were homogenized for 60 seconds at high
speed using Kinematica Polytron PT10/35 homogenizer (Brinkmann Instruments Co.,
Westbury, NY).
For quantitative bacteriology, the lung homogenate was diluted with PBS in tenfold serial dilutions, spread on TSA plates, and incubated at 37°C overnight. Colonies per
mouse lung were calculated. The spleens were also removed from mice whose lungs were
designated for quantitative bacteriology, homogenized in 1 ml sterile PBS, and plated at a
dilution of 1: 100 to determine if bacteremia was present.
For cytokine analysis, the homogenized lungs were further processed by freezing
at -80°C, thawing on ice, and sonicating in ice-cold water for 45 sec. The processed lung
homogenates were centrifuged at 1500xg at 4°C for 10 min, supernatants collected, and
stored at -80°C. Cytokine levels were measured using a customized Bio-Plex cytokine kit
(Bio-Rad) for detection ofIL-1~, IL-6, TNF-a, KC, and MIP-1a. Analysis was conducted
using the Bio-Plex multiplex suspension array system (Bio-Rad) following the
company's protocol. Each sample was performed in duplicate. Cytokine concentrations
were standardized for lung weight by multiplying the cytokine value by the volume of
sample (2ml) and dividing by the lung weight to obtain final values in picogram (pg) per
gram of lung tissue.
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Statistical analysis

Data are presented as average ± SD. Change in body weight is expressed as the
percentage of weight lost from the original weight three days before inoculation.
Statistical analysis of percentage weight loss, cytokine levels, H&E scoring, and
differential cell count and percentages were determined by unpaired, two-tailed Student's
t test using the Graph Pad InStat statistics software program (GraphPad Software, San
Diego, CA). Welch correction was applied when standard deviations were significantly
different. For all data sets, p values less than 0.05 were determined to be statistically
significant.
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5.3 Results

Gut-corrected CFTR knockout mice have high mortality and inflammatory
cytokine production in dosing studies with P. aeruginosa-Iaden bead by aspiration
challenge with surfactant phospholipids

6
Anesthetized mice were either infected with 5x105 , 1x106, and 5xl0 cfu P.
aeruginosa-Iaden beads or not infected and sacrificed 3 days later.

In mice infected with 5xl05 cfu P. aeruginosa-Iaden beads (n=6), the average preinfection weight was 26.0 g with mice losing an average 27.1 % of their body weight
following infection (Table 5.1). There was 33.3% mortality at this dose. Mice receiving
the lxl06 cfu dose (n=12) had an average initial weight of 23.1 g, losing an average
26.5% of their body weight. There was also 33.3% mortality at this dose. The average
pre-infection weight of the mice in the 5xl06 cfu dose group (n=4) was 23.4 g; all mice
died 2-3 days after infection. Mice that were not infected with P. aeruginosa (n=4) had
an average initial weight of 19.8 g with mice gaining an average body weight of 0.3%.
Proinflammatory cytokine levels in the lung homogenates were compared
between mice infected with the 5xl05 and lxl06 cfu P. aeruginosa dose (Figure 5.2).
There was not a dose-dependent difference with cytokine levels; however, all cytokines
in infected mice were greater than in uninfected mice (Figure 5.2 and Table 5.1). These
studies suggested that a higher dose of P. aeruginosa did not correlate with higher
proinflammatory cytokines, which could be achieved with a lower dose of infection. Due
to the high mortality (33.3%) associated with 5xl05 and lxl06 cfu of P. aeruginosa-Iaden
beads, we decided to perform our experimental studies with a lower dose of 1x 105 cfu.
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Figure 5.2
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Figure 5.2 Higher dose of P. aeruginosa-Iaden beads does not correlate to higher
pro-inflammatory cytokine levels in gut-corrected CFTR knockout mice.
Anesthetized mice were either not infected with P. aeruginosa or received 5x 105 or
lxl06 cfu P. aeruginosa-laden agarose beads by aspiration challenge with surfactant
phospholipids. Mice were sacrificed 3 days later. Lungs were collected, homogenized,
and cytokine levels measured. Levels of IL-lJi, IL-6, TNF-a, KC, and MIP-la were
measured for uninfected mice (0) and mice infected with 5xl05~) or lxl06 (II) cfu P.
aeruginosa-laden agarose beads. Data shown are the average ± standard deviation for 4
mice in the uninfected group and 2 mice in each of the infection groups and 8 mice in the
intratracheal injection group from 2 experiments. Statistical analysis could not be
performed due to the small sample sizes.
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Table 5.1 Cumulative data from dosing study of P. aeruginosa-Iaden beads
by aspiration challenge with surfactant phospholipids
in gut-corrected CFTR knockout mice.

Parameter

Initial body weight (g)
Average percentage change in
body weight§
Mortality
Cytokine levels (ng-gram lung tissue)
IL-l~

IL-6
TNF-a
KC
MIP-la

Uninfected

P. aeruginosa dose (cfu)

19.8±O.6 (4)
-0.3%±2.5 (4)

5xl05
26.0±2.2 (6)
27.1%±3.4 (4)

lxl06
23.1±3.2 (12)
26.5%±2.9 (8)

5xl06
23.4±2.0 (4)
NA

0% (0/4)
(n=4)
2.9±0.5
0.7±0.1
4.0±0.8
5.5±0.3
15.7+1.4

33.3% (2/6)
(n=2)
38.3±3.6
63.2±10.3
70.2±5.0
204.4±1.1
178.7+18.6

33.3% (4/12)
(n=2)
0.5±10.0
24.8±4.3
28.2±3.6
121.4±5.7
153.9+8.8

100% (4/4)
ND
ND
ND
ND
ND

Data shown is the average ± standard deviation. Body weight data are combined from 2
different experiments with 5x 105 and 1x 106 cfu doses and 1 experiment with 5x 106 cfu
and uninfected mice, which were censored by death. Anesthetized gut-corrected CFTR
knockout mice were either not infected with P. aeruginosa or received 5xl05, lxl06 , or
5xl06 cfu P. aeruginosa-Iaden agarose beads by aspiration challenge with surfactant
phospholipids. Mice were sacrificed 3 days later. Mice were weighed before infection
and before sacrifice. Lungs were collected, homogenized, and cytokine levels measured.
Statistical analysis could not be performed due to the small sample size. §Change in body
weight is expressed as the average percentage change of weight lost from the original
weight 3 days before infection.
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AAV5.CtJ-mILl 0 significantly reduces percentage weight loss in mice infected with
P. aeruginosa-Iaden beads.

Gut-corrected CFTR knockout mice received 8xl09 vector genomes (vg) of
AAV5.C~-mILI0 (n=17) or PBS (n=16) by aspiration challenge with surfactant
phospholipids. Six weeks later, they were infected with lxl05 cfu P. aeruginosa-Iaden
beads administered by aspiration challenge with surfactant phospholipids. Additionally,
there was a group of PBS (n=6) and

AAV5.C~-mILI0

(n=6) that were not infected with

P. aeruginosa. Mice were sacrificed after 4 days.

The first assessment for the therapeutic effect of IL-I0 gene transfer was
percentage weight loss. To ensure that AAV5.C~-mILI0 did not impact mouse weight,
the mice were weighed before administration with AAV5.C~-mILI0 or PBS and 6 wks
later before P. aeruginosa-Iaden bead infection. There was no significant difference in
the percentage weight gain between the groups (p>0.05).
The mice were weighed a second time before administration with P. aeruginosaladen beads and 4 days later before sacrifice (Figure 5.3). The average pre-infection
weight of the mice receiving

AAV5.C~-mILI0

(n=17) was 23.2 g with mice gaining an

average of 0.3% of their body weight. Mice that were not infected with P. aeruginosa
(n=6) had an average weight of 23.2 g, and a similar average weight gain of 2.0%. The
average weight of the mice in the PBS group infected with P. aeruginosa (n=16) was
24.1 g with mice losing an average body weight of 5.7%.
There was no significant difference in the percentage weight loss between
uninfected mice and infected mice that received AAV5.C~-mILI0 treatment (p>0.05)
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while infected mice treated with PBS had a significant increase in percentage weight loss
(p<O.05) (Figure 5.3). There was no mortality at either dose of P. aeruginosa infection.
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Figure 5.3
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Figure 5.3 AAV5.CfJ-mILIO treatment correlates with gain in percentage weight
that is similar to uninfected mice. Anesthetized mice received PBS or AAV5.C~
mILIO by aspiration challenge with surfactant phospholipids. After 6 weeks, AAV5.C~
mILlO-treated mice were infected with lxl0 5 cfu P. aeruginosa-Iaden beads while PBStreated mice were infected with P. aeruginosa-laden beads or not infected. Mice were
sacrificed 4 days later. Change in body weight was obtained by the average percentage of
weight lost from the original weight 4 days before inoculation for uninfected PBS-treated
mice (0), PBS-treated mice infected with P. aeruginosa ~), and AAV5.C~-mILI0treated mice infected with P. aeruginosa (iI).**p<O.005 and NSD is not significantly
different (p>0.05). Data shown are average ± standard deviation for 6 animals in the
uninfected PBS-treated group, 16 animals in PBS-treated infected with P. aeruginosa
group, and 17 animals in AAV5.C~-mILI0-treated infected with P. aeruginosa group
from 1 experiment.
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Inflammatory cytokines, but not IL-IO, increase with P. aeruginosa infection.
Pro-inflammatory cytokine expression with or without administration of P.

aeruginosa was analyzed to determine the change in cytokines, including IL-10, with
infection of gut-corrected CFTR knockout mice. Mice were inoculated with 1x105 cfu P.

aeruginosa-Iaden agarose beads by aspiration challenge with surfactant phospholipids or
were not infected. Four days later, the mice were sacrificed, lungs collected, and
cytokines levels measured in the lung homogenate.
Pro-inflammatory cytokine levels

(lL-1~,

IL-6, TNF-a, KC, and MIP-1a) in the

lung homogenates of infected mice were significantly greater than the mice that were not
infected (Figure 5.4A). However, the level of IL-10 with P. aeruginosa infection
remained the same (average, 10,000 pg/gram-Iung) when compared to IL-10 levels in the
absence of infection (average, 12,000 pg/gram-Iung) (Figure 5.4B).
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Figure 5.4
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Figure 5.4 P. aeruginosa infection causes a significant rise in lung homogenate
inflammatory cytokine levels, but not IL-IO. Anesthetized mice received PBS by
aspiration challenge with surfactant phospholipids. After 6 weeks, PBS-treated mice were
infected with P. aeruginosa-Iaden beads or not infected. Mice were sacrificed 4 days
later. Lungs were collected and homogenized. Cytokines (A) IL-l~, IL-6, TNF-a, KC,
and MIP-la and B) IL-IO were measured in uninfected (D) and infected groups ~).
**p<O.005 and NSD is not significantly different (p>O.05). Data shown are the average ±
standard deviation for 5 mice in each group from 1 experiment.

183

AAV5.CIJ-mILIO produces significant levels of IL-IO protein in the lung.

IL-I0 levels following AAV5.C~-mILI0 administration to the lungs of gutcorrected CFTR knockout mice infected with P. aeruginosa were measured to verify
gene transfer and expression. Gut-corrected CFTR knockout mice were either not
infected or infected with 1x 105 cfu P. aeruginosa-Iaden agarose beads by aspiration
challenge with surfactant phospholipids. Four days later, the mice were sacrificed, lungs
collected, and homogenized. Homogenized lungs were analyzed to determine IL-I0
levels.
AAV5.C~-mILIO-treated mice produced IL-I0 at 59,000 ng/gram of lung tissue
(Figure 5.5). IL-I0 production was also measured in the serum to determine whether

production was systemic. Serum levels of IL-IO were very low «30 pg/gram of lung
tissue) and not significantly different in the treatment groups (data not shown), thus
confirming localized secretion ofIL-lO from the AAV5.C~-mILI0 vector.

184

Figure 5.5
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Figure 5.5 Successful administration of AAV5.Cp-mILIO to lung using aspiration
challenge with surfactant phospholipids. Anesthetized mice received 8x 109 vg of
AAV5.C~-mILI0 or PBS by aspiration challenge with surfactant phospholipids. After 6
weeks, AAV5.C~-mILI0-treated mice were infected with 5xl06 cfu P. aeruginosa-Iaden
beads while PBS-treated mice were infected with P. aeruginosa-Iaden beads or not
infected. Mice were sacrificed 4 days later and lungs collected. IL-IO protein levels were
measured in the lung homogenate of PBS-treated uninfected mice (0), PBS-treated P.
aeruginosa-infected mice ~), and AAV5.C~-mILIO-treated P. aeruginosa-infected
mice (Ii). **p<0.005. Data shown are average ± standard deviation for 5 or more animals
in each group from 1 experiment.
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AAV5.Cp-mILl 0 decreases proinflammatory cytokine levels in the lungs of gutcorrected CFTR knockout mice.
The lung homogenates were also analyzed for pro-inflammatory cytokine levels
following P. aeruginosa infection of gut-corrected CFTR knockout mice receiving
AAV5.C~-mILI0 or PBS. AAV5.C~-mILI0 reduced chemokine levels: a 1.6-fold
reduction in KC and a 1.3-fold reduction in MIP-l (l compared to PBS treatment (Figure

5.6). There was also a decrease in proinflammatory cytokine levels: 1.4-fold reduction in
IL-l~,

1.7-fold reduction in IL-6, and a 2 fold reduction in TNF-(l.
While a decrease in proinflammatory cytokine levels upon P. aeruginosa

infection is desired, a decrease below uninfected levels could be damaging because this
effect could be immunosuppressive or immunostimulatory [244]. Cytokine decrease by
AAV5.C~-mILI0 was not below the cytokine levels in uninfected mice, except in the
level of TNF -(1 (Figure 5.6). Additionally, to determine if the reduction in lung
pro inflammatory

cytokines

had

a

systemic

effect,

we

measured

circulating

proinflammatory cytokine concentrations in the serum and did not observe a decrease
(p>O.05).
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Figure 5.6
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Figure S.6 AAVS.Cfl-mILIO decreases proinflammatory cytokine levels in the lung.
Anesthetized mice received 8x109 vg of AAVS.Cp-mIL10 or PBS by aspiration challenge
with surfactant phospholipids. After 6 weeks, AAV 5. C~-mIL 1O-treated mice were
infected with Sx 106 cfu P. aeruginosa-Iaden beads while PBS-treated mice were infected
with P. aeruginosa-laden beads or not infected. Mice were sacrificed 4 days later. Lungs
were collected and homogenized. Cytokines (A) IL-1P and IL-6 and (B) TNF-a, KC, and
MIP-1 a were measured in PBS-treated uninfected mice (0), PBS-treated P. aeruginosainfected mice ~), and AAV5.C~-mIL10-treated P. aeruginosa-infected mice (II).
*p<O.OS, **p<O.005 and NSD is not significantly different (p>O.05). Indication of
significance between infected mice receiving AAV5.Cp-mIL10 and uninfected mice is
shown above the AAV5.Cp-mIL10 bar. Data shown are the average ± standard deviation
for 5 or more mice in each group from 1 experiment.
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IL-IO expression from AAV5.Cp-mILIO decreases inflammation-associated lung
pathology.
Lung sections in the IL-10 treatment group that were infected with P. aeruginosa
contained fewer neutrophil and lymphocyte infiltration, primarily found in discrete
nodules that were fewer in number (Figure 5.7A, B). In contrast, histological
examination of lung sections obtained from mice in the PBS-treatment group infected
with P. aeruginosa, revealed more inflammatory nodules and lung consolidation (Figure

5.7C, D). Histology sections taken from uninfected mice did not exhibit any
inflammatory changes (Figure 5.7E, F). Histological scoring was used to show that
inflammatory changes were diminished in AAV5.C~-mIL10-treated mice (Table I).
This pathology corroborates our cytokine findings and supports our hypothesis
that AAV5.C~-mIL10 can effectively reduce inflammation in P. aeruginosa-infected
lungs. Moreover, despite fairly high IL-IO levels in the lung, there was no indication of
systemic infection or immunosuppression modulated by IL-I o.
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Figure 5.7
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Figure 5.7 AAV5.Cp-mILIO reduces inflammation-associated pathology in P.
aeruginosa-infected mice when com~ared to similarly-infected mice treated with
PBS. Anesthetized mice received 8xlO vg of AAV5.CJ3-mILIO or PBS. After 6 weeks,
AAV5.CJ3-mILIO-treated mice were infected with lxI0 5 cfu P. aeruginosa-Iaden beads
while PBS-treated mice were infected with P. aeruginosa-Iaden beads or not treated.
Mice were sacrificed 4 days later. Lungs were collected and fixed in paraformaldehyde,
then sectioned and H&E stained. (A, B) AAV5.C~-mILIO with P. aeruginosa-Iaden
beads, (C, D) PBS with P. aeruginosa-Iaden beads, and (E, F) PBS. Magnifications are
lOx (A, C, E) and 20x (B, D, F). Observations represent the findings from 1 animal in the
uninfected group and 5 animals in the infected group and are from 1 experiment.
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Table 5.2 Histolopathologic scores of lung sections from gut-corrected CFTR
knockout mice infected with P. aeruginosa following PBS or AAV5.C lJ-mILl 0
administration.

PBS

Number of
mice
5

AAV5.C~-mILI0

5

P. aeruginosa-infected treatment

grOUp

P value

Score

Average+ SD

2.5
2.5
3
2.5
2.5
2
2
2
1
1

2.6

±0.2

1.6

±0.5

p>O.OO5

Anesthetized mice received 8xl09 vg of AAV5.C~-mILIO or PBS. After 6 weeks,
anesthetized mice were infected with lxl0 s cfu P. aeruginosa-Iaden beads and sacrificed
4 days later. Lungs were collected and fixed in paraformaldehyde, then sectioned and
H&E stained. Sections were graded by a blinded pathologist.
Histopathologic scoring parameters were based on previously published criteria [217].
O=within normal limits
1=darker red than normal
2=0-2 lymphocytic infiltrated nodules present
3=3-6 lymphocytic infiltrated nodules, <Y.tlung consolidated
4=Y.t to 'l2 lung consolidated
5='l2 to % lung consolidated
6=>% lung consolidated
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Bacterial burden is similar in mice receiving PBS or AAVS.Cp-mILIO treatment.
Gut-corrected CFTR knockout mice treated with PBS or AAV5.C~-mILIO and, 6
weeks later, were infected with lxl05 cfu P. aeruginosa-Iaden agarose beads. Four days
later, the mice were sacrificed, lungs and spleen collected, and homogenized. To
determine if treatment with AAV5.C~-mILIO resulted in any change in bacterial burden,
quantitative bacteriology was performed on lung homogenates. There was no different in
the amount of P. aeruginosa recovered from the lungs of AAV5.C~-mILIO-treated mice
when compared to PBS-treated mice (p<O.05). No bacteria grew in cultures of spleen
homogenates in AAV5.C~-mILIO-treated or PBS-treated mice.

Neutrophil migration is decreased with AAVS.Cp-mILIO administration.
Gut-corrected CFTR knockout mice were inoculated with lxl0 5 P. aeruginosaladen agarose beads 6 weeks after receiving AAV5.C~-mILIO or PBS. Four days later,
the mice were sacrificed and BALF was collected. BALF cells were obtained through
centrifugation, resuspended in PBS, and cytospun onto a slide which was H&E stained.
BALF cells were counted and identified on the H&E slide as alveolar macrophages
(AM), neutrophils (PMN), or lymphocytes. While the percentage of individual cell types
in the BALF was not significantly different between the treatment groups in the presence
of P. aeruginosa infection, the absolute number neutrophils was decreased 2.5-fold
(p<O.OS) in AAV5.CP-mILIO-treated mice compared to mice that received PBS (Figure
5.8). There was also a trend toward a decrease in the percentage of neutrophils with
AAVS.Cp-mILIO treatment (data not shown).
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Figure 5.8
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Figure 5.8 AAV5.C~-mILI0 significantly decreases neutrophil migration to the
lungs of gut-corrected CFTR knockout mice infected with P. aeruginosa.
Anesthetized mice received PBS or AAV5.C~-mILI0. After 6 weeks, anesthetized mice
were infected with 1x 105 cfu P. aeruginosa-Iaden agarose beads. Mice were sacrificed 4
days later. BALF was collected and analyzed for cell number and type. *p<0.05 Data
points are neutrophil cell counts for 6 mice in each group from one experiment; the black
line is the average of each group.
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5.4 Discussion
Several lines of evidence suggest that in CF lung disease, inflammation is
excessive relative to bacterial infection [35, 267]. Infants with CF have large quantities of
IL-8, neutrophils, and neutrophil elastase (NE) in their BALF, compared to non-CF infants,
which occurs in the presence and absence of detectable bacterial infection [64]. When
compared to normal mice that were infected with the P. aeruginosa-laden beads, CF mice
demonstrated greater weight loss, a more marked inflammatory response, and higher
mortality despite having the same bacterial load as their non-CF counterparts [220, 223].
Furthermore, treatment of patients with CF using anti-inflammatory therapeutics slows the
progression of lung disease without exacerbating infection [96-100]. Taken together, these
studies suggest that inflammation is dysregulated and disproportionately severe to the
bacterial infection, resulting in a pathologic response in the CF lung. In addition to excessive
levels of proinflammatory cytokines, there are lower levels of anti-inflammatory cytokine,
IL-I0, in the airways of patients with CF, compared to healthy subject controls [30]. IL-I0
deficiency and corresponding excessive inflammation are related as shown in studies with
IL-I0-deficient transgenic (IL-I0T) mice [139, 141, 236]. Furthermore, many of the
pathologies noted with P. aeruginosa infection were reversed by administration of IL-l 0 in
wild-type mice [139, 141] and CFTR knockout mouse models [37, 140].
Previous use of IL-I0 as a therapeutic for inflammation in a chronic lung
infection model has administered the recombinant protein, systemically, leading to a
corresponding systemic reduction in proinflammatory cytokines [139]. Because
dysregulated inflammation occurs exclusively in the CF lung, we were interested in lungtargeted delivery and expression of IL-l 0 using adeno-associated virus (AAV)-based gene
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transfer. The use of AAV vectors to deliver therapeutic genes in CF has been studied
extensively in animal studies and clinical trials. These vectors have a proven safety
profile and are capable of producing long-term gene expression with a minimal
inflammatory response [17, 19, 182,240].
We found that treatment with AAV5.C~-mILI0 resulted in reduced inflammation
in a model of chronic P. aeruginosa lung infection in gut-corrected CFTR knockout
mice. First, we performed a P. aeruginosa-laden bead dosing study in gut-corrected
CFTR knockout mice to determine the amount of bacteria to administer by aspiration
challenge with surfactant phospholipids. Our finding that lower doses of P. aeruginosa
result in higher morbidity in gut-corrected CFTR mice, compared to previous studies
with CD-l mice, is supported by the literature [220, 224]. Then, gut-corrected CFTR
knockout mice were treated with PBS or AAV5.C~-mILI0. Six weeks later, the mice
were infected with lxl05 cfu P. aeruginosa-laden agarose beads and sacrifice after 4
days. While proinflammatory cytokines

(IL-l~,

IL-6, TNF-a, KC, and MIP-la) were

significantly increased with P. aeruginosa infection, IL-I0 levels remained the same
(p>0.05). Treatment with AAV5.C~-mILI0 corresponded with high levels of lungspecific IL-I0 expression, decreased proinflammatory cytokine levels, inflammationassociated lung pathology and neutrophil migration with no effect on bacterial burden
(p>0.05). This last point is important because of concerns regarding the administration of
an anti-inflammatory agent during an active bacterial infection. Like corticosteroid and
ibuprofen use in patients with CF, modulation of inflammation mediated by IL-IO does
not exacerbate bacterial infection in our chronic model. Additionally, blood levels of
proinflammatory cytokines and IL-IO from mice receiving AAV5.C~-mILI0 were not
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significantly different from those measured in the PBS-treated mice (data not shown). The
most significant finding was the percentage weight loss between the groups of mice. P.
aeruginosa-infected mice treated with AAV5.C~-mILI0 had the same percentage weight

loss as uninfected mice (p>0.05); both groups were significantly lower in percentage
weight loss compared to infected mice treated with PBS (p<0.005).
Our data agree with the findings of others who used related animal models and
exogenous IL-IO treatment. In a chronic P. aeruginosa infection in CD-l mice,
intraperitoneal administration of recombinant IL-I0 (rIL-IO) resulted in increased
survival, fewer neutrophils in the BAL, and decreased area of lung inflammation when
compared to placebo-treated mice; there was no decrease in bacterial burden [139].
Recombinant IL-10 was also administered, subcutaneously, in an acute model using
intratracheal LPS challenge in CF mice and resulted in a significant decrease of PMNs
and TNF-a, which correlated with decreased NFlCB activity and increased IlCBa [37]. The
anti-inflammatory activity of IL-l 0 most likely occurs by stabilizing IlCBa, an inhibitor of
NFlCB, reducing the ability of NFKB to induce proinflammatory cytokine expression and
secretion by airway epithelial cells [70].
In this study, there was no infection with an AAV vector expressing a reporter
gene or inert protein to determine the effect of AAV on pro inflammatory cytokine
expression and neutrophil migration, separate from the effects of IL-10. While AAVmediated gene transfer leads to the development of antibodies against the vector capsid
which can prevent vector re-administration, the lack of inflammatory responses
documented in numerous in vivo gene transfer models employing AAV vectors suggest
that these agents do not interact significantly with the innate immune system [143].
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Studies in non-human primates with AAV-CFTR showed the vector did not result in an
increase in proinflammatory cytokines and neutrophil influx as measured in the BALF
[143]. Additionally, studies in murine models have shown that AAV-GFP has the same
response as PBS when measuring percentage weight loss and neutrophil migration (Dr.
Tom Ferkol, unpublished studies), supporting our use of PBS as a negative control.
Future studies should analyze the duration of AAV-mediated IL-I0 gene
expression, shown for some transgenes to persist for 1.5 years in animal models [159162]. This would be important for clinical applications of AAV5.C~-mILI0 because the
anticipated dosage could be administered less frequently than most CF medications
(typically, multiple times per day or week), potentially increasing patient adherence,
currently an obstacle in CF [245].
In conclusion, we have demonstrated gene transfer of IL-I0 reduces local
inflammation without modulating a systemic cytokine decrease or promoting an increase in
bacterial burden. Our results support the hypothesis that decreased IL-IO levels are linked
to high levels of proinflammatory cytokine production in CF and that exogenous
administration of IL-I0 may reduce the pathogenesis of the excessive inflammatory
response to the chronic endobronchial P. aeruginosa infection in patients with CF.
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Chapter 6.
Implications

Although the life expectancy of patients with CF has significantly improved during
the past 30 years, the beneficial effects of antibiotics, airway clearance, and improved
nutrition appears to have reached a plateau. Despite the initial success in vitro for treatments
aimed at modifying the basic CFTR defect, current attempts in clinical trials have not been
successful in ameliorating the CF phenotype. Additionally, while targeting the CFTR may
improve the clinical outcome of young patients, it may not benefit patients with extensive
irreversible lung damage resulting from years of chronic infection and inflammation.
Therapeutics targeting the inflammatory cascade and slowing disease progression offer the most
benefit for the majority of patients with CF.
The airways of patients with CF are pro inflammatory, due to innate features of the CF
immune system caused by CFTR mutations, multiple acute infections with bacteria, and/or
persistent, chronic bacterial infections. Upon bacterial colonization, components of P.
aeruginosa (LPS, flagellin) interact with toll-like receptors (TLR) expressed from alveolar

macrophages, leading to activation of NFKB, production of proinflammatory cytokines, and
recruitment of inflammatory cells. Supporting the recruitment of B and T cells during this
response are the presence of circulating IgG subclass antibodies against P. aeruginosa;
however, the airway is predominantly characterized by large quantities of neutrophils. These
neutrophils are recruited to the airway and release reactive oxidant species, but are not
effectively phagocytosed, contributing to the viscous secretions lining the airway.
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The production of regulatory cytokines and antioxidants and apoptosis promote
tissue repair (fibrosis) and resolution of the inflammatory response. Patients with CF
appear to have an inflammatory response that is not effectively resolved because the
modulators of the immune response, including IL-IO, IKBa, and AAT, are produced at
low levels, rapidly degraded, and/or overwhelmed by the levels of proinflammatory
cytokines, reactive oxidant species, and proteases produced. Fibrosis occurs in the CF
airway, but the lungs are continuously in a cycle of tissue injury and repair.
Our therapeutic, AAV-directed IL-IO gene transfer, could prove beneficial in
patients with CF. Using an administration technique such as aerosolization or single-Iobelung delivery of IL-l 0, the vector will efficiently transduce the airway epithelia, as was
shown in our animal studies and previous human clinical trials. AAV vectors have been
found to predominantly persist in episomal form and, over a period of 6 weeks, mediate
maximal expression of IL-IO protein. Our animal studies showed IL-IO was produced
from alveolar cells, and because the protein is secreted, IL-IO may also demonstrate its
anti-inflammatory effects in sites removed from the successfully transduced cells, including
the upper and lower respiratory tract.
Therapeutic IL-IO protein expression decreased production of cytokines

IL-l~,

IL-6, and TNF-a and chemokine IL-8 (KC and MIP-la), which are elevated in the CF

lung, and their reduction may aid in resolution of the excessive inflammatory response in
the human lung as was observed in our animal studies. Decreased cytokine expression led
to decreased inflammation-associated lung pathology and neutrophil recruitment,
supporting the finding that IL-IO facilitates resolution of lung inflammation, decreases
myeloid-derived cells (neutrophils), and prevents cell-to-cell communication between
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macro phages and T cells, resulting in decreased production of proinflammatory cytokines
and cytotoxic factors. Bacterial killing was not affected with IL-I0 treatment in our
studies, suggesting that the host response was not decreased enough to cause an increase
in bacterial proliferation. In patients with CF, IL-I0 treatment is also not likely to cause
bacterial proliferation because prior treatment with anti-inflammatory therapeutics (such
as ibuprofen and glucocorticoids) have not caused an increase in bacterial burden because
the inflammatory response is decreased from a heightened state, but not decreased to a
state of immunosuppression. The goal of anti-inflammatory treatment in patients with CF
is not to reduce P. aeruginosa infection, but to decrease the pathologic response that
results in tissue injury and respiratory failure.
Our studies also support the use of surfactant as a carrier for non-invasive lung
delivery of gene transfer agents in animal models and may improve clinical delivery of
AAV to produce a clinical outcome, not yet demonstrated in clinical trials [16, 18].
Surfactant has been instilled into the lungs of critically ill adults and children, supporting
the use of this vehicle as safe and well-tolerated [268]. Because obtaining high titers of
AAV vectors is a current limitation for clinical trials, dosing of AAVS. C~-mIL 10 should
be conducted in animal and hwnan studies to determine if the addition of surfactant
phospholipids will increase gene transfer.
Currently, an obstacle in CF treatment is patient adherence to medicine regiments
because patients are typically on several medications, administered multiple times per
day or week. AAVS.Cp-mILI0 could be administered less frequently than most CF
medications due to the ability of AAV-based vectors to convey long-term gene
expression of therapeutic proteins. Future studies should analyze the duration of AAV-

204

mediated IL-I0 gene expression, shown for some transgenes to persist for 1.5 years in
animal models [159-162].
In conclusion, we demonstrated gene transfer of IL-l 0 reduces local inflammation
without modulating a systemic cytokine decrease or promoting an increase in bacterial
burden. Our results support the hypothesis that decreased IL-I0 levels are linked to high
levels of proinflarnmatory cytokine production in CF and that exogenous administration of
IL-'10 may reduce the pathogenesis of the excessive inflammatory response to the chronic
endobronchial P. aeruginosa infection in patients with CF. These studies add to a
significant body of research that suggests inflammation in CF is pathologic, and
regulation of this response aids in resolving excessive cytokine release, neutrophil
migration, and lung destruction. In addition, we developed a technique for non-invasive
P. aeruginosa infection and gene transfer that will be beneficial to CF researchers

working with in vivo models. Both contributions further develop AAV-based gene
transfer as a promising therapeutic against inflammation in CF.
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YFP imaging and patch-clamp analYsis of ha!f-CFIR modules

•

•

Learned YFP and bisoxonal imaging procedures
Further trained in patch-clamp technique and analysis

Department ofMicrobiology and Immunology
Basic Science Building
Medical University of South Carolina
Charleston, South Carolina, 2000-2005
Mentor: John Y. Dong, M.D., Ph.D.
Functional analYsis of ha!f-CFrR modules and development of a novel strate!!Jl for hightiterAAV

•
•
•
•

•
•
•

Established collaboration with Micheal Bowman, M.D., Ph.D.
Attended cystic fibrosis educational sessions with third and fourth
year medical students
Established collaboration with Roger Young, M.D., Ph.D. to learn
patch-clamp analysis technique
Successfully patched positive and negative controls, and found novel
activity from N -terminal module
Weeldy attended CF clinic briefings ill MUSC Pediatric
Comprehensive CF Center
Initiated development of SPQ imaging assay
Collaborated with Raymond Frizzell, Ph.D. and traveled to Pittsburg
to conduct functional analysis
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•

•
•
•
•

Successfully demonstrated function by all half-CFTR co-expression
systems by imaging assay and found novel activity of C-terminal
module
Established collaboration with William Guggino, Ph.D. Oohns
Hopkins)
Established collaboration with Richard Boucher, M.D. and Jude
Samulski, Ph.D. (UN C-Chapel Hill)
Traveled to UNC-Chapel Hill to pursue other possible collaborations
Edited, wrote, and submitted numerous grants on cystic fibrosis and
infectious disease vaccines

ACTIVITIES
Medical University ofSouth Carolina
Fellow, Presidential Scholars
Student Academic Subcommittee, Student Government Association
Representative, Student Diversity Advisory Committee
Student Handbook Chairperson, Graduate Student Association

Wofford CoUege
Secretary, American Chemical Society
Tutor, General Chemistry
Laboratory Assistant and Instructor, General Chemistry
Community
Assistant Coach, A YSO Soccer
Girl Scout counselor and leader, Camp Mary Elizabeth
VOLUNTEER EXPERIENCE
Founder and Director
'Junior Doctors of Health'
Wilmot J. Fraser Elementary School
Charleston, South Carolina, 2004-present
• Initiated and implemented Nutrition, Exercise, and Mentoring program in
inner-city school
• Ensured program's sustainability
• Received monetary donations and grant funding
• Established multiple collaborations
• Recruited and gave orientations for MUSC student volunteers
• Implemented teacher exercise program
• Incorporated new activities to expand program each year
• Coordinated book drive raising in excess of 300 books and $200 monetary
donations
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Extramural Grant Awards
Buff (Awardee)
$1,500
Coastal Community Foundation, Cooper River Bridge Run, 2007
MUSC-Junior Doctors of Health
This project is to fund Wilmot J. Fraser Elementary School students and
their parents to attend the Cooper River Bridge Kids Run to promote family
exercise in a healthy environment.
Role: Coordinator/Co-PI
Intramural Grant Awards
Buff (Awardee)
$2,500
MUSC, President's Office, 2006-2007
Junior Doctors of Health
This project is a mentorship based program between MUSC students and
Wilmot J. Fraser Elementary School (grades 2nd_6th) where MUSC students
teach about the importance of nutrition, exercise, and leading a healthy
lifestyle. It has expanded to include 7th grade and now includes information
about safety.
Role: Coordinator/PI

Stevens (PI)
$2,480
MUSC Family Fund, YES Grant, 2004-2005
MUSC-based Clinics, Diabetes Awareness (project II)
This project was to provide Wilmot J. Fraser Elementary School with MUSC
students to teach about healthy eating and exercise. Presentations were also
given to parents.
Role: Coordinator

Related Presentations
Scotty Buff. Oral Presentation. 'Junior Doctors
Trustees, Education subcommittee. 2007

of Health':

MUSC Board of

Scotty Buff. Oral Presentation. Combating PediatnOc Obesity with 'Junior Doctors
of Health': Society for Pediatric Nurses. 2007
Scotty Buff, Pamella Gibbs, Rachel Rozansky, Ashley Costa, and Brittany
Ray. Oral Presentation. Enhandng Diabetes and Obesi!)' Awareness fry Implementing
a Healtl[y Eating/Exerdse Program in a "Local Elementary School- 'Junior Doctors of
Health". South Carolina Association for Public Health Conference. 2006
MUSC President Raymond Greenberg, M.D., Ph.D., Rosetta Swinton, R.N.,
and Scotty Morrow. Oral Co-presentation. Communi!), Intcroentions for Obesi!)':
A Hea1!Jweight Solution. College of Medicine Dean's Prevention Lecture. Fall
2004.
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MUSC President Raymond Greenberg, M.D., Ph.D. and Scotty Morrow.
Oral Co-presentation. Making a Difference: Think GloballY, Act ucalIY. MUSC
Presidential Scholars' Fellow Lecture. Fall 2004.

S Morrow, D Klos, T Johnson, Sav Gunasinghe, K Kelleher, 0 Peck, S
Johnson, and L Egede. Poster Presentation. Enhancement of Diabetes Education
1!Y Implementing a Healt1!J Eating/Exercise Program in Two ucal Elementary Schools,
'Junior Doctors of Health'~ MUSC Presidential Scholars Day, Charleston, SC.
2004.

Medical University ofSouth Carolina
• United Methodist Relief Center
• Happy Days and Special Times
• Alterra Clare Bridge
• American Cancer Society
• Habitat for Humanity
• V oter Registration Drive
Wofford CoDege
Co-organizer, Art in Action
Community
Event Organizer, Cystic Fibrosis Foundation
Tutor, Summer of Success
ADDITIONAL WORK EXPERIENCE

•
•
•
•

•

Ticket and concession sales, Regal Converse Cinema 6
Surgeon assistant and animal care, Smith Animal Hospital
Waitress, Denny's
Chemical inventory and MSDS, Wofford College
Waitress, Cracker Barrel

MEETINGS ATTENDED

•
•
•
•
•
•
•
•
•
•

American Society of Gene Therapy, Seattle (Oral), 2007
20th Annual North American Cystic Fibrosis Conference, Denver (poster), 2006
South Carolina Association for Public Health Conference, Myrtle Beach (Oral and
poster), 2006
American Thoracic Society International Conference, San Diego (Oral and poster),
2006
19th Annual North American Cystic Fibrosis Conference, Baltimore (poster), 2005
American Society of Gene Therapy Stakeholder's Meeting, Arlington, 2004
18th Annual North American Cystic Fibrosis Conference, St. Louis (poster), 2004
American Society for Microbiology, Clemson (poster), 2004
17th Annual North American Cystic Fibrosis Conference, Anaheim, 2003
American Society of Gene Therapy, Boston (poster), 2002
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•
•
•

15th Annual North American Cystic Fibrosis Conference, Orlando (poster), 2001
American Society of Gene Therapy, Seattle, 2001
International Society of Cancer Gene Therapy, San Diego, 2000

PROFESSIONAL MEMBERSHIPS
American Society of Microbiology
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